assay_description,canonical_smiles,document_chembl_id,relation,standard_relation,standard_type,standard_units,standard_value,type,units,value,SMILES,year
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,125.0,EC50,nM,125.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,1.0,RE,,1.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,190.0,EC50,nM,190.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,1.7,RE,,1.7,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,85.0,EC50,nM,85.0,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,0.7,RE,,0.7,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,650.0,EC50,nM,650.0,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,0.3,RE,,0.3,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,CHEMBL1135404,=,=,EC50,nM,190.0,EC50,nM,190.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,CHEMBL1135404,=,=,RE,,0.9,RE,,0.9,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,CHEMBL1135404,=,=,EC50,nM,700.0,EC50,nM,700.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,CHEMBL1135404,=,=,RE,,0.4,RE,,0.4,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(F)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,CHEMBL1135404,=,=,EC50,nM,250.0,EC50,nM,250.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,CHEMBL1135404,=,=,RE,,0.7,RE,,0.7,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,CHEMBL1135404,=,=,EC50,nM,910.0,EC50,nM,910.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,CHEMBL1135404,=,=,RE,,0.5,RE,,0.5,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1F,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,CHEMBL1135404,=,=,EC50,nM,260.0,EC50,nM,260.0,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,CHEMBL1135404,=,=,RE,,0.2,RE,,0.2,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay; Not tested,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,CHEMBL1135404,,,NT,,,NT,,,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,CHEMBL1135404,,,NT,,,NT,,,COc1ccc(CN(CCCOc2cccc(C(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1OC,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1135404,=,=,EC50,nM,60.0,EC50,nM,60.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1135404,=,=,RE,,1.0,RE,,1.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1135404,=,=,EC50,nM,85.0,EC50,nM,85.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1135404,=,=,RE,,2.5,RE,,2.5,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1135404,=,=,EC50,nM,95.0,EC50,nM,95.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1135404,=,=,RE,,1.0,RE,,1.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1135404,=,=,EC50,nM,3000.0,EC50,nM,3000.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1135404,=,=,RE,,1.0,RE,,1.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,45.0,EC50,nM,45.0,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,1.1,RE,,1.1,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,425.0,EC50,nM,425.0,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,1.5,RE,,1.5,NC(=O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,CHEMBL1135404,=,=,EC50,nM,660.0,EC50,nM,660.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,CHEMBL1135404,=,=,RE,,0.7,RE,,0.7,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,CHEMBL1135404,=,=,EC50,nM,4000.0,EC50,nM,4000.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,CHEMBL1135404,=,=,RE,,0.6,RE,,0.6,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)c(OC)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,EC50,nM,860.0,EC50,nM,860.0,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,RE,,0.8,RE,,0.8,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,EC50,nM,8000.0,EC50,nM,8000.0,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,RE,,0.9,RE,,0.9,COc1ccc(CN(CCCOc2cccc(CC(=O)O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,85.0,EC50,nM,85.0,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,0.9,RE,,0.9,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,EC50,nM,945.0,EC50,nM,945.0,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in LXR alpha-Gal4 receptor gene assay",NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1135404,=,=,RE,,0.4,RE,,0.4,NC(=O)Cc1cccc(OCCCN(Cc2ccc(F)c(C(F)(F)F)c2)CC(c2ccccc2)c2ccccc2)c1,2002
Ligand-dependent recruitment of steroid receptor co-activator 1 (SRC1) to Liver X receptor-alpha,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,EC50,nM,260.0,EC50,nM,260.0,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
"Relative efficacy compared to 24(S),25-epoxy cholesterol in Liver X receptor-alpha ligand-sensing assay",COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,=,=,RE,,0.8,RE,,0.8,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
Effective concentration in LXR alpha-Gal4 receptor gene assay; inactive at 10 uM,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,CHEMBL1135404,,,IA,,,IA,,,COc1ccc(CN(CCCOc2cccc(CC(N)=O)c2)CC(c2ccccc2)c2ccccc2)cc1,2002
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,170.0,EC50,nM,170.0,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.4,RE,,1.4,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,3000.0,EC50,nM,3000.0,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.2,RE,,0.2,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,1160.0,EC50,nM,1160.0,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.35,RE,,0.35,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@H](CC[C@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,670.0,EC50,nM,670.0,C[C@H](CC[C@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CC[C@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.0,RE,,1.0,C[C@H](CC[C@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,180.0,EC50,nM,180.0,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.3,RE,,1.3,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)C[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,CC(C)C[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CNC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,C[C@H](CNC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](C[C@@H](CO)C(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,C[C@H](C[C@@H](CO)C(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,130.0,EC50,nM,130.0,CC(C)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.0,RE,,1.0,CC(C)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,460.0,EC50,nM,460.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.0,RE,,1.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,COC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,105.0,EC50,nM,105.0,COC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,COC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,1.1,RE,,1.1,COC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,220.0,EC50,nM,220.0,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.85,RE,,0.85,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CNC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,720.0,EC50,nM,720.0,CNC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CNC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.55,RE,,0.55,CNC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,C[C@@H](CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,250.0,EC50,nM,250.0,C[C@@H](CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,C[C@@H](CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.3,RE,,0.3,C[C@@H](CO)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)CCC[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,CHEMBL1134370,=,=,EC50,nM,470.0,EC50,nM,470.0,CC(C)CCC[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)CCC[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,CHEMBL1134370,=,=,RE,,1.0,RE,,1.0,CC(C)CCC[C@](C)(O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)C(=O)NC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,CC(C)C(=O)NC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA by 100 uM,CC(C)CC[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,<,<,RE,,0.1,RE,,0.1,CC(C)CC[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Binding affinity towards LXR alpha receptor was determined in LiSA,CC(C)CC[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,Ki,nM,180.0,Ki,nM,180.0,CC(C)CC[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,325.0,EC50,nM,325.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.85,RE,,0.85,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA.,CC(C)C[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,EC50,nM,5900.0,EC50,nM,5900.0,CC(C)C[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA,CC(C)C[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1134370,=,=,RE,,0.7,RE,,0.7,CC(C)C[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2001
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1145169,=,=,EC50,nM,80.0,EC50,nM,80.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1145169,=,=,RE,,1.0,RE,,1.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1145169,=,=,EC50,nM,55.0,EC50,nM,55.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1145169,=,=,RE,,1.1,RE,,1.1,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1145169,=,=,RE,,0.8,RE,,0.8,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,EC50,nM,50.0,EC50,nM,50.0,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.9,RE,,0.9,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.9,RE,,0.9,COc1ccc(NC2=C(c3ccccc3)C(=O)N(Cc3ccccc3)C2=O)cc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,EC50,nM,100.0,EC50,nM,100.0,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,RE,,0.3,RE,,0.3,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,RE,,0.5,RE,,0.5,O=C1C(Nc2ccccc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,EC50,nM,130.0,EC50,nM,130.0,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,RE,,0.3,RE,,0.3,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,CHEMBL1145169,=,=,RE,,0.4,RE,,0.4,O=C1C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C(=O)N1Cc1ccccc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,EC50,nM,300.0,EC50,nM,300.0,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,1.1,RE,,1.1,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.9,RE,,0.9,CCN1C(=O)C(Nc2ccc(OC)cc2)=C(c2ccccc2)C1=O,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,EC50,nM,275.0,EC50,nM,275.0,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.7,RE,,0.7,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.6,RE,,0.6,COc1ccc(NC2=C(c3ccccc3)C(=O)N(c3ccccc3)C2=O)cc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,CHEMBL1145169,=,=,EC50,nM,575.0,EC50,nM,575.0,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.9,RE,,0.9,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,CHEMBL1145169,=,=,RE,,0.9,RE,,0.9,COc1ccc(NC2=C(c3ccccc3)C(=O)N(C)C2=O)cc1,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,EC50,nM,890.0,EC50,nM,890.0,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.7,RE,,0.7,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.7,RE,,0.7,CCN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,EC50,nM,725.0,EC50,nM,725.0,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.5,RE,,0.5,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.6,RE,,0.6,CCN1C(=O)C(Nc2ccc(Cl)cc2)=C(c2ccccc2)C1=O,2005
Effective concentration for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha (Liver X receptor),CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,EC50,nM,1590.0,EC50,nM,1590.0,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.5,RE,,0.5,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Relative efficacy for Steroid receptor coactivator-1 (SRC1) recruitment to human LXRalpha compared to GW-3965,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,CHEMBL1145169,=,=,RE,,0.6,RE,,0.6,CN1C(=O)C(Nc2ccccc2)=C(c2ccccc2)C1=O,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,IC50,nM,35.4,IC50,nM,35.4,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,IC50,nM,35.4,IC50,nM,35.4,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,EC50,nM,35.4,EC50,nM,35.4,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,EC50,nM,35.4,EC50,nM,35.4,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,EC50,nM,1790.0,EC50,nM,1790.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,EC50,nM,1790.0,EC50,nM,1790.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,Activity,,20.0,Activity,,20.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1145279,=,=,Activity,,20.0,Activity,,20.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,>,>,IC50,nM,50000.0,IC50,nM,50000.0,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,>,>,EC50,nM,50000.0,EC50,nM,50000.0,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay; Not tested,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay; Not tested,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,,,Activity,,,Activity,,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,CHEMBL1145279,=,=,IC50,nM,2.0,IC50,nM,2.0,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,CHEMBL1145279,=,=,EC50,nM,1.0,EC50,nM,1.0,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,CHEMBL1145279,=,=,EC50,nM,1.0,EC50,nM,1.0,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,CHEMBL1145279,=,=,Activity,,50.0,Activity,,50.0,CC1(C(=O)OC(=O)C2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCCC2(C)c3cc(O)ccc3CCC12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1145279,=,=,IC50,nM,2.0,IC50,nM,2.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1145279,=,=,EC50,nM,2.0,EC50,nM,2.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1145279,=,=,EC50,nM,10.0,EC50,nM,10.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1145279,=,=,Activity,,60.0,Activity,,60.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,IC50,nM,1.0,IC50,nM,1.0,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,EC50,nM,1.0,EC50,nM,1.0,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,<,<,EC50,nM,3.0,EC50,nM,3.0,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,Activity,,24.0,Activity,,24.0,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,IC50,nM,14.0,IC50,nM,14.0,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha; Not tested,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,~,~,EC50,nM,100.0,EC50,nM,100.0,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,Activity,,88.0,Activity,,88.0,CC1(COC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,CHEMBL1145279,=,=,IC50,nM,90.0,IC50,nM,90.0,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha; Not tested,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay; Not tested,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay; Not tested,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,CHEMBL1145279,,,Activity,,,Activity,,,CC1(C(=O)O)CCC[C@]2(C)c3cc(OC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)ccc3CC[C@@H]12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,IC50,nM,67.0,IC50,nM,67.0,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,EC50,nM,320.0,EC50,nM,320.0,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Activity against liver X receptor-alpha in HEK293 cell transactivation assay at 10 uM,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,Activty,%,231.0,Activty,%,231.0,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1145279,=,=,Activity,,33.0,Activity,,33.0,CC1(C(=O)CC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay; Not active,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,CHEMBL1145279,,,IC50,nM,,IC50,nM,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha; Not active,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay; Not tested,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,CHEMBL1145279,,,EC50,nM,,EC50,nM,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay; Not tested,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,CHEMBL1145279,,,Activity,,,Activity,,,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(OP(=O)(O)Oc4ccc5c(c4)[C@@]4(C)CCC[C@](C)(C(=O)O)[C@@H]4CC5)ccc3CC[C@@H]12,2005
Percent inhibition of [3H2]-F3-methyl AA (1) binding to liver X receptor-alpha at 100 uM,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1145279,=,=,Inhibition,%,70.0,Inhibition,%,70.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1145279,=,=,EC50,nM,15000.0,EC50,uM,15.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay; not calculated as plateau not reached at doses tested,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1145279,=,=,EC50,nM,,EC50,nM,,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1145279,=,=,Activity,,4.0,Activity,,4.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Displacement of [3H2]-F3-methyl AA (1) from liver X receptor-alpha in SPA assay; Not active,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,CHEMBL1145279,,,IC50,nM,,IC50,nM,,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,2005
Effective concentration for cofactor association with recombinant liver X receptor-alpha; Not active,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,CHEMBL1145279,,,EC50,nM,,EC50,nM,,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,2005
Effective concentration against liver X receptor-alpha in HEK293 cell transactivation assay; Not tested,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,CHEMBL1145279,,,EC50,nM,,EC50,nM,,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,2005
Maximal induction of liver X receptor-alpha receptor in transactivation assay; Not tested,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,CHEMBL1145279,,,Activity,,,Activity,,,CC1OC(Oc2cc3c(cc2-c2cc4c(cc2O)[C@@]2(C)CCC[C@](C)(C(=O)O)[C@@H]2CC4)CC[C@H]2[C@@](C)(C(=O)O)CCC[C@]32C)C(O)C(O)C1O,2005
Inhibitory concentration in LXRSPA alpha binding assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1142856,=,=,IC50,nM,2.0,IC50,uM,0.002,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1142856,=,=,EC50,nM,2.0,EC50,uM,0.002,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1142856,=,=,EC50,nM,10.0,EC50,uM,0.01,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
TA max fold induction against LXR alpha,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1142856,=,=,Induction,,60.0,Induction,,60.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCCC(C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Inhibitory concentration in LXRSPA alpha binding assay,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,1.0,IC50,uM,0.001,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,1.0,EC50,uM,0.001,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,<,<,EC50,nM,3.0,EC50,uM,0.003,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,24.0,Induction,,24.0,CC1(C(=O)NC(=O)[C@@]2(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]23)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,2800.0,IC50,uM,2.8,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,>,>,EC50,nM,15000.0,EC50,uM,15.0,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,Induction,,,Induction,,,C[C@]1(C(=O)OCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,>,>,IC50,nM,15000.0,IC50,uM,15.0,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,>,>,EC50,nM,50000.0,EC50,uM,50.0,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,Induction,,,Induction,,,C=CCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,5060.0,IC50,uM,5.06,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,>,>,EC50,nM,50000.0,EC50,uM,50.0,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,Induction,,,Induction,,,C=CCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,3800.0,IC50,uM,3.8,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,>,>,EC50,nM,50000.0,EC50,uM,50.0,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,Induction,,,Induction,,,C=CCCCOC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,2930.0,IC50,uM,2.93,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,5200.0,EC50,uM,5.2,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Percent activation in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,40.0,Activation,%,40.0,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,10.5,Induction,,10.5,C[C@]1(C(=O)NCCc2ccccc2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,3100.0,IC50,uM,3.1,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,3100.0,EC50,uM,3.1,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,2.2,Induction,,2.2,C[C@]1(C(=O)NC2CC3CCC2C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,100.0,IC50,uM,0.1,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,230.0,EC50,uM,0.23,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,860.0,EC50,uM,0.86,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,22.6,Induction,,22.6,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,CHEMBL1142856,=,=,IC50,nM,90.0,IC50,uM,0.09,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,CHEMBL1142856,=,=,EC50,nM,140.0,EC50,uM,0.14,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,CHEMBL1142856,=,=,Activation,%,136.0,Activation,%,136.0,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,2005
TA max fold induction against LXR alpha,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,CHEMBL1142856,=,=,Induction,,29.5,Induction,,29.5,CC(NC(=O)[C@@]1(C)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12)C12CC3CC(CC(C3)C1)C2,2005
Inhibitory concentration in LXRSPA alpha binding assay,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,CHEMBL1142856,=,=,IC50,nM,350.0,IC50,uM,0.35,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,CHEMBL1142856,=,=,EC50,nM,240.0,EC50,uM,0.24,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,CHEMBL1142856,=,=,Activation,%,63.0,Activation,%,63.0,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,2005
TA max fold induction against LXR alpha,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,CHEMBL1142856,=,=,Induction,,11.7,Induction,,11.7,CC1(C)C2CCC(NC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(O)ccc5CC[C@@H]34)C1C2,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,CHEMBL1142856,=,=,IC50,nM,270.0,IC50,uM,0.27,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,CHEMBL1142856,=,=,EC50,nM,280.0,EC50,uM,0.28,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,CHEMBL1142856,=,=,EC50,nM,1700.0,EC50,uM,1.7,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,2005
TA max fold induction against LXR alpha,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,CHEMBL1142856,=,=,Induction,,12.7,Induction,,12.7,C[C@@H]1[C@H]2C[C@@H](C[C@H]1NC(=O)[C@@]1(C)CCC[C@]3(C)c4cc(O)ccc4CC[C@@H]13)C2(C)C,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,140.0,IC50,uM,0.14,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,220.0,EC50,uM,0.22,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Percent activation in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,130.0,Activation,%,130.0,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,41.2,Induction,,41.2,C[C@]1(C(=O)NC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,130.0,IC50,uM,0.13,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,320.0,EC50,uM,0.32,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,900.0,EC50,uM,0.9,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,2.6,Induction,,2.6,C[C@]1(C(=O)NC2C3CC4CC(C3)CC2C4)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,CHEMBL1142856,=,=,IC50,nM,30.0,IC50,uM,0.03,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,CHEMBL1142856,=,=,EC50,nM,760.0,EC50,uM,0.76,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,CHEMBL1142856,=,=,EC50,nM,830.0,EC50,uM,0.83,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,2005
TA max fold induction against LXR alpha,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,CHEMBL1142856,=,=,Induction,,14.3,Induction,,14.3,CCOC(=O)C12CC3CC(CC(NC(=O)[C@@]4(C)CCC[C@]5(C)c6cc(O)ccc6CC[C@@H]45)(C3)C1)C2,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,300.0,IC50,uM,0.3,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,320.0,EC50,uM,0.32,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,430.0,Activation,%,430.0,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,47.5,Induction,,47.5,C[C@]1(C(=O)N2C3CCCCC3C3CCCCC32)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,50.0,IC50,uM,0.05,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,50.0,EC50,uM,0.05,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,164.0,Activation,%,164.0,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,33.7,Induction,,33.7,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,170.0,EC50,uM,0.17,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,98.0,Activation,%,98.0,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,18.9,Induction,,18.9,C[C@]1(C(=O)NCC2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,CHEMBL1142856,=,=,IC50,nM,490.0,IC50,uM,0.49,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,CHEMBL1142856,=,=,EC50,nM,360.0,EC50,uM,0.36,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,CHEMBL1142856,=,=,Activation,%,42.0,Activation,%,42.0,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,2005
TA max fold induction against LXR alpha,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,CHEMBL1142856,=,=,Induction,,21.7,Induction,,21.7,CC(CNC(=O)[C@@]1(C)CCC[C@]2(C)c3ccccc3CC[C@@H]12)(c1ccccc1)c1ccccc1,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,200.0,IC50,uM,0.2,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,70.0,EC50,uM,0.07,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,92.0,Activation,%,92.0,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,22.8,Induction,,22.8,C[C@]1(C(=O)N2CCC(c3ccccc3)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,750.0,IC50,uM,0.75,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,430.0,EC50,uM,0.43,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,175.0,Activation,%,175.0,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,5.6,Induction,,5.6,C[C@]1(C(=O)N2CCC3(C=Cc4ccccc43)CC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,360.0,IC50,uM,0.36,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,150.0,EC50,uM,0.15,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,144.0,Activation,%,144.0,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,24.2,Induction,,24.2,C[C@]1(C(=O)N2CCCC(c3ccccc3)C2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,290.0,IC50,uM,0.29,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,1500.0,EC50,uM,1.5,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,20.0,Activation,%,20.0,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,5.1,Induction,,5.1,C[C@]1(C(=O)NC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,420.0,IC50,uM,0.42,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,EC50,nM,170.0,EC50,uM,0.17,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,,,EC50,nM,,EC50,uM,,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,,,Induction,,,Induction,,,C[C@]1(C(=O)NC(=O)C2(c3ccccc3)CCCCC2)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Inhibitory concentration in LXRSPA alpha binding assay,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,IC50,nM,1670.0,IC50,uM,1.67,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in recombinant human LXRalpha ligand binding domain in homogeneous time-resolved fluorescence assay ,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,>,>,EC50,nM,50000.0,EC50,uM,50.0,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Effective concentration in transactivation assay using a chimeric LXR construct in HEK293 cells for LXRalpha receptor,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Activation,%,62.0,Activation,%,62.0,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
TA max fold induction against LXR alpha,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,CHEMBL1142856,=,=,Induction,,5.4,Induction,,5.4,C[C@]1(C(=O)CC(=O)C23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3ccccc3CC[C@@H]12,2005
Activity against LXR alpha transiently transfected in HEK293 cells,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1146053,=,=,max activation,%,5.4,max activation,%,5.4,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(Cc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,3.7,max activation,%,3.7,CN(Cc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(Cc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,3000.0,EC50,uM,3.0,CN(Cc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1cccc(C(O)(C(F)(F)F)C(F)(F)F)c1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,4.0,max activation,%,4.0,CN(c1cccc(C(O)(C(F)(F)F)C(F)(F)F)c1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1cccc(C(O)(C(F)(F)F)C(F)(F)F)c1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,1000.0,EC50,uM,1.0,CN(c1cccc(C(O)(C(F)(F)F)C(F)(F)F)c1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,max activation,%,4.5,max activation,%,4.5,O=S(=O)(c1ccccc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,EC50,nM,100.0,EC50,uM,0.1,O=S(=O)(c1ccccc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,max activation,%,3.9,max activation,%,3.9,O=S(=O)(c1ccccc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,EC50,nM,30.0,EC50,uM,0.03,O=S(=O)(c1ccccc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,max activation,%,3.8,max activation,%,3.8,O=S(=O)(c1ccccc1)N1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,EC50,nM,50.0,EC50,uM,0.05,O=S(=O)(c1ccccc1)N1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C1CCCC1,CHEMBL1146053,=,=,max activation,%,4.8,max activation,%,4.8,O=S(=O)(c1ccccc1)N(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C1CCCC1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C1CCCC1,CHEMBL1146053,=,=,EC50,nM,8.0,EC50,uM,0.008,O=S(=O)(c1ccccc1)N(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C1CCCC1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,max activation,%,6.1,max activation,%,6.1,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,EC50,nM,10.0,EC50,uM,0.01,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,CHEMBL1146053,=,=,max activation,%,4.3,max activation,%,4.3,O=S(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,4000.0,EC50,uM,4.0,O=S(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,CHEMBL1146053,>,>,EC50,nM,5000.0,EC50,uM,5.0,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,5.2,max activation,%,5.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,200.0,EC50,uM,0.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,EC50,nM,10.0,EC50,uM,0.01,O=S(=O)(c1ccccc1)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,O=S(=O)(c1ccccc1)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL1146053,=,=,max activation,%,4.2,max activation,%,4.2,O=S(=O)(c1ccccc1)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,0.0,max activation,%,0.0,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1146053,=,=,EC50,nM,500.0,EC50,uM,0.5,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(C(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,CHEMBL1146053,=,=,max activation,%,4.0,max activation,%,4.0,CN(C(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(C(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,200.0,EC50,uM,0.2,CN(C(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccccc1)S(=O)(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,max activation,%,5.3,max activation,%,5.3,CN(c1ccccc1)S(=O)(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccccc1)S(=O)(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,EC50,nM,100.0,EC50,uM,0.1,CN(c1ccccc1)S(=O)(=O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CC(C)COC(=O)N(C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,max activation,%,5.1,max activation,%,5.1,CC(C)COC(=O)N(C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CC(C)COC(=O)N(C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,EC50,nM,100.0,EC50,uM,0.1,CC(C)COC(=O)N(C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,max activation,%,3.9,max activation,%,3.9,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1146053,=,=,EC50,nM,100.0,EC50,uM,0.1,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CC(C)CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,CHEMBL1146053,=,=,max activation,%,6.1,max activation,%,6.1,CC(C)CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CC(C)CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,CHEMBL1146053,=,=,EC50,nM,40.0,EC50,uM,0.04,CC(C)CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,CHEMBL1146053,=,=,max activation,%,6.3,max activation,%,6.3,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,CHEMBL1146053,=,=,EC50,nM,600.0,EC50,uM,0.6,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccs1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(-c2ccccc2)c1,CHEMBL1146053,=,=,max activation,%,5.2,max activation,%,5.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(-c2ccccc2)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(-c2ccccc2)c1,CHEMBL1146053,=,=,EC50,nM,30.0,EC50,uM,0.03,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(-c2ccccc2)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(S(N)(=O)=O)c1,CHEMBL1146053,=,=,max activation,%,4.9,max activation,%,4.9,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(S(N)(=O)=O)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(S(N)(=O)=O)c1,CHEMBL1146053,=,=,EC50,nM,80.0,EC50,uM,0.08,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(S(N)(=O)=O)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccc(C#N)cc1,CHEMBL1146053,=,=,max activation,%,4.4,max activation,%,4.4,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccc(C#N)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccc(C#N)cc1,CHEMBL1146053,=,=,EC50,nM,2000.0,EC50,uM,2.0,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccc(C#N)cc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(C#N)c1,CHEMBL1146053,=,=,max activation,%,6.2,max activation,%,6.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(C#N)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(C#N)c1,CHEMBL1146053,=,=,EC50,nM,20.0,EC50,uM,0.02,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1cccc(C#N)c1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1C#N,CHEMBL1146053,=,=,max activation,%,6.2,max activation,%,6.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1C#N,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1C#N,CHEMBL1146053,=,=,EC50,nM,700.0,EC50,uM,0.7,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1C#N,2006
Activity against LXR alpha transiently transfected in HEK293 cells,COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1146053,=,=,max activation,%,4.5,max activation,%,4.5,COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,2006
Activity against LXR alpha transiently transfected in HEK293 cells,COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1146053,=,=,EC50,nM,1000.0,EC50,uM,1.0,COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(C)(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,5.1,max activation,%,5.1,CN(c1ccc(C(C)(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(C)(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,5000.0,EC50,uM,5.0,CN(c1ccc(C(C)(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,0.0,max activation,%,0.0,CN(c1ccc(C(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,>,>,EC50,nM,5000.0,EC50,uM,5.0,CN(c1ccc(C(O)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,max activation,%,5.3,max activation,%,5.3,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Activity against LXR alpha transiently transfected in HEK293 cells,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL1146053,=,=,EC50,nM,200.0,EC50,uM,0.2,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2006
Inhibition of LXR alpha,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,32.0,IC50,nM,32.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,26.0,IC50,nM,26.0,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2cnc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,90.0,IC50,nM,90.0,CCCc1c(OCCCN(C)c2cnc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)s2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,67.0,IC50,nM,67.0,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)s2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,105.0,IC50,nM,105.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C(F)(F)F)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,60.0,IC50,nM,60.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C(F)(F)F)c2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(Cl)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,12.0,IC50,nM,12.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(Cl)c2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,117.0,IC50,nM,117.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C)c2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2C)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,580.0,IC50,nM,580.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2C)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2ccc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,72.0,IC50,nM,72.0,CCCc1c(OCCCn2ccc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2ccc3cc(CCC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,18.0,IC50,nM,18.0,CCCc1c(OCCCn2ccc3cc(CCC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN2C(=O)Cc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,97.0,IC50,nM,97.0,CCCc1c(OCCCN2C(=O)Cc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN2C(=O)Cc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,19.0,IC50,nM,19.0,CCCc1c(OCCCN2C(=O)Cc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2nnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,410.0,IC50,nM,410.0,CCCc1c(OCCCn2nnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2ncc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,73.0,IC50,nM,73.0,CCCc1c(OCCCn2ncc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2cnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,180.0,IC50,nM,180.0,CCCc1c(OCCCn2cnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCn2ccc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,16.0,IC50,nM,16.0,CCCc1c(OCCCn2ccc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(C(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,79.0,IC50,nM,79.0,CCCc1c(OCCCN(C)c2ccc(C(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccccc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,372.0,IC50,nM,372.0,CCCc1c(OCCCN(C)c2ccccc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2cccc(CC(=O)O)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,102.0,IC50,nM,102.0,CCCc1c(OCCCN(C)c2cccc(CC(=O)O)c2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C(C)=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,6400.0,IC50,nM,6400.0,CCCc1c(OCCCN(C(C)=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,6400.0,IC50,nM,6400.0,CCCc1c(OCCCN(C=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(CC)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,110.0,IC50,nM,110.0,CCCc1c(OCCCN(CC)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCNc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,68.0,IC50,nM,68.0,CCCc1c(OCCCNc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,18.0,IC50,nM,18.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,630.0,IC50,nM,630.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCCc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,530.0,IC50,nM,530.0,CCCc1c(OCCCCc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,730.0,IC50,nM,730.0,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Inhibition of LXR alpha,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,IC50,nM,39.0,IC50,nM,39.0,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,5900.0,EC50,nM,5900.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,620.0,EC50,nM,620.0,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2cnc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,540.0,EC50,nM,540.0,CCCc1c(OCCCN(C)c2cnc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)s2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,1100.0,EC50,nM,1100.0,CCCc1c(OCCCN(C)c2ncc(CC(=O)O)s2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,5000.0,EC50,nM,5000.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cn2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C(F)(F)F)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,3600.0,EC50,nM,3600.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C(F)(F)F)c2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(Cl)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,170.0,EC50,nM,170.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(Cl)c2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,1300.0,EC50,nM,1300.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)c(C)c2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCn2ccc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,1900.0,EC50,nM,1900.0,CCCc1c(OCCCn2ccc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCn2ccc3cc(CCC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,820.0,EC50,nM,820.0,CCCc1c(OCCCn2ccc3cc(CCC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN2C(=O)Cc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,3000.0,EC50,nM,3000.0,CCCc1c(OCCCN2C(=O)Cc3cc(C(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN2C(=O)Cc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,180.0,EC50,nM,180.0,CCCc1c(OCCCN2C(=O)Cc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCn2nnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,2300.0,EC50,nM,2300.0,CCCc1c(OCCCn2nnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCn2ncc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,480.0,EC50,nM,480.0,CCCc1c(OCCCn2ncc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCn2ccc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,590.0,EC50,nM,590.0,CCCc1c(OCCCn2ccc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCNc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,8000.0,EC50,nM,8000.0,CCCc1c(OCCCNc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,450.0,EC50,nM,450.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 10 uM,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,50.0,Activity,%,50.0,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 10 uM,CCCc1c(OCCCn2cnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,50.0,Activity,%,50.0,CCCc1c(OCCCn2cnc3cc(CC(=O)O)ccc32)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 10 uM,CCCc1c(OCCCN(CC)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,50.0,Activity,%,50.0,CCCc1c(OCCCN(CC)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 10 uM,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,50.0,Activity,%,50.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 10 uM,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,50.0,Activity,%,50.0,CCCc1c(OCCCOc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 15 uM,CCCc1c(OCCCCc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,10.0,Activity,%,10.0,CCCc1c(OCCCCc2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 15 uM,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2C)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,10.0,Activity,%,10.0,CCCc1c(OCCCN(C)c2ccc(CC(=O)O)cc2C)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 15 uM,CCCc1c(OCCCN(C)c2ccccc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,10.0,Activity,%,10.0,CCCc1c(OCCCN(C)c2ccccc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 15 uM,CCCc1c(OCCCN(C(C)=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,10.0,Activity,%,10.0,CCCc1c(OCCCN(C(C)=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells at 15 uM,CCCc1c(OCCCN(C=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,<,<,Activity,%,10.0,Activity,%,10.0,CCCc1c(OCCCN(C=O)c2ccc(CC(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2cccc(CC(=O)O)c2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,2600.0,EC50,nM,2600.0,CCCc1c(OCCCN(C)c2cccc(CC(=O)O)c2)ccc2c(C(F)(F)F)noc12,2006
Activity at LXR alpha as beta-lactamase transactivation in CHO cells,CCCc1c(OCCCN(C)c2ccc(C(=O)O)cc2)ccc2c(C(F)(F)F)noc12,CHEMBL1148661,=,=,EC50,nM,6000.0,EC50,nM,6000.0,CCCc1c(OCCCN(C)c2ccc(C(=O)O)cc2)ccc2c(C(F)(F)F)noc12,2006
Activity at human recombinant LXRalpha by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells at 10 uM,CCC(CC)(c1ccc(OCC(=O)O)c(C)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C(C)C)c(C)c1,CHEMBL1148498,,,Activity,,,Activity,,,CCC(CC)(c1ccc(OCC(=O)O)c(C)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C(C)C)c(C)c1,2006
Activity at human recombinant LXRalpha by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells at 10 uM,CCC(Oc1ccc(C2(c3ccc(OC(CC)C(=O)O)c(C)c3)CCCCC2)cc1C)C(=O)O,CHEMBL1148498,,,Activity,,,Activity,,,CCC(Oc1ccc(C2(c3ccc(OC(CC)C(=O)O)c(C)c3)CCCCC2)cc1C)C(=O)O,2006
Activity at human recombinant LXRalpha by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells at 10 uM,CCC(Oc1ccc(C(CC)(CC)c2ccc(OC(CC)C(=O)O)c(C)c2)cc1C)C(=O)O,CHEMBL1148498,,,Activity,,,Activity,,,CCC(Oc1ccc(C(CC)(CC)c2ccc(OC(CC)C(=O)O)c(C)c2)cc1C)C(=O)O,2006
Binding affinity to LXRalpha by radioligand displacement assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,30.0,IC50,uM,0.03,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,60.0,IC50,uM,0.06,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,100.0,IC50,uM,0.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,100.0,IC50,uM,0.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,100.0,IC50,uM,0.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,200.0,IC50,uM,0.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,60.0,IC50,uM,0.06,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,900.0,IC50,uM,0.9,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,18000.0,IC50,uM,18.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,61000.0,IC50,uM,61.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,12000.0,IC50,uM,12.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,600.0,IC50,uM,0.6,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,200.0,IC50,uM,0.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,400.0,IC50,uM,0.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,500.0,IC50,uM,0.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,1300.0,IC50,uM,1.3,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,200.0,IC50,uM,0.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,1100.0,IC50,uM,1.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,500.0,IC50,uM,0.5,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,60.0,IC50,uM,0.06,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,50.0,IC50,uM,0.05,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,200.0,IC50,uM,0.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,60.0,IC50,uM,0.06,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,50.0,IC50,uM,0.05,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,50.0,IC50,uM,0.05,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,5400.0,IC50,uM,5.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,2200.0,IC50,uM,2.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,13800.0,IC50,uM,13.8,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,11200.0,IC50,uM,11.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,5200.0,IC50,uM,5.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,IC50,nM,700.0,IC50,uM,0.7,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,13.0,IC50,uM,0.013,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,IC50,nM,6.0,IC50,uM,0.006,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,6.0,IC50,uM,0.006,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,30.0,IC50,uM,0.03,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,IC50,nM,2.0,IC50,uM,0.002,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,5.0,IC50,uM,0.005,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,IC50,nM,6.0,IC50,uM,0.006,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,120.0,IC50,uM,0.12,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,1700.0,IC50,uM,1.7,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,2700.0,IC50,uM,2.7,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,1500.0,IC50,uM,1.5,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,IC50,nM,20.0,IC50,uM,0.02,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,600.0,IC50,uM,0.6,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,IC50,nM,3.0,IC50,uM,0.003,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Binding affinity to LXRalpha by radioligand displacement assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,IC50,nM,50.0,IC50,uM,0.05,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Binding affinity to LXRalpha by radioligand displacement assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,IC50,nM,1.0,IC50,uM,0.001,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,2006
Binding affinity to LXRalpha by radioligand displacement assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,IC50,nM,70.0,IC50,uM,0.07,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,1000.0,EC50,uM,1.0,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,250.0,EC50,uM,0.25,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,4500.0,EC50,uM,4.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,5500.0,EC50,uM,5.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,3700.0,EC50,uM,3.7,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,1400.0,EC50,uM,1.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,1100.0,EC50,uM,1.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,700.0,EC50,uM,0.7,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,800.0,EC50,uM,0.8,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,CHEMBL1149525,>,>,EC50,nM,40000.0,EC50,uM,40.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,10000.0,EC50,uM,10.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,CHEMBL1149525,>,>,EC50,nM,40000.0,EC50,uM,40.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,1900.0,EC50,uM,1.9,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,900.0,EC50,uM,0.9,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,500.0,EC50,uM,0.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,1500.0,EC50,uM,1.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,400.0,EC50,uM,0.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,1900.0,EC50,uM,1.9,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,90.0,EC50,uM,0.09,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,200.0,EC50,uM,0.2,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,400.0,EC50,uM,0.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,500.0,EC50,uM,0.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,300.0,EC50,uM,0.3,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,100.0,EC50,uM,0.1,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,8500.0,EC50,uM,8.5,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,9300.0,EC50,uM,9.3,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,10900.0,EC50,uM,10.9,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,9400.0,EC50,uM,9.4,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,EC50,nM,2300.0,EC50,uM,2.3,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,700.0,EC50,uM,0.7,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,EC50,nM,100.0,EC50,uM,0.1,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,200.0,EC50,uM,0.2,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,1000.0,EC50,uM,1.0,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,EC50,nM,300.0,EC50,uM,0.3,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,200.0,EC50,uM,0.2,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,EC50,nM,800.0,EC50,uM,0.8,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,1000.0,EC50,uM,1.0,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,2100.0,EC50,uM,2.1,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,4300.0,EC50,uM,4.3,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,700.0,EC50,uM,0.7,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,EC50,nM,500.0,EC50,uM,0.5,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,3300.0,EC50,uM,3.3,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,EC50,nM,200.0,EC50,uM,0.2,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha by luciferase reporter gene assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,EC50,nM,1100.0,EC50,uM,1.1,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha by luciferase reporter gene assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,EC50,nM,100.0,EC50,uM,0.1,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,2006
Transactivation of LXRalpha by luciferase reporter gene assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,EC50,nM,900.0,EC50,uM,0.9,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,72.0,Activity,%,72.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,65.0,Activity,%,65.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,61.0,Activity,%,61.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)O)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,43.0,Activity,%,43.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CCC(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,65.0,Activity,%,65.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(CC(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,94.0,Activity,%,94.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(COc1ccc(C(=O)OC)cc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,Activity,%,87.0,Activity,%,87.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,CHEMBL1149525,=,=,Activity,%,10.0,Activity,%,10.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)O)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,CHEMBL1149525,,,Activity,,,Activity,,,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCCO)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,54.0,Activity,%,54.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,55.0,Activity,%,55.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCc1ccccc1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,111.0,Activity,%,111.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,CHEMBL1149525,=,=,Activity,%,73.0,Activity,%,73.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@H](CO)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,CHEMBL1149525,=,=,Activity,%,65.0,Activity,%,65.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)[C@@H](CO)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,CHEMBL1149525,=,=,Activity,%,75.0,Activity,%,75.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CO)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,CHEMBL1149525,=,=,Activity,%,87.0,Activity,%,87.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CO)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,63.0,Activity,%,63.0,CCN(CC(O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,116.0,Activity,%,116.0,COC(=O)C1(c2ccccc2)CCCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,92.0,Activity,%,92.0,COC(=O)C1(c2ccccc2)CCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,Activity,%,67.0,Activity,%,67.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,99.0,Activity,%,99.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl)C(CC)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,94.0,Activity,%,94.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(CC)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,81.0,Activity,%,81.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C)(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,47.0,Activity,%,47.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCOCC1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,CHEMBL1149525,=,=,Activity,%,49.0,Activity,%,49.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N1CCCCC1)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,CHEMBL1149525,=,=,Activity,%,18.0,Activity,%,18.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)N(C)C)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,24.0,Activity,%,24.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)NC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,CHEMBL1149525,=,=,Activity,%,77.0,Activity,%,77.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)O)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,CHEMBL1149525,=,=,Activity,%,33.0,Activity,%,33.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(C(=O)OC)c1ccccc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,130.0,Activity,%,130.0,Cc1oc(-c2cccc(C(F)(F)F)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,Activity,%,130.0,Activity,%,130.0,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,96.0,Activity,%,96.0,CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,117.0,Activity,%,117.0,Cc1oc(-c2cccc(Cl)c2)nc1CN(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,Activity,%,78.0,Activity,%,78.0,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,90.0,Activity,%,90.0,CCN(Cc1nc(-c2cccc(Cl)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,Activity,%,78.0,Activity,%,78.0,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,80.0,Activity,%,80.0,CCN(CCc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,108.0,Activity,%,108.0,CCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,88.0,Activity,%,88.0,CCN(Cc1cccnc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,70.0,Activity,%,70.0,CCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,Activity,%,122.0,Activity,%,122.0,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,132.0,Activity,%,132.0,CCN(Cc1cscn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,CHEMBL1149525,=,=,Activity,%,88.0,Activity,%,88.0,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1Cl,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149525,=,=,Activity,%,100.0,Activity,%,100.0,CCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,Activity,%,89.0,Activity,%,89.0,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)c(Cl)c1)(C(F)(F)F)C(F)(F)F,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1149525,=,=,Activity,%,87.0,Activity,%,87.0,OC(c1ccc(N(Cc2ccccc2)CC(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F,2006
Transactivation of LXRalpha relative to T0901317 by luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,CHEMBL1149525,,,Activity,,,Activity,,,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)C(COCC(=O)NC)c1ccccc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1137409,=,=,IC50,nM,100.0,IC50,nM,100.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,CN(Cc1ccc(CC(=O)O)cc1)c1cccc(-c2c(Cc3ccccc3)cnc3c(C(F)(F)F)cccc23)c1,CHEMBL1137409,=,=,IC50,nM,274.0,IC50,nM,274.0,CN(Cc1ccc(CC(=O)O)cc1)c1cccc(-c2c(Cc3ccccc3)cnc3c(C(F)(F)F)cccc23)c1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,IC50,nM,47.0,IC50,nM,47.0,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,IC50,nM,7.6,IC50,nM,7.6,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,IC50,nM,9.5,IC50,nM,9.5,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)Cc1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,IC50,nM,16.5,IC50,nM,16.5,O=C(O)Cc1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)c1ccc(COc2ccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)cc2)cc1,CHEMBL1137409,=,=,IC50,nM,723.0,IC50,nM,723.0,O=C(O)c1ccc(COc2ccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)cc2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)c1cccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1137409,=,=,IC50,nM,1871.0,IC50,nM,1871.0,O=C(O)c1cccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,COC(=O)c1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(O)c1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,IC50,nM,130.0,IC50,nM,130.0,O=C(O)c1ccc(COc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1ccccc1,CHEMBL1137409,=,=,IC50,nM,260.0,IC50,nM,260.0,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1ccccc1,2006
Displacement of [3H]T-0901317 from human LXR alpha receptor,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1137409,=,=,IC50,nM,10.0,IC50,nM,10.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2006
Agonist activity at human LXR alpha expressed in Huh7 cells by GAL4 transactivation assay,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,EC50,nM,240.0,EC50,nM,240.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Agonist activity at human LXR alpha expressed in Huh7 cells by GAL4 transactivation assay relative to TO901317,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,Efficacy,%,90.0,Efficacy,%,90.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Agonist activity at human LXR alpha expressed in Huh7 cells by GAL4 transactivation assay,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,EC50,nM,160.0,EC50,nM,160.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Agonist activity at human LXR alpha expressed in Huh7 cells by GAL4 transactivation assay relative to TO901317,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1137409,=,=,Efficacy,%,82.0,Efficacy,%,82.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2006
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,7.6,IC50,nM,7.6,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,5.0,IC50,nM,5.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,9.0,IC50,nM,9.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4ccccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,650.0,IC50,nM,650.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4ccccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,104.0,IC50,nM,104.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,CHEMBL1143039,=,=,IC50,nM,21.0,IC50,nM,21.0,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(C(=O)c3ccccc3)cnc12,CHEMBL1143039,=,=,IC50,nM,18.0,IC50,nM,18.0,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(C(=O)c3ccccc3)cnc12,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,NC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,CHEMBL1143039,>,>,IC50,nM,10000.0,IC50,nM,10000.0,NC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,N#Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,CHEMBL1143039,=,=,IC50,nM,150.0,IC50,nM,150.0,N#Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,384.0,IC50,nM,384.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,CHEMBL1143039,=,=,IC50,nM,16.0,IC50,nM,16.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CC(=O)O)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,7.0,IC50,nM,7.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C1NC(=S)S/C1=C/c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,479.0,IC50,nM,479.0,O=C1NC(=S)S/C1=C/c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C1NC(=O)/C(=C/c2ccc(CNc3cccc(-c4c(C(=O)c5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cc2)S1,CHEMBL1143039,=,=,IC50,nM,456.0,IC50,nM,456.0,O=C1NC(=O)/C(=C/c2ccc(CNc3cccc(-c4c(C(=O)c5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cc2)S1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CO)cc2)c1,CHEMBL1143039,=,=,IC50,nM,90.5,IC50,nM,90.5,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CO)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccccc2)c1,CHEMBL1143039,=,=,IC50,nM,241.0,IC50,nM,241.0,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccccc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CCO)cc2)c1,CHEMBL1143039,=,=,IC50,nM,34.0,IC50,nM,34.0,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(CCO)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,NC(=O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,11.0,IC50,nM,11.0,NC(=O)Cc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(F)(F)C(=O)O)cc2)c1,CHEMBL1143039,=,=,IC50,nM,30.2,IC50,nM,30.2,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(F)(F)C(=O)O)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(O)C(=O)O)cc2)c1,CHEMBL1143039,=,=,IC50,nM,33.6,IC50,nM,33.6,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(NCc2ccc(C(O)C(=O)O)cc2)c1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,CC(C)(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,17.2,IC50,nM,17.2,CC(C)(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,CC(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,15.2,IC50,nM,15.2,CC(C(=O)O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,420.0,IC50,nM,420.0,O=C(O)c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)/C=C/c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,>,>,IC50,nM,10000.0,IC50,nM,10000.0,O=C(O)/C=C/c1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)COc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1143039,=,=,IC50,nM,63.9,IC50,nM,63.9,O=C(O)COc1ccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from human recombinant LXRalpha expressed in CHO cells,O=C(O)Cc1cccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1143039,=,=,IC50,nM,33.6,IC50,nM,33.6,O=C(O)Cc1cccc(CNc2cccc(-c3c(C(=O)c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2007
Agonist activity at human recombinant LXRalpha expressed in Huh7 cells by GAL4 transactivation assay,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,CHEMBL1143039,=,=,EC50,nM,467.0,EC50,nM,467.0,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,2007
Agonist activity at human recombinant LXRalpha expressed in Huh7 cells by GAL4 transactivation assay relative to TO901317,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,CHEMBL1143039,=,=,Activity,%,101.0,Activity,%,101.0,Cc1cccc2c(-c3cccc(NCc4ccc(CC(=O)O)cc4)c3)c(Cc3ccccc3)cnc12,2007
Agonist activity at human recombinant LXRalpha expressed in Huh7 cells by GAL4 transactivation assay,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,CHEMBL1143039,=,=,EC50,nM,121.0,EC50,nM,121.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,2007
Agonist activity at human recombinant LXRalpha expressed in Huh7 cells by GAL4 transactivation assay relative to TO901317,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,CHEMBL1143039,=,=,Activity,%,89.0,Activity,%,89.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)cc1,2007
Displacement of [3H]T-0901317 from GAL-linked human LXRalpha expressed in THP1 cells at 20 uM by SPA relative to GW-3965,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1148736,=,=,Efficacy,%,100.0,Efficacy,%,100.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Displacement of [3H]T-0901317 from GAL-linked human LXRalpha expressed in THP1 cells at 20 uM by SPA relative to GW-3965,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Displacement of [3H]T-0901317 from GAL-linked human LXRalpha expressed in THP1 cells at 20 uM by SPA relative to GW-3965,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,80.0,Efficacy,%,80.0,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1148736,=,=,Efficacy,%,100.0,Efficacy,%,100.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,64.0,Efficacy,%,64.0,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,42.0,Efficacy,%,42.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1148736,=,=,EC50,nM,66.0,EC50,uM,0.066,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Activity at human LXRalpha by Gal4 transactivation assay relative to GW-3965,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1148736,=,=,Efficacy,%,100.0,Efficacy,%,100.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)c(OC)c2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,64.0,Efficacy,%,64.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)c(OC)c2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,346.0,EC50,uM,0.346,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,608.0,EC50,uM,0.608,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay relative to GW-3965,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc([C@@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay relative to GW-3965,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,41.0,Efficacy,%,41.0,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Activity at human LXRalpha by Gal4 transactivation assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,19.0,Efficacy,%,19.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)c(OC)c2F)c1OC,CHEMBL1148736,=,=,EC50,nM,700.0,EC50,uM,0.7,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)c(OC)c2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1148736,=,=,EC50,nM,97.0,EC50,uM,0.097,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,2300.0,EC50,uM,2.3,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,1600.0,EC50,uM,1.6,COc1cccc([C@H]2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(Br)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,43.0,Efficacy,%,43.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(Br)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(Br)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,900.0,EC50,uM,0.9,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(Br)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cc(F)c(C(=O)N2N=C(c3ccc(F)cc3)SC2c2cccc(OC)c2OC)c(F)c1,CHEMBL1148736,=,=,Efficacy,%,47.0,Efficacy,%,47.0,COc1cc(F)c(C(=O)N2N=C(c3ccc(F)cc3)SC2c2cccc(OC)c2OC)c(F)c1,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cc(F)c(C(=O)N2N=C(c3ccc(F)cc3)SC2c2cccc(OC)c2OC)c(F)c1,CHEMBL1148736,=,=,EC50,nM,900.0,EC50,uM,0.9,COc1cc(F)c(C(=O)N2N=C(c3ccc(F)cc3)SC2c2cccc(OC)c2OC)c(F)c1,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)ccc2C)c1OC,CHEMBL1148736,=,=,Efficacy,%,46.0,Efficacy,%,46.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)ccc2C)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)ccc2C)c1OC,CHEMBL1148736,=,=,EC50,nM,2400.0,EC50,uM,2.4,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)ccc2C)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)cc(F)c2)c1OC,CHEMBL1148736,=,=,Efficacy,%,40.0,Efficacy,%,40.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)cc(F)c2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)c(F)c3)=NN2C(=O)c2cccc(F)c2)c1OC,CHEMBL1148736,=,=,Efficacy,%,30.0,Efficacy,%,30.0,COc1cccc(C2SC(c3ccc(F)c(F)c3)=NN2C(=O)c2cccc(F)c2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)cc(F)c2)c1OC,CHEMBL1148736,=,=,EC50,nM,2100.0,EC50,uM,2.1,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)cc(F)c2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)c(F)c3)=NN2C(=O)c2cccc(F)c2)c1OC,CHEMBL1148736,=,=,EC50,nM,1500.0,EC50,uM,1.5,COc1cccc(C2SC(c3ccc(F)c(F)c3)=NN2C(=O)c2cccc(F)c2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cc(F)ccc1C1SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,CHEMBL1148736,=,=,Efficacy,%,92.0,Efficacy,%,92.0,COc1cc(F)ccc1C1SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,50.0,Efficacy,%,50.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1cccc2c1OC(F)(F)O2,CHEMBL1148736,=,=,Efficacy,%,71.0,Efficacy,%,71.0,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1cccc2c1OC(F)(F)O2,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(F)cc2)SC1c1ccccc1OC(F)F,CHEMBL1148736,=,=,Efficacy,%,76.0,Efficacy,%,76.0,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(F)cc2)SC1c1ccccc1OC(F)F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,6700.0,EC50,uM,6.7,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1ccccc1C1SC(c2ccc(Cl)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,CHEMBL1148736,=,=,Efficacy,%,80.0,Efficacy,%,80.0,COc1ccccc1C1SC(c2ccc(Cl)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(C)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,52.0,Efficacy,%,52.0,COc1cccc(C2SC(c3ccc(C)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,62.0,Efficacy,%,62.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1cccc2c1OC(F)(F)O2,CHEMBL1148736,=,=,EC50,nM,3900.0,EC50,uM,3.9,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1cccc2c1OC(F)(F)O2,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(F)cc2)SC1c1ccccc1OC(F)F,CHEMBL1148736,=,=,EC50,nM,1900.0,EC50,uM,1.9,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(F)cc2)SC1c1ccccc1OC(F)F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cc(F)ccc1C1SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,CHEMBL1148736,=,=,EC50,nM,70.0,EC50,uM,0.07,COc1cc(F)ccc1C1SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1ccccc1C1SC(c2ccc(Cl)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,CHEMBL1148736,=,=,EC50,nM,180.0,EC50,uM,0.18,COc1ccccc1C1SC(c2ccc(Cl)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)c(Cl)c3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(Cl)c(Cl)c3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cccc(Cl)c2)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cccc(Cl)c2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(C)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,1400.0,EC50,uM,1.4,COc1cccc(C2SC(c3ccc(C)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)cc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2cc(F)c(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,EC50,nM,1400.0,EC50,uM,1.4,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)ccc(F)c2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(F)cc3)=NN2C(=O)c2c(F)ccc(F)c2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccccc2F)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccccc2F)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccccc2)c1OC,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2ccccc2)c1OC,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1ccccc1C1(C)SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1ccccc1C1(C)SC(c2ccc(F)cc2)=NN1C(=O)c1c(F)cc(F)cc1F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1ccccc1OC(F)(F)F,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,O=C(c1c(F)cc(F)cc1F)N1N=C(c2ccc(Cl)cc2)SC1c1ccccc1OC(F)(F)F,2007
Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1,CHEMBL1148736,<,<,Efficacy,%,15.0,Efficacy,%,15.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1,2007
Displacement of [3H]T-0901317 from GAL-linked human LXRalpha expressed in THP1 cells at 20 uM by SPA relative to GW-3965,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,CHEMBL1148736,=,=,Efficacy,%,52.0,Efficacy,%,52.0,COc1cccc(C2SC(c3ccc(Cl)cc3)=NN2C(=O)c2c(F)cc(F)cc2F)c1OC,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccccc2)C3)cc2ccccc21,CHEMBL1149572,=,=,EC50,nM,1500.0,EC50,uM,1.5,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccccc2)C3)cc2ccccc21,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,N#CCCc1ccc(-c2cc3ccccc3n2C(=O)c2ccccc2)cc1,CHEMBL1149572,=,=,EC50,nM,220.0,EC50,uM,0.22,N#CCCc1ccc(-c2cc3ccccc3n2C(=O)c2ccccc2)cc1,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc(CCC(N)=O)cc2)cc2ccccc21,CHEMBL1149572,=,=,EC50,nM,1110.0,EC50,uM,1.11,CC(C)(C)OC(=O)n1c(-c2ccc(CCC(N)=O)cc2)cc2ccccc21,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc(CCC(=O)O)cc2)cc2ccccc21,CHEMBL1149572,=,=,EC50,nM,1150.0,EC50,uM,1.15,CC(C)(C)OC(=O)n1c(-c2ccc(CCC(=O)O)cc2)cc2ccccc21,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc(CCC#N)cc2)cc2ccccc21,CHEMBL1149572,=,=,EC50,nM,1190.0,EC50,uM,1.19,CC(C)(C)OC(=O)n1c(-c2ccc(CCC#N)cc2)cc2ccccc21,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1149572,=,=,EC50,nM,40.0,EC50,uM,0.04,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2007
Agonist activity at human LXRalpha receptor after 1 hr by HTRF cofactor recruitment assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1149572,=,=,EC50,nM,367.0,EC50,uM,0.367,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccccc2)C3)cc2ccccc21,CHEMBL1139922,=,=,EC50,nM,1500.0,EC50,uM,1.5,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccccc2)C3)cc2ccccc21,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1139922,=,=,EC50,nM,40.0,EC50,uM,0.04,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1139922,=,=,EC50,nM,367.0,EC50,uM,0.367,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccc(-c4ccon4)s2)C3)cc2ccccc21,CHEMBL1139922,>,>,EC50,nM,30000.0,EC50,uM,30.0,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccc(-c4ccon4)s2)C3)cc2ccccc21,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2cccs2)C3)cc2ccccc21,CHEMBL1139922,=,=,EC50,nM,540.0,EC50,uM,0.54,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2cccs2)C3)cc2ccccc21,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2c(F)cccc2F)C3)cc2ccccc21,CHEMBL1139922,=,=,EC50,nM,570.0,EC50,uM,0.57,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2c(F)cccc2F)C3)cc2ccccc21,2007
Agonist activity at LXRalpha LBD by HTRF cofactor peptide recruitment assay,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccc(F)cc2)C3)cc2ccccc21,CHEMBL1139922,=,=,EC50,nM,4300.0,EC50,uM,4.3,CC(C)(C)OC(=O)n1c(-c2ccc3c(c2)CC(NS(=O)(=O)c2ccc(F)cc2)C3)cc2ccccc21,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCCCCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCCCCCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1Cc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,60.0,Inhibition,%,60.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1Cc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2cc(Cl)c(Cl)cc2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,50.0,Inhibition,%,50.0,O=C1c2cc(Cl)c(Cl)cc2C(=O)N1CCCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2ccc(Cl)cc2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,66.0,Inhibition,%,66.0,O=C1c2ccc(Cl)cc2C(=O)N1CCCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,CC(C)c1cccc(C(C)C)c1N1C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C1=O,CHEMBL1139976,=,=,Inhibition,%,61.0,Inhibition,%,61.0,CC(C)c1cccc(C(C)C)c1N1C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C1=O,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,CHEMBL1139976,=,=,Inhibition,%,94.0,Inhibition,%,94.0,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,42.0,Inhibition,%,42.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,53.0,Inhibition,%,53.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,59.0,Inhibition,%,59.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation at 100 uM by luciferase assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCc1ccccc1,CHEMBL1139976,=,=,Inhibition,%,38.0,Inhibition,%,38.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCc1ccccc1,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation by luciferase assay,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL1139976,=,=,IC50,nM,13000.0,IC50,uM,13.0,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,2007
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activation by luciferase assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1139976,=,=,IC50,nM,9800.0,IC50,uM,9.8,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2cc(Cl)c(Cl)cc2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2cc(Cl)c(Cl)cc2C(=O)N1CCCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2ccc(Cl)cc2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2ccc(Cl)cc2C(=O)N1CCCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL1139976,,,Activity,,,Activity,,,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,CC(C)c1cccc(C(C)C)c1N1C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C1=O,CHEMBL1139976,,,Activity,,,Activity,,,CC(C)c1cccc(C(C)C)c1N1C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2C1=O,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,CHEMBL1139976,,,Activity,,,Activity,,,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCCCCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCCCCCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1CCc1ccccc1,2007
Agonist activity at human recombinant LXRalpha expressed in HEK293 cells,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1Cc1ccccc1,CHEMBL1139976,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1Cc1ccccc1,2007
Binding affinity at human LXRalpha,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140778,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Binding affinity at human LXRalpha,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,IC50,nM,745.0,IC50,nM,745.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Binding affinity at human LXRalpha,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,CHEMBL1140778,=,=,IC50,nM,211.0,IC50,nM,211.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,2008
Binding affinity at human LXRalpha,O=C(O)c1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,IC50,nM,157.0,IC50,nM,157.0,O=C(O)c1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Binding affinity at human LXRalpha,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c2ccccc12,CHEMBL1140778,=,=,IC50,nM,21.0,IC50,nM,21.0,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c2ccccc12,2008
Binding affinity at human LXRalpha,O=C(O)Cc1cccc2c(OCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,IC50,nM,161.0,IC50,nM,161.0,O=C(O)Cc1cccc2c(OCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Binding affinity at human LXRalpha,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,IC50,nM,123.0,IC50,nM,123.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Binding affinity at human LXRalpha,Cc1c(CC(=O)O)ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1C,CHEMBL1140778,=,=,IC50,nM,58.0,IC50,nM,58.0,Cc1c(CC(=O)O)ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1C,2008
Binding affinity at human LXRalpha,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,47.0,IC50,nM,47.0,O=C(O)Cc1ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Binding affinity at human LXRalpha,Cc1cc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c(C)cc1CC(=O)O,CHEMBL1140778,=,=,IC50,nM,21.0,IC50,nM,21.0,Cc1cc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c(C)cc1CC(=O)O,2008
Binding affinity at human LXRalpha,Cc1cc(OCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c(C)cc1CC(=O)O,CHEMBL1140778,=,=,IC50,nM,31.0,IC50,nM,31.0,Cc1cc(OCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c(C)cc1CC(=O)O,2008
Binding affinity at human LXRalpha,Cc1cc(CC(=O)O)c(C)cc1COc1cccc(-c2c(Cc3ccccc3)cnc3c(C(F)(F)F)cccc23)c1,CHEMBL1140778,=,=,IC50,nM,11.0,IC50,nM,11.0,Cc1cc(CC(=O)O)c(C)cc1COc1cccc(-c2c(Cc3ccccc3)cnc3c(C(F)(F)F)cccc23)c1,2008
Binding affinity at human LXRalpha,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Binding affinity at human LXRalpha,C#CCC(CC#C)(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,2.0,IC50,nM,2.0,C#CCC(CC#C)(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Binding affinity at human LXRalpha,CCC#CCC(CC#CCC)(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,147.0,IC50,nM,147.0,CCC#CCC(CC#CCC)(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Binding affinity at human LXRalpha,CCC#CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,21.0,IC50,nM,21.0,CCC#CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Binding affinity at human LXRalpha,CC#CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,6.0,IC50,nM,6.0,CC#CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Binding affinity at human LXRalpha,C=CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,16.0,IC50,nM,16.0,C=CCC(C(=O)O)c1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Binding affinity at human LXRalpha,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)ccc(-c3cccc(OCc4ccc(C(Cc5ccc(-c6ccccc6)cc5)C(=O)O)cc4)c3)c2c1,CHEMBL1140778,=,=,IC50,nM,528.0,IC50,nM,528.0,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)ccc(-c3cccc(OCc4ccc(C(Cc5ccc(-c6ccccc6)cc5)C(=O)O)cc4)c3)c2c1,2008
Binding affinity at human LXRalpha,CC(C)(C)c1ccc(CC(C(=O)O)c2ccc(COc3cccc(-c4ccc(C(F)(F)F)c5ncc(C(=O)c6ccccc6)cc45)c3)cc2)cc1,CHEMBL1140778,=,=,IC50,nM,65.0,IC50,nM,65.0,CC(C)(C)c1ccc(CC(C(=O)O)c2ccc(COc3cccc(-c4ccc(C(F)(F)F)c5ncc(C(=O)c6ccccc6)cc45)c3)cc2)cc1,2008
Binding affinity at human LXRalpha,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)ccc(-c3cccc(OCc4ccc(C(Cc5ccccc5)C(=O)O)cc4)c3)c2c1,CHEMBL1140778,=,=,IC50,nM,112.0,IC50,nM,112.0,O=C(c1ccccc1)c1cnc2c(C(F)(F)F)ccc(-c3cccc(OCc4ccc(C(Cc5ccccc5)C(=O)O)cc4)c3)c2c1,2008
Binding affinity at human LXRalpha,O=C(O)Cc1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,CHEMBL1140778,=,=,IC50,nM,17.0,IC50,nM,17.0,O=C(O)Cc1ccc(COc2cccc(-c3ccc(C(F)(F)F)c4ncc(C(=O)c5ccccc5)cc34)c2)cc1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140778,=,=,EC50,nM,135.0,EC50,nM,135.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,EC50,nM,1189.0,EC50,nM,1189.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,CHEMBL1140778,=,=,EC50,nM,7866.0,EC50,nM,7866.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,EC50,nM,685.0,EC50,nM,685.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1140778,=,=,EC50,nM,240.0,EC50,nM,240.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay relative to TO901317,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140778,=,=,Activity,%,100.0,Activity,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay relative to TO901317,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,Activity,%,13.0,Activity,%,13.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4ccnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay relative to TO901317,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,CHEMBL1140778,=,=,Activity,%,47.0,Activity,%,47.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(CNc2cccc3c(CC(=O)O)cccc23)c1,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay relative to TO901317,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,CHEMBL1140778,=,=,Activity,%,57.0,Activity,%,57.0,O=C(O)Cc1cccc2c(NCc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)cccc12,2008
Agonist activity at human LXRalpha expressed in Huh7 cells by Gal4 transactivation assay relative to TO901317,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1140778,=,=,Activity,%,90.0,Activity,%,90.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,CHEMBL1144755,>,>,IC50,nM,100000.0,IC50,uM,100.0,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,c1cc2cc(c1)Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,CHEMBL1144755,=,=,IC50,nM,7100.0,IC50,uM,7.1,c1cc2cc(c1)Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1cc2ccc1-c1ccccc1CCc1ccc(cc1)Oc1cccc(c1)CC2,CHEMBL1144755,=,=,IC50,nM,3200.0,IC50,uM,3.2,Oc1cc2ccc1-c1ccccc1CCc1ccc(cc1)Oc1cccc(c1)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,CHEMBL1144755,=,=,IC50,nM,5700.0,IC50,uM,5.7,Oc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cccc(c1)CCc1ccc-2c(O)c1,CHEMBL1144755,=,=,IC50,nM,8400.0,IC50,uM,8.4,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cccc(c1)CCc1ccc-2c(O)c1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2cc1,CHEMBL1144755,=,=,IC50,nM,4400.0,IC50,uM,4.4,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2cc1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1O)CC2,CHEMBL1144755,=,=,IC50,nM,6600.0,IC50,uM,6.6,Oc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1O)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1cc2ccc1-c1ccccc1CCc1ccc(cc1)Oc1cccc(c1)CC2,CHEMBL1144755,=,=,IC50,nM,2500.0,IC50,uM,2.5,COc1cc2ccc1-c1ccccc1CCc1ccc(cc1)Oc1cccc(c1)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,CHEMBL1144755,=,=,IC50,nM,7600.0,IC50,uM,7.6,COc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cccc(c1)CCc1ccc-2c(OC)c1,CHEMBL1144755,=,=,IC50,nM,25000.0,IC50,uM,25.0,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cccc(c1)CCc1ccc-2c(OC)c1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2cc1,CHEMBL1144755,=,=,IC50,nM,3600.0,IC50,uM,3.6,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2cc1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1OC)CC2,CHEMBL1144755,=,=,IC50,nM,2200.0,IC50,uM,2.2,COc1ccc2cc1Oc1ccc(cc1)CCc1ccccc1-c1ccc(cc1OC)CC2,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(OC)c1,CHEMBL1144755,=,=,IC50,nM,2000.0,IC50,uM,2.0,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(OC)c1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,CHEMBL1144755,=,=,IC50,nM,3100.0,IC50,uM,3.1,CC(C)c1cccc(C(C)C)c1N1C(=O)c2ccccc2C1=S,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL1144755,=,=,IC50,nM,13000.0,IC50,uM,13.0,CCCCCCc1ccccc1N1C(=O)c2ccccc2C1=O,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1144755,=,=,IC50,nM,9800.0,IC50,uM,9.8,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,CHEMBL1144755,=,=,IC50,nM,31000.0,IC50,uM,31.0,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,2008
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,CHEMBL1144755,=,=,IC50,nM,4900.0,IC50,uM,4.9,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,2008
Agonist activity at human LXRalpha by SRC1 cofactor recruitment assay,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCCN2CCc1ccccc1,CHEMBL1145555,,,Activity,,,Activity,,,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCCN2CCc1ccccc1,2008
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153298,=,=,IC50,nM,3300.0,IC50,uM,3.3,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(F)cc1,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(F)cc1,CHEMBL1153298,=,=,EC50,nM,5810.0,EC50,uM,5.81,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(F)cc1,2009
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1153298,=,=,IC50,nM,87900.0,IC50,uM,87.9,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(Cl)c(Cl)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(Cl)c(Cl)c1,CHEMBL1153298,=,=,EC50,nM,5800.0,EC50,uM,5.8,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccc(Cl)c(Cl)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,IC50,nM,820.0,IC50,uM,0.82,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,EC50,nM,2180.0,EC50,uM,2.18,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153298,=,=,IC50,nM,540.0,IC50,uM,0.54,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1Cl,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153298,=,=,EC50,nM,2080.0,EC50,uM,2.08,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1Cl,2009
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1OC,CHEMBL1153298,=,=,IC50,nM,2250.0,IC50,uM,2.25,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1OC,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1OC,CHEMBL1153298,=,=,EC50,nM,2300.0,EC50,uM,2.3,COC(=O)[C@](C)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1OC,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,IC50,nM,100.0,IC50,uM,0.1,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,EC50,nM,2170.0,EC50,uM,2.17,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(Cl)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(F)c1,CHEMBL1153298,=,=,IC50,nM,73.0,IC50,uM,0.073,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(F)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(F)c1,CHEMBL1153298,=,=,EC50,nM,1390.0,EC50,uM,1.39,COC(=O)[C@](F)([C@@H]1CCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1cccc(F)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(OC)c1,CHEMBL1153298,=,=,IC50,nM,62.0,IC50,uM,0.062,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(OC)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(OC)c1,CHEMBL1153298,=,=,EC50,nM,1070.0,EC50,uM,1.07,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(OC)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,IC50,nM,1210.0,IC50,uM,1.21,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Cl)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Cl)c1,CHEMBL1153298,=,=,EC50,nM,840.0,EC50,uM,0.84,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Cl)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(F)c1,CHEMBL1153298,=,=,IC50,nM,49.0,IC50,uM,0.049,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(F)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(F)c1,CHEMBL1153298,=,=,EC50,nM,1350.0,EC50,uM,1.35,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(F)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Br)c1,CHEMBL1153298,=,=,IC50,nM,100.0,IC50,uM,0.1,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Br)c1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Br)c1,CHEMBL1153298,=,=,EC50,nM,850.0,EC50,uM,0.85,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccc(Br)c1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccnc1,CHEMBL1153298,=,=,IC50,nM,20000.0,IC50,uM,20.0,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccnc1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccnc1,CHEMBL1153298,=,=,EC50,nM,1070.0,EC50,uM,1.07,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1cccnc1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccn1,CHEMBL1153298,=,=,IC50,nM,12200.0,IC50,uM,12.2,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccn1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccn1,CHEMBL1153298,=,=,EC50,nM,2750.0,EC50,uM,2.75,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccn1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)nc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,IC50,nM,2580.0,IC50,uM,2.58,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)nc3c2C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)nc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,EC50,nM,4230.0,EC50,uM,4.23,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)nc3c2C1)S(=O)(=O)c1ccccc1,2009
Binding affinity to LXRalpha,CNC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,IC50,nM,2700.0,IC50,uM,2.7,CNC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,CNC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,EC50,nM,1550.0,EC50,uM,1.55,CNC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Binding affinity to LXRalpha,CN(C)C(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,IC50,nM,1790.0,IC50,uM,1.79,CN(C)C(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,CN(C)C(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,EC50,nM,1090.0,EC50,uM,1.09,CN(C)C(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Binding affinity to LXRalpha,O=S(=O)(c1ccccc1)[C@](F)(c1nnco1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,CHEMBL1153298,=,=,IC50,nM,2300.0,IC50,uM,2.3,O=S(=O)(c1ccccc1)[C@](F)(c1nnco1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,2009
Transactivation of LXRalpha,O=S(=O)(c1ccccc1)[C@](F)(c1nnco1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,CHEMBL1153298,=,=,EC50,nM,770.0,EC50,uM,0.77,O=S(=O)(c1ccccc1)[C@](F)(c1nnco1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,2009
Binding affinity to LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,IC50,nM,920.0,IC50,uM,0.92,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Transactivation of LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,EC50,nM,1500.0,EC50,uM,1.5,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Binding affinity to LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,IC50,nM,590.0,IC50,uM,0.59,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Transactivation of LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,EC50,nM,1350.0,EC50,uM,1.35,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Binding affinity to LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,IC50,nM,2200.0,IC50,uM,2.2,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Transactivation of LXRalpha,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,EC50,nM,1850.0,EC50,uM,1.85,Cc1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Binding affinity to LXRalpha,O=S(=O)(c1ccccc1)[C@](F)(c1nnc(C2CC2)o1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,CHEMBL1153298,=,=,IC50,nM,290.0,IC50,uM,0.29,O=S(=O)(c1ccccc1)[C@](F)(c1nnc(C2CC2)o1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,2009
Transactivation of LXRalpha,O=S(=O)(c1ccccc1)[C@](F)(c1nnc(C2CC2)o1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,CHEMBL1153298,=,=,EC50,nM,430.0,EC50,uM,0.43,O=S(=O)(c1ccccc1)[C@](F)(c1nnc(C2CC2)o1)[C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1,2009
Binding affinity to LXRalpha,CN(C)c1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,IC50,nM,300.0,IC50,uM,0.3,CN(C)c1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Transactivation of LXRalpha,CN(C)c1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,CHEMBL1153298,=,=,EC50,nM,890.0,EC50,uM,0.89,CN(C)c1nnc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)o1,2009
Binding affinity to LXRalpha,Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,IC50,nM,210.0,IC50,uM,0.21,Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Transactivation of LXRalpha,Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,EC50,nM,1090.0,EC50,uM,1.09,Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Binding affinity to LXRalpha,COC(=O)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,IC50,nM,1630.0,IC50,uM,1.63,COC(=O)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Transactivation of LXRalpha,COC(=O)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,EC50,nM,1260.0,EC50,uM,1.26,COC(=O)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Binding affinity to LXRalpha,CN(C)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,IC50,nM,29.0,IC50,uM,0.029,CN(C)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Transactivation of LXRalpha,CN(C)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,EC50,nM,370.0,EC50,uM,0.37,CN(C)c1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Binding affinity to LXRalpha,N#Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,IC50,nM,100.0,IC50,uM,0.1,N#Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Transactivation of LXRalpha,N#Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,CHEMBL1153298,=,=,EC50,nM,160.0,EC50,uM,0.16,N#Cc1noc([C@](F)([C@H]2Cc3[nH]c4ccc(Cl)cc4c3C2)S(=O)(=O)c2ccccc2)n1,2009
Binding affinity to LXRalpha,COC(=O)C(C)(C1CCCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,,,Activity,,,Activity,,,COC(=O)C(C)(C1CCCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,COC(=O)C(C)(C1CCCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,,,Activity,,,Activity,,,COC(=O)C(C)(C1CCCc2c([nH]c3ccc(Cl)cc23)C1)S(=O)(=O)c1ccccc1,2009
Binding affinity to LXRalpha,COC(=O)[C@](C)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,IC50,nM,1100.0,IC50,uM,1.1,COC(=O)[C@](C)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,COC(=O)[C@](C)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,EC50,nM,1600.0,EC50,uM,1.6,COC(=O)[C@](C)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Binding affinity to LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,IC50,nM,90.0,IC50,uM,0.09,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Transactivation of LXRalpha,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,CHEMBL1153298,=,=,EC50,nM,480.0,EC50,uM,0.48,COC(=O)[C@](F)([C@H]1Cc2[nH]c3ccc(Cl)cc3c2C1)S(=O)(=O)c1ccccc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1153343,=,=,EC50,nM,280.0,EC50,uM,0.28,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153343,=,=,EC50,nM,10.0,EC50,uM,0.01,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1153343,=,=,EC50,nM,280.0,EC50,uM,0.28,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,CHEMBL1153343,=,=,EC50,nM,3300.0,EC50,uM,3.3,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,,,EC50,,,EC50,,,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,Cc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,=,=,EC50,nM,1970.0,EC50,uM,1.97,Cc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,=,=,EC50,nM,1000.0,EC50,uM,1.0,CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CC(O)(C(=O)Nc1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,CHEMBL1153343,>,>,EC50,nM,100000.0,EC50,uM,100.0,CC(O)(C(=O)Nc1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CC(O)(C(=O)Nc1ccc(N(CC2CC2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,CHEMBL1153343,=,=,EC50,nM,1080.0,EC50,uM,1.08,CC(O)(C(=O)Nc1ccc(N(CC2CC2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,C=CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,=,=,EC50,nM,470.0,EC50,uM,0.47,C=CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,CHEMBL1153343,=,=,EC50,nM,3400.0,EC50,uM,3.4,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,COC(=O)c1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,=,=,EC50,nM,3100.0,EC50,uM,3.1,COC(=O)c1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C(=O)O)cc1,CHEMBL1153343,>,>,EC50,nM,100000.0,EC50,uM,100.0,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C(=O)O)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,COC(=O)CCc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,=,=,EC50,nM,3500.0,EC50,uM,3.5,COC(=O)CCc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at LXRalpha ligand binding domain by FRET based SRC1 recruitment assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(CCC(=O)O)cc1,CHEMBL1153343,>,>,EC50,nM,100000.0,EC50,uM,100.0,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(CCC(=O)O)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1153343,,,EC50,,,EC50,,,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153343,=,=,EC50,nM,85.0,EC50,uM,0.085,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1153343,=,=,EC50,nM,310.0,EC50,uM,0.31,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,CHEMBL1153343,=,=,EC50,nM,5000.0,EC50,uM,5.0,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,=,=,EC50,nM,1820.0,EC50,uM,1.82,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,Cc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,=,=,EC50,nM,5000.0,EC50,uM,5.0,Cc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,=,=,EC50,nM,8500.0,EC50,uM,8.5,CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CC(O)(C(=O)Nc1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,CC(O)(C(=O)Nc1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CC(O)(C(=O)Nc1ccc(N(CC2CC2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,CC(O)(C(=O)Nc1ccc(N(CC2CC2)S(=O)(=O)c2ccccc2Cl)cc1Cl)C(F)(F)F,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,C=CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,C=CCN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,CHEMBL1153343,=,=,EC50,nM,5000.0,EC50,uM,5.0,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,COC(=O)c1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,=,=,EC50,nM,3610.0,EC50,uM,3.61,COC(=O)c1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C(=O)O)cc1,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C(=O)O)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,COC(=O)CCc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,COC(=O)CCc1ccc(S(=O)(=O)N(C)c2ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c2)cc1,2009
Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(CCC(=O)O)cc1,CHEMBL1153343,>,>,EC50,nM,30000.0,EC50,uM,30.0,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(CCC(=O)O)cc1,2009
Agonist activity at human LXRalpha expressed in human U2OS cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,CHEMBL1153343,,,Activity,,,Activity,,,CN(c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccc(C#N)cc1,2009
Agonist activity at human LXRalpha expressed in human U2OS cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,CHEMBL1153343,,,Activity,,,Activity,,,CN(c1ccc(NC(=O)[C@](C)(O)C(F)(F)F)c(Cl)c1)S(=O)(=O)c1ccccc1Cl,2009
Displacement of [3H2]F3-methyl AA from LXRalpha by scintillation proximity assay,Cc1cc(O)cc2c1[C@H]1O[C@](C)(Cc3cc4c(c(O)c31)C(=O)c1c(O)cc(O)cc1C4(C)C)O2,CHEMBL1158822,=,=,IC50,nM,2000.0,IC50,uM,2.0,Cc1cc(O)cc2c1[C@H]1O[C@](C)(Cc3cc4c(c(O)c31)C(=O)c1c(O)cc(O)cc1C4(C)C)O2,2005
Displacement of [3H2]F3-methyl AA from LXRalpha by scintillation proximity assay,COc1cc(C)c2c(c1)O[C@@]1(C)Cc3cc4c(c(O)c3[C@@H]2O1)C(=O)c1c(O)c(Cl)c(O)c(Cl)c1C4(C)C,CHEMBL1158822,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(C)c2c(c1)O[C@@]1(C)Cc3cc4c(c(O)c3[C@@H]2O1)C(=O)c1c(O)c(Cl)c(O)c(Cl)c1C4(C)C,2005
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1140134,=,=,IC50,nM,235.0,IC50,nM,235.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)c(OC)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,170.0,IC50,nM,170.0,CCCCN(Cc1cc(Cl)c(OC)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)cc(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,195.0,IC50,nM,195.0,CCCCN(Cc1cc(Cl)cc(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,180.0,IC50,nM,180.0,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)c(OC)c(OC)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,165.0,IC50,nM,165.0,CCCCN(Cc1cc(Cl)c(OC)c(OC)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)c(O)c(OC)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,775.0,IC50,nM,775.0,CCCCN(Cc1cc(Cl)c(O)c(OC)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccc(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,560.0,IC50,nM,560.0,CCCCN(Cc1ccc(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)ccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,220.0,IC50,nM,220.0,CCCCN(Cc1cc(Cl)ccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(Cl)cc(Cl)c1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,890.0,IC50,nM,890.0,CCCCN(Cc1cc(Cl)cc(Cl)c1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cc(OC(F)(F)F)ccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,190.0,IC50,nM,190.0,CCCCN(Cc1cc(OC(F)(F)F)ccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cccc(F)c1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,615.0,IC50,nM,615.0,CCCCN(Cc1cccc(F)c1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccc(O)cc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,955.0,IC50,nM,955.0,CCCCN(Cc1ccc(O)cc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cccc(O)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,160.0,IC50,nM,160.0,CCCCN(Cc1cccc(O)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,180.0,IC50,nM,180.0,CCCCN(Cc1ccccc1O)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,90.0,IC50,nM,90.0,CCCCN(Cc1ccncc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,120.0,IC50,nM,120.0,CCCCN(Cc1ccccn1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1cccc(CCO)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,115.0,IC50,nM,115.0,CCCCN(Cc1cccc(CCO)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,OC(c1ccc(N(Cc2ccccc2)Cc2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,CHEMBL1140134,=,=,IC50,nM,315.0,IC50,nM,315.0,OC(c1ccc(N(Cc2ccccc2)Cc2ccccc2)cc1)(C(F)(F)F)C(F)(F)F,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CCCCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,170.0,IC50,nM,170.0,CCCCN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,CN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,310.0,IC50,nM,310.0,CN(Cc1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [N-methyl-3H]GW0438 from human biotinylated LXRalpha ligand binding domain,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,IC50,nM,75.0,IC50,nM,75.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Induction of LXRalpha SUMOylation by SUMO2 in human HeLa cells at 1 uM by Western blot analysis,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1140134,,,Activity,,,Activity,,,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Induction of LXRalpha SUMOylation by SUMO2 in human HeLa cells at 1 uM by Western blot analysis,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,,,Activity,,,Activity,,,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Activation of LXRalpha by GAL4 reporter gene assay,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,=,=,EC50,nM,3000.0,EC50,uM,3.0,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Induction of LXRalpha SUMOylation by SUMO3 in human HeLa cells at 1 uM by Western blot analysis,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1140134,,,Activity,,,Activity,,,CCCCN(Cc1cc(Cl)c(O)c(Cl)c1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Induction of LXRalpha SUMOylation by SUMO3 in human HeLa cells at 1 uM by Western blot analysis,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1140134,,,Activity,,,Activity,,,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Agonist activity at LXRalpha expressed in african green monkey CV1 cells co-expressing LXRE by luciferase reporter gene assay,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,CHEMBL1140941,,,Activity,,,Activity,,,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,2009
Agonist activity at LXRalpha expressed in african green monkey CV1 cells co-expressing LXRE up to 10 uM by luciferase reporter gene assay relative to control,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,CHEMBL1140941,,,Activity,,,Activity,,,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,2009
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1152299,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1152299,=,=,IC50,nM,100.0,IC50,nM,100.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,IC50,nM,10.0,IC50,nM,10.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,IC50,nM,8.0,IC50,nM,8.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,CHEMBL1152299,=,=,IC50,nM,279.0,IC50,nM,279.0,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,CHEMBL1152299,=,=,IC50,nM,78.0,IC50,nM,78.0,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1152299,=,=,IC50,nM,179.0,IC50,nM,179.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,CHEMBL1152299,=,=,IC50,nM,248.0,IC50,nM,248.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,CHEMBL1152299,=,=,IC50,nM,297.0,IC50,nM,297.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,CHEMBL1152299,=,=,IC50,nM,317.0,IC50,nM,317.0,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,CHEMBL1152299,=,=,IC50,nM,401.0,IC50,nM,401.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,IC50,nM,260.0,IC50,nM,260.0,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,CHEMBL1152299,=,=,IC50,nM,252.0,IC50,nM,252.0,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,CHEMBL1152299,=,=,IC50,nM,379.0,IC50,nM,379.0,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,IC50,nM,304.0,IC50,nM,304.0,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,IC50,nM,465.0,IC50,nM,465.0,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,FC(F)(F)c1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)cc1,CHEMBL1152299,=,=,IC50,nM,3101.0,IC50,nM,3101.0,FC(F)(F)c1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1152299,=,=,EC50,nM,140.0,EC50,uM,0.14,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1152299,=,=,EC50,nM,660.0,EC50,uM,0.66,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,EC50,nM,240.0,EC50,uM,0.24,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,EC50,nM,160.0,EC50,uM,0.16,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,CHEMBL1152299,=,=,EC50,nM,4270.0,EC50,uM,4.27,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,CHEMBL1152299,=,=,EC50,nM,1810.0,EC50,uM,1.81,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1152299,=,=,EC50,nM,6660.0,EC50,uM,6.66,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,CHEMBL1152299,=,=,EC50,nM,6100.0,EC50,uM,6.1,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,CHEMBL1152299,=,=,EC50,nM,5020.0,EC50,uM,5.02,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,CHEMBL1152299,=,=,EC50,nM,8400.0,EC50,uM,8.4,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,CHEMBL1152299,=,=,EC50,nM,12770.0,EC50,uM,12.77,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,EC50,nM,13280.0,EC50,uM,13.28,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,CHEMBL1152299,=,=,EC50,nM,14400.0,EC50,uM,14.4,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,CHEMBL1152299,=,=,EC50,nM,15210.0,EC50,uM,15.21,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,EC50,nM,13440.0,EC50,uM,13.44,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,EC50,nM,15830.0,EC50,uM,15.83,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay,FC(F)(F)c1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)cc1,CHEMBL1152299,,,EC50,,,EC50,,,FC(F)(F)c1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1152299,=,=,Efficacy,%,100.0,Efficacy,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1152299,=,=,Efficacy,%,58.0,Efficacy,%,58.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,Efficacy,%,90.0,Efficacy,%,90.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152299,=,=,Efficacy,%,82.0,Efficacy,%,82.0,O=C(O)Cc1ccc(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,CHEMBL1152299,=,=,Efficacy,%,31.0,Efficacy,%,31.0,FC(F)(F)c1cccc2c(-c3ccccc3)n(Cc3ccccc3)nc12,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,CHEMBL1152299,=,=,Efficacy,%,58.0,Efficacy,%,58.0,Cc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)c(C)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1152299,=,=,Efficacy,%,53.0,Efficacy,%,53.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,CHEMBL1152299,=,=,Efficacy,%,35.0,Efficacy,%,35.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2F)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,CHEMBL1152299,=,=,Efficacy,%,32.0,Efficacy,%,32.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccccc2Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,CHEMBL1152299,=,=,Efficacy,%,43.0,Efficacy,%,43.0,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(F)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,CHEMBL1152299,=,=,Efficacy,%,35.0,Efficacy,%,35.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(Cl)cc2)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,Efficacy,%,64.0,Efficacy,%,64.0,Fc1cc(Cl)ccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,CHEMBL1152299,=,=,Efficacy,%,45.0,Efficacy,%,45.0,Fc1ccc(Cn2nc3c(C(F)(F)F)cccc3c2-c2ccc(Cl)cc2)c(Cl)c1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,CHEMBL1152299,=,=,Efficacy,%,36.0,Efficacy,%,36.0,FC(F)(F)c1cccc2c(-c3ccc(Cl)cc3)n(Cc3ccccc3Cl)nc12,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,Efficacy,%,50.0,Efficacy,%,50.0,Fc1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,CHEMBL1152299,=,=,Efficacy,%,5.0,Efficacy,%,5.0,FC(F)(F)c1ccccc1Cn1nc2c(C(F)(F)F)cccc2c1-c1ccc(Cl)cc1,2008
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 30 mmol/L after 24 hrs relative to control,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,CHEMBL1143284,=,=,FC,,15.0,FC,,15.0,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation after 24 hrs,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,CHEMBL1143284,,,Activity,,,Activity,,,Oc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(OC)c1,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(OC)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(O)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1cc2ccc1-c1ccc(O)cc1CCc1ccc(cc1)Oc1cc(ccc1O)CC2,CHEMBL1143284,,,Activity,,,Activity,,,COc1cc2ccc1-c1ccc(O)cc1CCc1ccc(cc1)Oc1cc(ccc1O)CC2,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2cc1Oc1ccc(cc1)CCc1cc(O)ccc1-c1ccc(cc1O)CC2,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2cc1Oc1ccc(cc1)CCc1cc(O)ccc1-c1ccc(cc1O)CC2,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(OC)c1,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1O)CCc1ccc-2c(OC)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(O)c1,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2c(c1)CCc1ccc(cc1)Oc1cc(ccc1OC)CCc1ccc-2c(O)c1,2009
Agonist activity at full length LXRalpha expressed in african green monkey COS7 cells co-transfected with RXRalpha assessed as increase in LXR-response element driven luciferase reporter gene transactivation at 10 to 30 uM after 24 hrs,COc1ccc2cc1Oc1ccc(cc1)CCc1cc(O)ccc1-c1ccc(cc1OC)CC2,CHEMBL1143284,,,Activity,,,Activity,,,COc1ccc2cc1Oc1ccc(cc1)CCc1cc(O)ccc1-c1ccc(cc1OC)CC2,2009
Displacement of [3H2]F3-methylAA from human LXRalpha expressed in Escherichia coli BL21 cells by scintillation proximity assay,CC(C)=CCC/C(C)=C/C[C@H]1C[C@]2(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(C(=O)C(C(=O)c3ccc(O)c(O)c3)=C2O)[C@]1(C)CCC=C(C)C,CHEMBL1158745,=,=,IC50,nM,3400.0,IC50,uM,3.4,CC(C)=CCC/C(C)=C/C[C@H]1C[C@]2(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(C(=O)C(C(=O)c3ccc(O)c(O)c3)=C2O)[C@]1(C)CCC=C(C)C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,CHEMBL1141780,=,=,LC50,nM,250.0,LC50,uM,0.25,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,CHEMBL1141780,=,=,LC50,nM,190.0,LC50,uM,0.19,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,CHEMBL1141780,=,=,LC50,nM,100.0,LC50,uM,0.1,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,CHEMBL1141780,=,=,LC50,nM,120.0,LC50,uM,0.12,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,CHEMBL1141780,=,=,LC50,nM,700.0,LC50,uM,0.7,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,CHEMBL1141780,=,=,LC50,nM,1200.0,LC50,uM,1.2,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,CHEMBL1141780,=,=,LC50,nM,1700.0,LC50,uM,1.7,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,CHEMBL1141780,=,=,LC50,nM,25000.0,LC50,uM,25.0,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL1141780,,,LC50,,,LC50,,,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,LC50,nM,1300.0,LC50,uM,1.3,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,LC50,nM,70.0,LC50,uM,0.07,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1141780,=,=,LC50,nM,35.0,LC50,uM,0.035,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1141780,=,=,LC50,nM,2.0,LC50,uM,0.002,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1141780,>,>,LC50,nM,50000.0,LC50,uM,50.0,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1141780,=,=,LC50,nM,100.0,LC50,uM,0.1,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)NCC45CC6CC(CC(C6)C4)C5)CCC[C@@]23C)C1,CHEMBL1141780,>,>,LC50,nM,15000.0,LC50,uM,15.0,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)NCC45CC6CC(CC(C6)C4)C5)CCC[C@@]23C)C1,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,CHEMBL1141780,=,=,EC50,nM,180.0,EC50,uM,0.18,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,CHEMBL1141780,=,=,EC50,nM,390.0,EC50,uM,0.39,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,CHEMBL1141780,>,>,EC50,nM,15000.0,EC50,uM,15.0,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,CHEMBL1141780,=,=,EC50,nM,30.0,EC50,uM,0.03,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,CHEMBL1141780,>,>,EC50,nM,50000.0,EC50,uM,50.0,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,CHEMBL1141780,,,EC50,,,EC50,,,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,CHEMBL1141780,,,EC50,,,EC50,,,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,CHEMBL1141780,>,>,EC50,nM,50000.0,EC50,uM,50.0,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL1141780,=,=,EC50,nM,170.0,EC50,uM,0.17,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,EC50,nM,450.0,EC50,uM,0.45,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,EC50,nM,50.0,EC50,uM,0.05,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1141780,=,=,EC50,nM,35.0,EC50,uM,0.035,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1141780,=,=,EC50,nM,1.0,EC50,uM,0.001,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1141780,>,>,EC50,nM,50000.0,EC50,uM,50.0,C[C@]1(C(=O)O)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1141780,=,=,EC50,nM,210.0,EC50,uM,0.21,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)NCC45CC6CC(CC(C6)C4)C5)CCC[C@@]23C)C1,CHEMBL1141780,>,>,EC50,nM,50000.0,EC50,uM,50.0,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)NCC45CC6CC(CC(C6)C4)C5)CCC[C@@]23C)C1,2005
Agonist activity at human recombinant LXRalpha expressed in Escherichia coli BL21 cells assessed as association of recombinant SRC1 to LXRalpha ligand binding domain by HTRF assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1141780,>,>,EC50,nM,15000.0,EC50,uM,15.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,CHEMBL1141780,,,FC,,,FC,,,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(CO)CCC[C@@]23C)C1,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,CHEMBL1141780,,,FC,,,FC,,,CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC(=O)[C@H]4C[C@@H](O)CC[C@]4(C)[C@@]3(O)CC[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,CHEMBL1141780,,,FC,,,FC,,,C/C(=C\CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@@H](O)C4(C)C)[C@]3(C)CC[C@]12C)C(=O)O,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,CHEMBL1141780,,,FC,,,FC,,,C=C(C)C(O)CC[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,CHEMBL1141780,,,FC,,,FC,,,C/C(=C\C(=O)C[C@@H](C)[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)C(=O)CC[C@@]45C[C@@]35CC[C@]12C)C(=O)O,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,CHEMBL1141780,,,FC,,,FC,,,C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL1141780,,,FC,,,FC,,,C=C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,CHEMBL1141780,=,=,FC,,20.0,FC,,20.0,CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc2c(C(F)(F)F)noc12,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,CHEMBL1141780,=,=,FC,,50.0,FC,,50.0,CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@](C)(C(=O)OC(=O)[C@@]3(C)CCC[C@]4(C)c5cc(OC(C)=O)ccc5CC[C@@H]34)[C@@H]1CC2,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid by luciferase reporter assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1141780,=,=,FC,,4.0,FC,,4.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Displacement of [3H2]F3-methyl AA from human recombinant LXRalpha expressed in Escherichia coli BL21 cells at 100 uM,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL1141780,=,=,Activity,%,70.0,Activity,%,70.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid at 100 uM by luciferase reporter assay,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,CHEMBL1141780,=,=,FC,,15.9,FC,,15.9,C=C[C@@]1(C)CC=C2[C@@H](CC[C@@H]3[C@](C)(C(=O)O)CCC[C@@]23C)C1,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid at 2.2 uM by luciferase reporter assay,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,CHEMBL1141780,=,=,FC,,8.0,FC,,8.0,CC(C)=CCC[C@@H](C)[C@H]1C[C@H](O)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)C3=CC[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid at 30 uM by luciferase reporter assay,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,FC,,10.1,FC,,10.1,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid at 10 uM by luciferase reporter assay,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,CHEMBL1141780,=,=,FC,,13.0,FC,,13.0,CC(C)[C@H](C)[C@@]1(C)C[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@@H](O)[C@@]4(O)C[C@@H](O)CC[C@]4(C)[C@@]3(O)[C@H](O)C[C@]12C,2005
Activity of human recombinant LXRalpha ligand binding domain-mediated transcriptional activity in human HEK293 cells with Gal4 reporter plasmid at 10 uM by luciferase reporter assay,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,CHEMBL1141780,=,=,FC,,22.0,FC,,22.0,C[C@]1(C(=O)NCC23CC4CC(CC(C4)C2)C3)CCC[C@]2(C)c3cc(O)ccc3CC[C@@H]12,2005
Agonist activity at LXRalpha assessed as receptor-coactivator peptide interaction by FRET assay,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,CHEMBL1155854,>,>,XC50,nM,20000.0,XC50,nM,20000.0,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,2008
Increase in transcriptional activity of LXRalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay,O=C(O)[C@H](Cc1ccccc1)Oc1ccc(-c2ccccc2)cc1,CHEMBL1151755,,,Activity,,,Activity,,,O=C(O)[C@H](Cc1ccccc1)Oc1ccc(-c2ccccc2)cc1,2008
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152700,=,=,IC50,nM,9.5,IC50,nM,9.5,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,231.0,IC50,nM,231.0,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,91.0,IC50,nM,91.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CC(C)NC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,74.0,IC50,nM,74.0,CC(C)NC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,12.0,IC50,nM,12.0,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,CHEMBL1152700,=,=,IC50,nM,12.0,IC50,nM,12.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,CHEMBL1152700,=,=,IC50,nM,20.0,IC50,nM,20.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,CHEMBL1152700,=,=,IC50,nM,15.0,IC50,nM,15.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,1002.0,IC50,nM,1002.0,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,125.0,IC50,nM,125.0,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,272.0,IC50,nM,272.0,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,280.0,IC50,nM,280.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)NC(C)C)c2)c1,CHEMBL1152700,=,=,IC50,nM,357.0,IC50,nM,357.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)NC(C)C)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,IC50,nM,108.0,IC50,nM,108.0,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCC3)c2)c1,CHEMBL1152700,=,=,IC50,nM,34.0,IC50,nM,34.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCC3)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCCC3)c2)c1,CHEMBL1152700,=,=,IC50,nM,50.0,IC50,nM,50.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCCC3)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain expressed in Escherichia coli,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,CHEMBL1152700,=,=,IC50,nM,158.0,IC50,nM,158.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152700,=,=,EC50,nM,238.0,EC50,nM,238.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,EC50,nM,2709.0,EC50,nM,2709.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CC(C)NC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,CC(C)NC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,EC50,nM,675.0,EC50,nM,675.0,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,CHEMBL1152700,=,=,EC50,nM,435.0,EC50,nM,435.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,CHEMBL1152700,=,=,EC50,nM,477.0,EC50,nM,477.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,CHEMBL1152700,=,=,EC50,nM,345.0,EC50,nM,345.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,EC50,nM,1306.0,EC50,nM,1306.0,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,EC50,nM,2102.0,EC50,nM,2102.0,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,EC50,nM,1633.0,EC50,nM,1633.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)NC(C)C)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)NC(C)C)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCC3)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCC3)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCCC3)c2)c1,CHEMBL1152700,,,EC50,,,EC50,,,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCCCC3)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,CHEMBL1152700,=,=,EC50,nM,1237.0,EC50,nM,1237.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152700,=,=,Efficacy,%,90.0,Efficacy,%,90.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,Efficacy,%,43.0,Efficacy,%,43.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152700,=,=,Efficacy,%,73.0,Efficacy,%,73.0,CCN(CC)C(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,CHEMBL1152700,=,=,Efficacy,%,75.0,Efficacy,%,75.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,CHEMBL1152700,=,=,Efficacy,%,99.0,Efficacy,%,99.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCCCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,CHEMBL1152700,=,=,Efficacy,%,90.0,Efficacy,%,90.0,O=C(c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1)N1CCOCC1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,Efficacy,%,37.0,Efficacy,%,37.0,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,Efficacy,%,28.0,Efficacy,%,28.0,CCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152700,=,=,Efficacy,%,8.0,Efficacy,%,8.0,CCCNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to T0901317,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,CHEMBL1152700,=,=,Efficacy,%,33.0,Efficacy,%,33.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(=O)N3CCOCC3)c2)c1,2009
Agonist activity at LXRalpha by FRET assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1152711,=,=,EC50,nM,175.0,EC50,nM,175.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at LXRalpha by FRET assay,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n[nH]1,CHEMBL1152711,=,=,EC50,nM,23.0,EC50,nM,23.0,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n[nH]1,2009
Agonist activity at LXRalpha by FRET assay,COC(=O)c1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)no1,CHEMBL1152711,=,=,EC50,nM,63.0,EC50,nM,63.0,COC(=O)c1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)no1,2009
Agonist activity at LXRalpha by FRET assay,FC(F)(F)c1cccc(CN(CCCOc2n[nH]c3ccccc23)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,EC50,nM,110.0,EC50,nM,110.0,FC(F)(F)c1cccc(CN(CCCOc2n[nH]c3ccccc23)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay,Cc1cc(C)c2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)n[nH]c2n1,CHEMBL1152711,>,>,EC50,nM,3000.0,EC50,nM,3000.0,Cc1cc(C)c2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)n[nH]c2n1,2009
Agonist activity at LXRalpha by FRET assay,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n2ncnc2n1,CHEMBL1152711,=,=,EC50,nM,790.0,EC50,nM,790.0,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n2ncnc2n1,2009
Agonist activity at LXRalpha by FRET assay,COC(=O)Cc1c[nH]c2ccc(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc12,CHEMBL1152711,=,=,EC50,nM,630.0,EC50,nM,630.0,COC(=O)Cc1c[nH]c2ccc(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc12,2009
Agonist activity at LXRalpha by FRET assay,FC(F)(F)c1cccc(CN(CCCOc2ccc3[nH]ccc3c2)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,EC50,nM,226.0,EC50,nM,226.0,FC(F)(F)c1cccc(CN(CCCOc2ccc3[nH]ccc3c2)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay,FC(F)(F)c1cccc(CN(CCCOc2cccc3[nH]ccc23)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,EC50,nM,60.0,EC50,nM,60.0,FC(F)(F)c1cccc(CN(CCCOc2cccc3[nH]ccc23)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay,Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,EC50,nM,39.0,EC50,nM,39.0,Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at LXRalpha by FRET assay,CS(=O)(=O)n1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,EC50,nM,20.0,EC50,nM,20.0,CS(=O)(=O)n1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at LXRalpha by FRET assay,O=C(O)Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,EC50,nM,14.0,EC50,nM,14.0,O=C(O)Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n[nH]1,CHEMBL1152711,=,=,Activity,%,25.0,Activity,%,25.0,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n[nH]1,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,COC(=O)c1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)no1,CHEMBL1152711,=,=,Activity,%,65.0,Activity,%,65.0,COC(=O)c1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)no1,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,FC(F)(F)c1cccc(CN(CCCOc2n[nH]c3ccccc23)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,Activity,%,17.0,Activity,%,17.0,FC(F)(F)c1cccc(CN(CCCOc2n[nH]c3ccccc23)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n2ncnc2n1,CHEMBL1152711,=,=,Activity,%,25.0,Activity,%,25.0,Cc1cc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)n2ncnc2n1,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,COC(=O)Cc1c[nH]c2ccc(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc12,CHEMBL1152711,=,=,Activity,%,19.0,Activity,%,19.0,COC(=O)Cc1c[nH]c2ccc(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc12,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,FC(F)(F)c1cccc(CN(CCCOc2ccc3[nH]ccc3c2)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,Activity,%,36.0,Activity,%,36.0,FC(F)(F)c1cccc(CN(CCCOc2ccc3[nH]ccc3c2)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,FC(F)(F)c1cccc(CN(CCCOc2cccc3[nH]ccc23)CC(c2ccccc2)c2ccccc2)c1Cl,CHEMBL1152711,=,=,Activity,%,90.0,Activity,%,90.0,FC(F)(F)c1cccc(CN(CCCOc2cccc3[nH]ccc23)CC(c2ccccc2)c2ccccc2)c1Cl,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,Activity,%,57.0,Activity,%,57.0,Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,CS(=O)(=O)n1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,Activity,%,50.0,Activity,%,50.0,CS(=O)(=O)n1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at LXRalpha by FRET assay relative to GW-3965A,O=C(O)Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1152711,=,=,Activity,%,132.0,Activity,%,132.0,O=C(O)Cn1ccc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Activity at LXRalpha assessed as coactivator peptide interaction with receptor ligand binding domain by FRET assay,CC(C)c1onc(C[S+]([O-])c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,CHEMBL1136905,=,=,XC50,nM,1400.0,XC50,nM,1400.0,CC(C)c1onc(C[S+]([O-])c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,2009
Activity at LXRalpha assessed as coactivator peptide interaction with receptor ligand binding domain by FRET assay relative to standard control,CC(C)c1onc(C[S+]([O-])c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,CHEMBL1136905,=,=,%max,%,33.0,%max,%,33.0,CC(C)c1onc(C[S+]([O-])c2c(Cl)cccc2Cl)c1COc1ccc(/C=C/c2cccc(C(=O)O)c2)c(Cl)c1,2009
Activity at LXRalpha receptor up to 10 uM by transactivation assay,CC[C@@H](Oc1cccc(Cn2c(C)c(C(=O)c3ccc(Cl)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,CHEMBL1158459,,,Activity,,,Activity,,,CC[C@@H](Oc1cccc(Cn2c(C)c(C(=O)c3ccc(Cl)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,2009
Binding affinity to LXRalpha up to 10 uM,CC[C@@H](Oc1cccc(Cn2c(C)c(C(=O)c3ccc(Cl)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,CHEMBL1158459,,,Activity,,,Activity,,,CC[C@@H](Oc1cccc(Cn2c(C)c(C(=O)c3ccc(Cl)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1151902,=,=,IC50,nM,14000.0,IC50,uM,14.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1151902,=,=,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cc1c(CC(=O)O)ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1C,CHEMBL1151902,=,=,IC50,nM,58000.0,IC50,uM,58.0,Cc1c(CC(=O)O)ccc(NCc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1C,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Clc1cccc2c(-c3cccc(OCc4ccccc4)c3)c(Cc3ccccc3)nnc12,CHEMBL1151902,=,=,IC50,nM,180000.0,IC50,uM,180.0,Clc1cccc2c(-c3cccc(OCc4ccccc4)c3)c(Cc3ccccc3)nnc12,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Clc1ccccc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(Cl)cccc23)c1,CHEMBL1151902,=,=,IC50,nM,92000.0,IC50,uM,92.0,Clc1ccccc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(Cl)cccc23)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,CHEMBL1151902,=,=,IC50,nM,62000.0,IC50,uM,62.0,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,IC50,nM,837000.0,IC50,uM,837.0,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1ccc(Cl)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,CHEMBL1151902,=,=,IC50,nM,147000.0,IC50,uM,147.0,FC(F)(F)c1ccc(Cl)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(Cl)cccc23)c1,CHEMBL1151902,=,=,IC50,nM,1826000.0,IC50,uM,1826.0,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(Cl)cccc23)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,CHEMBL1151902,=,=,IC50,nM,1191000.0,IC50,uM,1191.0,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,IC50,nM,1124000.0,IC50,uM,1124.0,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Fc1ccc(C(F)(F)F)c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,CHEMBL1151902,>,>,IC50,nM,1000000.0,IC50,uM,1000.0,Fc1ccc(C(F)(F)F)c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(-c3ccccc3)nnc3c(Cl)cccc23)c1,CHEMBL1151902,=,=,IC50,nM,332000.0,IC50,uM,332.0,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(-c3ccccc3)nnc3c(Cl)cccc23)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc(CNc2cccc(-c3c(-c4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,IC50,nM,179000.0,IC50,uM,179.0,FC(F)(F)c1cccc(CNc2cccc(-c3c(-c4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(C(F)(F)F)cccc23)c1,CHEMBL1151902,>,>,IC50,nM,1000000.0,IC50,uM,1000.0,FC(F)(F)c1ccc(Cl)cc1COc1cccc(-c2c(Cc3ccccc3)nnc3c(C(F)(F)F)cccc23)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1151902,=,=,IC50,nM,1194000.0,IC50,uM,1194.0,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Fc1c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)cccc1C(F)(F)F,CHEMBL1151902,=,=,IC50,nM,1336000.0,IC50,uM,1336.0,Fc1c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)cccc1C(F)(F)F,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,CHEMBL1151902,=,=,IC50,nM,2927000.0,IC50,uM,2927.0,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,CHEMBL1151902,>,>,IC50,nM,1000000.0,IC50,uM,1000.0,Cn1c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,>,>,IC50,nM,1000000.0,IC50,uM,1000.0,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)nnc5c(Cl)cccc45)c3)c21,CHEMBL1151902,>,>,IC50,nM,1000000.0,IC50,uM,1000.0,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)nnc5c(Cl)cccc45)c3)c21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,IC50,nM,603000.0,IC50,uM,603.0,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1ccc2cccc(CNc3cccc(-c4c(-c5ccccc5)nnc5c(Cl)cccc45)c3)c21,CHEMBL1151902,=,=,IC50,nM,62000.0,IC50,uM,62.0,Cn1ccc2cccc(CNc3cccc(-c4c(-c5ccccc5)nnc5c(Cl)cccc45)c3)c21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,IC50,nM,1415000.0,IC50,uM,1415.0,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,IC50,nM,668000.0,IC50,uM,668.0,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,IC50,nM,1123000.0,IC50,uM,1123.0,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,2009
Displacement of [3H]T0901317 from human recombinant N-terminal biotinylated tagged LXRalpha ligand binding domain (197-447) expressed in Escherichia coli,FC(F)(F)c1cccc2c(-c3cccc(NCc4cccc5cc[nH]c45)c3)c(Cc3ccccc3)cnc12,CHEMBL1151902,=,=,IC50,nM,134000.0,IC50,uM,134.0,FC(F)(F)c1cccc2c(-c3cccc(NCc4cccc5cc[nH]c45)c3)c(Cc3ccccc3)cnc12,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,EC50,nM,13500.0,EC50,uM,13.5,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,EC50,nM,12000.0,EC50,uM,12.0,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,EC50,nM,6000.0,EC50,uM,6.0,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,EC50,nM,8320.0,EC50,uM,8.32,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,CHEMBL1151902,=,=,EC50,nM,18100.0,EC50,uM,18.1,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1151902,=,=,EC50,nM,8410.0,EC50,uM,8.41,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,EC50,nM,11100.0,EC50,uM,11.1,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,EC50,nM,15300.0,EC50,uM,15.3,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1151902,=,=,EC50,nM,240.0,EC50,uM,0.24,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1151902,=,=,Efficacy,%,90.0,Efficacy,%,90.0,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,Efficacy,%,13.0,Efficacy,%,13.0,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc2ccccc21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,Efficacy,%,15.0,Efficacy,%,15.0,Cn1ccc2cccc(CNc3cccc(-c4c(Cc5ccccc5)cnc5c(C(F)(F)F)cccc45)c3)c21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,CHEMBL1151902,=,=,Efficacy,%,11.0,Efficacy,%,11.0,Cn1c(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)cc2ccccc21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,CHEMBL1151902,=,=,Efficacy,%,23.0,Efficacy,%,23.0,Cn1ccc2cccc(COc3cccc(-c4c(Cc5ccccc5)nnc5c(C(F)(F)F)cccc45)c3)c21,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,CHEMBL1151902,=,=,Efficacy,%,5.5,Efficacy,%,5.5,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1151902,=,=,Efficacy,%,9.5,Efficacy,%,9.5,Fc1ccc(C(F)(F)F)c(COc2cccc(-c3c(Cc4ccccc4)nnc4c(C(F)(F)F)cccc34)c2)c1,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,Efficacy,%,1.0,Efficacy,%,1.0,FC(F)(F)c1cccc(CNc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to TO901317,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,CHEMBL1151902,=,=,Efficacy,%,6.0,Efficacy,%,6.0,FC(F)(F)c1cccc(COc2cccc(-c3c(Cc4ccccc4)nnc4c(Cl)cccc34)c2)c1Cl,2009
Agonist activity at human LXRalpha ligand binding domain (205-448) expressed in human HuH7 cells co-transfected with Gal4-DBD by luciferase transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1151902,=,=,EC50,nM,135.0,EC50,uM,0.135,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,=,=,Inhibition,%,50.0,INH,%,50.0,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL1154095,=,=,Inhibition,%,56.0,INH,%,56.0,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,65.0,INH,%,65.0,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,66.0,INH,%,66.0,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,Inhibition,%,68.0,INH,%,68.0,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1154095,=,=,IC50,nM,200.0,IC50,uM,0.2,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,CHEMBL1154095,=,=,IC50,nM,2400.0,IC50,uM,2.4,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,CHEMBL1154095,=,=,IC50,nM,2600.0,IC50,uM,2.6,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,CHEMBL1154095,=,=,IC50,nM,2600.0,IC50,uM,2.6,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,2700.0,IC50,uM,2.7,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,=,=,IC50,nM,2900.0,IC50,uM,2.9,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,CHEMBL1154095,=,=,IC50,nM,3700.0,IC50,uM,3.7,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,3900.0,IC50,uM,3.9,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,CHEMBL1154095,=,=,IC50,nM,4200.0,IC50,uM,4.2,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,5100.0,IC50,uM,5.1,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,5500.0,IC50,uM,5.5,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,=,=,Inhibition,%,6.0,INH,%,6.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,CHEMBL1154095,=,=,IC50,nM,6100.0,IC50,uM,6.1,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,IC50,nM,6300.0,IC50,uM,6.3,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,IC50,nM,6600.0,IC50,uM,6.6,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,=,=,Inhibition,%,7.0,INH,%,7.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,7500.0,IC50,uM,7.5,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,CHEMBL1154095,=,=,IC50,nM,8800.0,IC50,uM,8.8,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,=,=,IC50,nM,15000.0,IC50,uM,15.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,19.0,INH,%,19.0,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,23.0,INH,%,23.0,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,=,=,Inhibition,%,24.0,INH,%,24.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,26.0,INH,%,26.0,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,CHEMBL1154095,=,=,Inhibition,%,28.0,INH,%,28.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,31.0,INH,%,31.0,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,=,=,Inhibition,%,32.0,INH,%,32.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,=,=,Inhibition,%,36.0,INH,%,36.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,CHEMBL1154095,=,=,Inhibition,%,53.0,INH,%,53.0,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,=,=,Inhibition,%,54.0,INH,%,54.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,Inhibition,%,56.0,INH,%,56.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,CHEMBL1154095,=,=,Inhibition,%,60.0,INH,%,60.0,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,=,=,Inhibition,%,60.0,INH,%,60.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,Inhibition,%,62.0,INH,%,62.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,CHEMBL1154095,=,=,Inhibition,%,62.0,INH,%,62.0,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,CHEMBL1154095,=,=,Inhibition,%,64.0,INH,%,64.0,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,Inhibition,%,65.0,INH,%,65.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,Inhibition,%,66.0,INH,%,66.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,CHEMBL1154095,=,=,Inhibition,%,70.0,INH,%,70.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,CHEMBL1154095,=,=,Inhibition,%,70.0,INH,%,70.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,CHEMBL1154095,=,=,Inhibition,%,72.0,INH,%,72.0,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,=,=,Inhibition,%,72.0,INH,%,72.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,CHEMBL1154095,=,=,Inhibition,%,72.0,INH,%,72.0,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1154095,=,=,Inhibition,%,95.0,INH,%,95.0,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,>,>,IC50,nM,20000.0,IC50,uM,20.0,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,>,>,IC50,nM,3000.0,IC50,uM,3.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,COc1cccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccccc2N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccccc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(/C=C/c2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(/C=C/c2ccc(O)c(O)c2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(/C=C/c2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,CHEMBL1154095,,,Activity,,,Activity,,,COc1cccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2cccc(O)c2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2cccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc(CCc2ccc(O)cc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,CHEMBL1154095,,,Activity,,,Activity,,,COc1cccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2cccc(O)c2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccc(N3C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C3=O)cc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccc(CCc2ccc(O)cc2)cc1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL1154095,,,Activity,,,Activity,,,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2009
Agonist activity at human LXRalpha expressed in HEK293 cells assessed as beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,1600.0,IC50,uM,1.6,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,CHEMBL1154095,=,=,IC50,nM,1700.0,IC50,uM,1.7,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccc(O)c(O)c2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,IC50,nM,3800.0,IC50,uM,3.8,COc1ccc(/C=C/c2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,CHEMBL1154095,=,=,IC50,nM,4800.0,IC50,uM,4.8,COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,CHEMBL1154095,=,=,IC50,nM,6100.0,IC50,uM,6.1,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccc(O)c(O)c2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL1154095,=,=,IC50,nM,7400.0,IC50,uM,7.4,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,=,=,IC50,nM,9800.0,IC50,uM,9.8,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,CHEMBL1154095,=,=,IC50,nM,9800.0,IC50,uM,9.8,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccc(O)c(O)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL1154095,=,=,Inhibition,%,23.0,INH,%,23.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,CHEMBL1154095,=,=,Inhibition,%,30.0,INH,%,30.0,O=C1c2ccccc2C(=O)N1c1ccc(/C=C/c2ccccc2)cc1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,CHEMBL1154095,=,=,Inhibition,%,33.0,INH,%,33.0,COc1ccc(CCc2cccc(N3C(=O)c4ccccc4C3=O)c2)cc1OC,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL1154095,=,=,Inhibition,%,34.0,INH,%,34.0,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,2009
Antagonist activity at human LXRalpha expressed in HEK293 cells assessed as inhibition of beta-galactosidase activity at 10 uM by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL1154095,=,=,Inhibition,%,40.0,INH,%,40.0,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,Activity,%,78.0,Activity,%,78.0,C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,Activity,%,39.0,Activity,%,39.0,C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,67.0,Activity,%,67.0,C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1155210,=,=,EC50,nM,56.0,EC50,nM,56.0,O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,EC50,nM,9.0,EC50,nM,9.0,C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,EC50,nM,380.0,EC50,nM,380.0,CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,EC50,nM,46.0,EC50,nM,46.0,CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,EC50,nM,43.0,EC50,nM,43.0,CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,CHEMBL1155210,=,=,EC50,nM,331.0,EC50,nM,331.0,O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,CHEMBL1155210,=,=,EC50,nM,305.0,EC50,nM,305.0,O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,EC50,nM,74.0,EC50,nM,74.0,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,EC50,nM,211.0,EC50,nM,211.0,C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,EC50,nM,200.0,EC50,nM,200.0,C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,EC50,nM,365.0,EC50,nM,365.0,C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,EC50,nM,280.0,EC50,nM,280.0,C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,EC50,nM,200.0,EC50,nM,200.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,91.0,Activity,%,91.0,C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,CHEMBL1155210,=,=,Activity,%,20.0,Activity,%,20.0,O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,CHEMBL1155210,=,=,Activity,%,53.0,Activity,%,53.0,O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,69.0,Activity,%,69.0,CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,70.0,Activity,%,70.0,C[C@@H](COc1cccc(CC(=O)O)c1)CN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,Activity,%,59.0,Activity,%,59.0,C[C@@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,CHEMBL1155210,=,=,Activity,%,76.0,Activity,%,76.0,C[C@H](CCN(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1)Oc1cccc(CC(=O)O)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,80.0,Activity,%,80.0,C[C@@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,89.0,Activity,%,89.0,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,CHEMBL1155210,=,=,Activity,%,26.0,Activity,%,26.0,O=C(O)Cc1ccc2oc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cc2c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,CHEMBL1155210,=,=,Activity,%,75.0,Activity,%,75.0,O=C(O)Cc1ccc2cc(CCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)oc2c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,95.0,Activity,%,95.0,CC(C)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,90.0,Activity,%,90.0,CC(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1155210,=,=,Activity,%,68.0,Activity,%,68.0,CCC(CC)(C(=O)O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,C[C@H](CCOc1cccc(C(C)(C)C(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,2009
"Agonist activity at human LXRalpha assessed as association of SRC1 to LXRalpha ligand binding domain by FRET based cell-free ligand sensing assay relative to 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid",O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,CHEMBL1155210,=,=,Activity,%,100.0,Activity,%,100.0,O=C(O)C1CCCc2c(OCCCN(Cc3cccc(C(F)(F)F)c3Cl)CC(c3ccccc3)c3ccccc3)cccc21,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,CC(C)(O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152683,=,=,IC50,nM,5.2,IC50,nM,5.2,CC(C)(O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(C)(C)O)c2)c1,CHEMBL1152683,=,=,IC50,nM,6.6,IC50,nM,6.6,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(C(C)(C)O)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152683,=,=,IC50,nM,9.5,IC50,nM,9.5,O=C(O)Cc1ccc(COc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,CHEMBL1152683,=,=,IC50,nM,10.2,IC50,nM,10.2,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1152683,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,CHEMBL1152683,=,=,IC50,nM,36.0,IC50,nM,36.0,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(Cl)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,OCc1cccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152683,=,=,IC50,nM,47.0,IC50,nM,47.0,OCc1cccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,CHEMBL1152683,=,=,IC50,nM,59.0,IC50,nM,59.0,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,OCc1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152683,=,=,IC50,nM,75.0,IC50,nM,75.0,OCc1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152683,=,=,IC50,nM,107.0,IC50,nM,107.0,OCc1ccc(Oc2cccc(-c3c(-c4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,Oc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152683,=,=,IC50,nM,115.0,IC50,nM,115.0,Oc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(CO)cc2)c1,CHEMBL1152683,=,=,IC50,nM,131.0,IC50,nM,131.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(CO)cc2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152683,=,=,IC50,nM,231.0,IC50,nM,231.0,COC(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,COc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152683,=,=,IC50,nM,494.0,IC50,nM,494.0,COc1ccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1152683,=,=,IC50,nM,1002.0,IC50,nM,1002.0,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1152683,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha ligand binding domain,COC(=O)c1ccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1152683,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COC(=O)c1ccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1,2009
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153239,=,=,IC50,nM,9.0,IC50,nM,9.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.0,IC50,nM,1.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,7.0,IC50,nM,7.0,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,7.3,IC50,nM,7.3,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2ccccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,269.0,IC50,nM,269.0,Cc1nc2ccccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,5.7,IC50,nM,5.7,CCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(Cl)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,5.1,IC50,nM,5.1,CCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(Cl)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153239,=,=,IC50,nM,5.4,IC50,nM,5.4,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153239,=,=,IC50,nM,5.6,IC50,nM,5.6,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,24.0,IC50,nM,24.0,CCCS(=O)(=O)c1cccc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,CHEMBL1153239,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,CHEMBL1153239,=,=,IC50,nM,20.0,IC50,nM,20.0,Cc1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cc(F)cc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cc(F)cc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cc(F)cc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,38.0,IC50,nM,38.0,CCS(=O)(=O)c1cc(F)cc(Oc2cccc(-n3c(C)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,44.0,IC50,nM,44.0,CS(=O)(=O)c1cccc(Oc2cccc(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(C(F)(F)F)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.3,IC50,nM,1.3,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(C(F)(F)F)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.7,IC50,nM,1.7,CCc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.0,IC50,nM,1.0,CC(C)c1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(C4CC4)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,4.2,IC50,nM,4.2,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(C4CC4)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,0.8,IC50,nM,0.8,CC(C)Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(-c4ccccc4)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.1,IC50,nM,1.1,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(-c4ccccc4)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(Cc4ccc(F)cc4)nc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.2,IC50,nM,1.2,CS(=O)(=O)c1cccc(Oc2cccc(-n3c(Cc4ccc(F)cc4)nc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153239,=,=,IC50,nM,1.5,IC50,nM,1.5,CC(C)c1nc2c(Cl)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,2.7,IC50,nM,2.7,CS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,2.4,IC50,nM,2.4,CCS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)S(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,4.0,IC50,nM,4.0,CC(C)S(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3cnc4c(C(F)(F)F)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(C)(=O)=O)c2)ccc1Cl,CHEMBL1153239,=,=,IC50,nM,3.7,IC50,nM,3.7,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(C)(=O)=O)c2)ccc1Cl,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3c(C)nc4c(Cl)cccc43)c2)c1,CHEMBL1153239,=,=,IC50,nM,3.5,IC50,nM,3.5,CCS(=O)(=O)c1cccc(Oc2ccc(Cl)c(-n3c(C)nc4c(Cl)cccc43)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(=O)(=O)C(C)C)c2)ccc1Cl,CHEMBL1153239,=,=,IC50,nM,3.6,IC50,nM,3.6,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(=O)(=O)C(C)C)c2)ccc1Cl,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cc(F)cc(S(C)(=O)=O)c2)ccc1Cl,CHEMBL1153239,=,=,IC50,nM,4.7,IC50,nM,4.7,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cc(F)cc(S(C)(=O)=O)c2)ccc1Cl,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)ccc1Cl,CHEMBL1153239,=,=,IC50,nM,17.0,IC50,nM,17.0,Cc1nc2c(Cl)cccc2n1-c1cc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)ccc1Cl,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,CHEMBL1153188,=,=,Efficacy,%,57.0,Efficacy,%,57.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,Efficacy,%,22.0,Efficacy,%,22.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay relative to T0901317,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1153188,=,=,Efficacy,%,53.0,Efficacy,%,53.0,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,CHEMBL1153188,=,=,EC50,nM,3000.0,EC50,uM,3.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,EC50,nM,4500.0,EC50,uM,4.5,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1153188,=,=,EC50,nM,6660.0,EC50,uM,6.66,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRalpha ligand binding domain expressed in human HuH7 cells co-transfected with Gal4-DBD by transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153188,=,=,EC50,nM,140.0,EC50,uM,0.14,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,543.0,IC50,nM,543.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(Cl)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4ccccc34)c2)c1,CHEMBL1153188,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4ccccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,12700.0,IC50,nM,12700.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Cc1cccc2c(-c3cccc(Oc4cccc(S(C)(=O)=O)c4)c3)c(C(N)=O)cnc12,CHEMBL1153188,=,=,IC50,nM,756.0,IC50,nM,756.0,Cc1cccc2c(-c3cccc(Oc4cccc(S(C)(=O)=O)c4)c3)c(C(N)=O)cnc12,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CC(C)S(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,286.0,IC50,nM,286.0,CC(C)S(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,1365.0,IC50,nM,1365.0,CCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,453.0,IC50,nM,453.0,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,1772.0,IC50,nM,1772.0,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cc(F)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,552.0,IC50,nM,552.0,CS(=O)(=O)c1cc(F)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(=N)N)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,29850.0,IC50,nM,29850.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(=N)N)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,445.0,IC50,nM,445.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4cnnn4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,26613.0,IC50,nM,26613.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4cnnn4)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C#N)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,13.4,IC50,nM,13.4,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C#N)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(=O)O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,6348.0,IC50,nM,6348.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(=O)O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CCOC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153188,=,=,IC50,nM,6.6,IC50,nM,6.6,CCOC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CCNC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153188,=,=,IC50,nM,6864.0,IC50,nM,6864.0,CCNC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CNC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153188,>,>,IC50,nM,10000.0,IC50,nM,10000.0,CNC(=O)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153188,=,=,IC50,nM,600.0,IC50,nM,600.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153188,=,=,IC50,nM,2.0,IC50,nM,2.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]TO901317 from human recombinant LXRalpha expressed in Escherichia coli by flashplate method,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153188,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(Cl)cc(S(C)(=O)=O)c2)c1,CHEMBL1153144,=,=,IC50,nM,3.0,IC50,nM,3.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(Cl)cc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(F)cc(S(C)(=O)=O)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.9,IC50,nM,1.9,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cc(F)cc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,COc1ccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,CHEMBL1153144,=,=,IC50,nM,8.2,IC50,nM,8.2,COc1ccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,COCCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,3.2,IC50,nM,3.2,COCCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)(C)O)c2)c1,CHEMBL1153144,=,=,IC50,nM,8.2,IC50,nM,8.2,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)(C)O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.4,IC50,nM,1.4,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)C)c2)c1,CHEMBL1153144,=,=,IC50,nM,13.0,IC50,nM,13.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CCC(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CC(C)C)c2)c1,CHEMBL1153144,=,=,IC50,nM,8.1,IC50,nM,8.1,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)CC(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CC(C)S(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,2.4,IC50,nM,2.4,CC(C)S(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.8,IC50,nM,1.8,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,2.6,IC50,nM,2.6,CCCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.6,IC50,nM,1.6,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(Cl)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,7.2,IC50,nM,7.2,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(Cl)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.1,IC50,nM,1.1,Cc1cnc2c(Cl)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.2,IC50,nM,1.2,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(Cl)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,2.8,IC50,nM,2.8,CS(=O)(=O)c1cccc(Oc2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,0.92,IC50,nM,0.92,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccccc2S(C)(=O)=O)c1,CHEMBL1153144,=,=,IC50,nM,560.0,IC50,nM,560.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccccc2S(C)(=O)=O)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153144,=,=,IC50,nM,1.0,IC50,nM,1.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(S(C)(=O)=O)cc2)c1,CHEMBL1153144,=,=,IC50,nM,42.0,IC50,nM,42.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2ccc(S(C)(=O)=O)cc2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,CHEMBL1153144,=,=,IC50,nM,3.0,IC50,nM,3.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(CO)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,CHEMBL1153144,=,=,IC50,nM,9.0,IC50,nM,9.0,CNC(=O)c1cccc(Oc2cccc(-c3c(C)cnc4c(Cl)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha-LBD,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153144,=,=,IC50,nM,9.0,IC50,nM,9.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153237,=,=,IC50,nM,9.0,IC50,nM,9.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,1.0,IC50,nM,1.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,7.0,IC50,nM,7.0,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,49.0,IC50,nM,49.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,30.0,IC50,nM,30.0,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153237,=,=,IC50,nM,33.0,IC50,nM,33.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,CHEMBL1153237,=,=,IC50,nM,188.0,IC50,nM,188.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,14.0,IC50,nM,14.0,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,3.5,IC50,nM,3.5,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,6.5,IC50,nM,6.5,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,7.2,IC50,nM,7.2,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,0.81,IC50,nM,0.81,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CBr)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,,,IC50,,,IC50,,,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CBr)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CN(C)Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CN(C)Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,279.0,IC50,nM,279.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,69.0,IC50,nM,69.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,2.0,IC50,nM,2.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,30.0,IC50,nM,30.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,10.0,IC50,nM,10.0,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,43.0,IC50,nM,43.0,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,CHEMBL1153237,=,=,IC50,nM,194.0,IC50,nM,194.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,COc1ccc(CN(Cc2ccc(OC)cc2)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,CHEMBL1153237,,,IC50,,,IC50,,,COc1ccc(CN(Cc2ccc(OC)cc2)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,CHEMBL1153237,=,=,IC50,nM,24.0,IC50,nM,24.0,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(N)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,136.0,IC50,nM,136.0,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(N)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,CHEMBL1153237,=,=,IC50,nM,7.5,IC50,nM,7.5,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(CS(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,187.0,IC50,nM,187.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(CS(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,79.0,IC50,nM,79.0,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(COc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,292.0,IC50,nM,292.0,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(COc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,IC50,nM,89.0,IC50,nM,89.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2ccc(S(C)(=O)=O)cc2)c1,CHEMBL1153237,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2ccc(S(C)(=O)=O)cc2)c1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1153237,=,=,IC50,nM,166.0,IC50,nM,166.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Displacement of [3H]T0901317 from human recombinant LXRalpha LBD,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,CHEMBL1153237,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1153237,=,=,EC50,nM,170.0,EC50,uM,0.17,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,31.0,EC50,uM,0.031,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,162.0,EC50,uM,0.162,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,840.0,EC50,uM,0.84,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,680.0,EC50,uM,0.68,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153237,=,=,EC50,nM,700.0,EC50,uM,0.7,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,CHEMBL1153237,=,=,EC50,nM,1420.0,EC50,uM,1.42,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,420.0,EC50,uM,0.42,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,950.0,EC50,uM,0.95,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,710.0,EC50,uM,0.71,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,570.0,EC50,uM,0.57,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,20.0,EC50,uM,0.02,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CBr)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CBr)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CN(C)Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CN(C)Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,204.0,EC50,uM,0.204,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,32.0,EC50,uM,0.032,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,850.0,EC50,uM,0.85,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,540.0,EC50,uM,0.54,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,1680.0,EC50,uM,1.68,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(F)(F)F)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,COc1ccc(CN(Cc2ccc(OC)cc2)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,CHEMBL1153237,,,EC50,,,EC50,,,COc1ccc(CN(Cc2ccc(OC)cc2)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,CHEMBL1153237,=,=,EC50,nM,890.0,EC50,uM,0.89,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(N)(=O)=O)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(N)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,CHEMBL1153237,=,=,EC50,nM,530.0,EC50,uM,0.53,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(CS(C)(=O)=O)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(CS(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,1570.0,EC50,uM,1.57,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(COc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(COc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,EC50,nM,3240.0,EC50,uM,3.24,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2ccc(S(C)(=O)=O)cc2)c1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2ccc(S(C)(=O)=O)cc2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,CHEMBL1153237,,,EC50,,,EC50,,,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,78.0,Efficacy,%,78.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,49.0,Efficacy,%,49.0,Cc1nc2c(C(F)(F)F)cccc2n1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,37.0,Efficacy,%,37.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,39.0,Efficacy,%,39.0,CCS(=O)(=O)c1cccc(Oc2cccc(-c3c(C)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,CHEMBL1153237,=,=,Efficacy,%,25.0,Efficacy,%,25.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)C(C)C)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,CHEMBL1153237,=,=,Efficacy,%,17.0,Efficacy,%,17.0,Cc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(=O)(=O)CCCO)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,62.0,Efficacy,%,62.0,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,68.0,Efficacy,%,68.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,71.0,Efficacy,%,71.0,CC(C)(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,64.0,Efficacy,%,64.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-c4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,88.0,Efficacy,%,88.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(Cc4ccccc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,56.0,Efficacy,%,56.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCCCC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,62.0,Efficacy,%,62.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(CN4CCSC4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,81.0,Efficacy,%,81.0,CS(=O)(=O)c1cccc(Oc2cccc(-c3c(-n4ccnc4)nc4c(C(F)(F)F)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,50.0,Efficacy,%,50.0,CC(C)c1nc2c(Cl)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,44.0,Efficacy,%,44.0,CC(C)c1nc2c(C#N)cccn2c1-c1cccc(Oc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,CHEMBL1153237,=,=,Efficacy,%,48.0,Efficacy,%,48.0,COc1ccc(CN(C)S(=O)(=O)c2cccc(Oc3cccc(-c4c(C(C)C)nc5c(Cl)cccn45)c3)c2)cc1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,CHEMBL1153237,=,=,Efficacy,%,61.0,Efficacy,%,61.0,CNS(=O)(=O)c1cccc(Oc2cccc(-c3c(C(C)C)nc4c(Cl)cccn34)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,48.0,Efficacy,%,48.0,CCc1nc2c(C(F)(F)F)cccn2c1-c1cccc(Cc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human Gal4-LBD fused LXRalpha LBD expressed in Huh7 cells by transient transactivation assay relative to T0901317,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,CHEMBL1153237,=,=,Efficacy,%,26.0,Efficacy,%,26.0,CC(C)c1nc2c(C(F)(F)F)cccn2c1-c1cccc(OCc2cccc(S(C)(=O)=O)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of p300-1 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of p300-1 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of p300-1 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of p300-1 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2ccccc2S(C)(=O)=O)cc1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2ccccc2S(C)(=O)=O)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C(F)(F)F)cccc2nc1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C(F)(F)F)cccc2nc1-c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CCS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,CCS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CNC(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,CNC(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,IC50,nM,165.0,IC50,uM,0.165,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CS(=O)(=O)c1cccc(-c2ccc(-c3cnc4c(C(F)(F)F)cccc4n3)cc2)c1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cnc4c(C(F)(F)F)cccc4n3)cc2)c1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,IC50,nM,734.0,IC50,uM,0.734,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,Cc1nc2c(C#N)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,Cc1nc2c(C#N)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,COc1cccc2nc(-c3ccc(-c4cccc(S(C)(=O)=O)c4)cc3)c(C)nc12,CHEMBL1156230,>,>,IC50,nM,1000.0,IC50,uM,1.0,COc1cccc2nc(-c3ccc(-c4cccc(S(C)(=O)=O)c4)cc3)c(C)nc12,2010
Displacement of [3H]T0901317 from human LXRalpha ligand binding domain,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,=,=,IC50,nM,1770.0,IC50,uM,1.77,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Binding affinity to human recombinant LXRalpha ligand binding domain,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,=,=,IC50,nM,13.0,IC50,uM,0.013,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,3.1,Efficacy,%,3.1,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,CHEMBL1156230,=,=,Efficacy,%,2.0,Efficacy,%,2.0,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,2010
Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,70.0,Efficacy,%,70.0,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,5.0,Efficacy,%,5.0,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,=,=,Efficacy,%,84.0,Efficacy,%,84.0,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,1.0,Efficacy,%,1.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,CHEMBL1156230,=,=,Efficacy,%,1.0,Efficacy,%,1.0,CNS(=O)(=O)c1cccc(-c2ccc(-c3nc4cccc(C(F)(F)F)c4nc3C)cc2)c1,2010
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,1.0,Efficacy,%,1.0,Cc1nc2c(Cl)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,13.0,Efficacy,%,13.0,CCc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay relative to TO901317,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,=,=,Efficacy,%,36.0,Efficacy,%,36.0,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta in HEK293 cells assessed as Gal4 transactivation relative to T0901317,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,45.0,Efficacy,%,45.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta in HEK293 cells assessed as Gal4 transactivation relative to T0901317,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,=,=,Efficacy,%,48.0,Efficacy,%,48.0,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRalpha in HEK293 cells assessed as Gal4 transactivation relative to T0901317,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,=,=,Efficacy,%,7.0,Efficacy,%,7.0,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRalpha in HEK293 cells assessed as Gal4 transactivation relative to T0901317,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,=,=,Efficacy,%,80.0,Efficacy,%,80.0,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-1 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-1 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-1 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-1 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-3 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-3 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-3 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC1-3 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-1 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-1 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-1 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-1 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-3 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-3 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-3 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC2-3 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC3-2 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC3-2 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of SRC3-2 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of SRC3-2 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of TRAP220-1 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of TRAP220-1 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of TRAP220-1 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of TRAP220-1 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC-1a cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC-1a cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC-1a cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of PGC-1a cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC1b-2 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC1b-2 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PGC1b-2 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of PGC1b-2 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of CPB/p300-2 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of CPB/p300-2 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of CPB/p300-2 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of CPB/p300-2 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PCAF cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PCAF cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of PCAF cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of PCAF cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRIP1-1 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRIP1-1 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRIP1-1 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of NRIP1-1 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-3 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-3 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-3 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-3 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-6 cofactor recruitment,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156230,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-6 cofactor recruitment,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Cc1nc2c(C(F)(F)F)cccc2nc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-6 cofactor recruitment,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1156230,,,Activity,,,Activity,,,CS(=O)(=O)c1cc(Cl)cc(Oc2cccc(-c3c(C(N)=O)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Agonist activity at human LXRbeta assessed as induction of NRP1-6 cofactor recruitment,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL1156230,,,Activity,,,Activity,,,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2010
Antagonist activity at LXRalpha ligand binding domain assessed as inhibition of T1317-induced transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1156210,=,=,IC50,nM,100.0,pIC50,,7.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL1156210,=,=,EC50,nM,794.33,pEC50,,6.1,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156210,=,=,EC50,nM,63.1,pEC50,,7.2,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,CHEMBL1156210,=,=,EC50,nM,10.0,pEC50,,8.0,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,CHEMBL1156210,=,=,EC50,nM,6.31,pEC50,,8.2,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C3CC3)cc2)c1,CHEMBL1156210,=,=,EC50,nM,100.0,pEC50,,7.0,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C3CC3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,Cc1ccccc1S(=O)(=O)N(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)Cc1c(F)cccc1Cl,CHEMBL1156210,=,=,EC50,nM,12.59,pEC50,,7.9,Cc1ccccc1S(=O)(=O)N(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)Cc1c(F)cccc1Cl,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c(C)c1,CHEMBL1156210,=,=,EC50,nM,79.43,pEC50,,7.1,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c(C)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(F)cc2Cl)c(C)c1,CHEMBL1156210,=,=,EC50,nM,125.89,pEC50,,6.9,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(F)cc2Cl)c(C)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(C(F)(F)F)o2)c(C)c1,CHEMBL1156210,,,pEC50,,,pEC50,,,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(C(F)(F)F)o2)c(C)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay,Cn1cnc(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c1,CHEMBL1156210,=,=,EC50,nM,79.43,pEC50,,7.1,Cn1cnc(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1156210,=,=,Ratio,,1.1,Ratio,,1.1,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,CHEMBL1156210,=,=,Ratio,,1.0,Ratio,,1.0,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3ccc(F)cc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,CHEMBL1156210,=,=,Ratio,,1.2,Ratio,,1.2,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)c3ccccc3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C3CC3)cc2)c1,CHEMBL1156210,=,=,Ratio,,0.9,Ratio,,0.9,CS(=O)(=O)c1cccc(-c2ccc(CN(Cc3c(F)cccc3Cl)S(=O)(=O)C3CC3)cc2)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,Cc1ccccc1S(=O)(=O)N(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)Cc1c(F)cccc1Cl,CHEMBL1156210,=,=,Ratio,,1.2,Ratio,,1.2,Cc1ccccc1S(=O)(=O)N(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)cc1)Cc1c(F)cccc1Cl,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c(C)c1,CHEMBL1156210,=,=,Ratio,,0.5,Ratio,,0.5,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c(C)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(F)cc2Cl)c(C)c1,CHEMBL1156210,=,=,Ratio,,0.2,Ratio,,0.2,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(F)cc2Cl)c(C)c1,2010
Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay relative to T1317,Cn1cnc(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c1,CHEMBL1156210,=,=,Ratio,,1.0,Ratio,,1.0,Cn1cnc(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2c(F)cccc2Cl)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1158561,=,=,IC50,nM,13.0,IC50,nM,13.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1158561,=,=,IC50,nM,68.0,IC50,nM,68.0,CS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1ccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1158561,>,>,IC50,nM,1000.0,IC50,nM,1000.0,CS(=O)(=O)c1ccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)cc1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1158561,=,=,IC50,nM,9.0,IC50,nM,9.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1,CHEMBL1158561,>,>,IC50,nM,1000.0,IC50,nM,1000.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2ccc(S(C)(=O)=O)cc2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1cccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1158561,=,=,IC50,nM,7.0,IC50,nM,7.0,CS(=O)(=O)c1cccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1ccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,CHEMBL1158561,=,=,IC50,nM,372.0,IC50,nM,372.0,CS(=O)(=O)c1ccc(-c2cccc(-c3c(Cc4ccccc4)cnc4c(C(F)(F)F)cccc34)c2)cc1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1158561,=,=,IC50,nM,4.8,IC50,nM,4.8,CCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CCCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1158561,=,=,IC50,nM,7.6,IC50,nM,7.6,CCCc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CC(C)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,CHEMBL1158561,=,=,IC50,nM,8.2,IC50,nM,8.2,CC(C)c1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cccc(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CCS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1158561,=,=,IC50,nM,362.0,IC50,nM,362.0,CCS(=O)(=O)c1cccc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CCS(=O)(=O)c1cccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,CHEMBL1158561,=,=,IC50,nM,73.0,IC50,nM,73.0,CCS(=O)(=O)c1cccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,Cc1ccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,CHEMBL1158561,=,=,IC50,nM,12.0,IC50,nM,12.0,Cc1ccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,COc1ccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,CHEMBL1158561,>,>,IC50,nM,1000.0,IC50,nM,1000.0,COc1ccc(-c2cccc(-c3c(C)cnc4c(C(F)(F)F)cccc34)c2)cc1S(C)(=O)=O,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2ccc(F)c(S(C)(=O)=O)c2)c1,CHEMBL1158561,=,=,IC50,nM,10.0,IC50,nM,10.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2ccc(F)c(S(C)(=O)=O)c2)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cc(S(C)(=O)=O)c(F)cc2F)c1,CHEMBL1158561,=,=,IC50,nM,10.0,IC50,nM,10.0,Cc1cnc2c(C(F)(F)F)cccc2c1-c1cccc(-c2cc(S(C)(=O)=O)c(F)cc2F)c1,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)ccc1F,CHEMBL1158561,=,=,IC50,nM,32.0,IC50,nM,32.0,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)ccc1F,2010
Displacement of [3H]T0901317 from LXRalpha ligand binding domain,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c(F)cc1F,CHEMBL1158561,=,=,IC50,nM,25.0,IC50,nM,25.0,CS(=O)(=O)c1cc(-c2cccc(-c3ccnc4c(C(F)(F)F)cccc34)c2)c(F)cc1F,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(N(C)Cc2ccc(C(=O)O)cc2)c(C(F)(F)F)n1,CHEMBL1208782,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(N(C)Cc2ccc(C(=O)O)cc2)c(C(F)(F)F)n1,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay,CN(Cc1cccc(C(=O)O)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,CHEMBL1208782,>,>,EC50,nM,10000.0,EC50,uM,10.0,CN(Cc1cccc(C(=O)O)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay,CN(Cc1ccc(C(=O)O)cc1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,CHEMBL1208782,>,>,EC50,nM,10000.0,EC50,uM,10.0,CN(Cc1ccc(C(=O)O)cc1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay relative to T0901317,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(N(C)Cc2ccc(C(=O)O)cc2)c(C(F)(F)F)n1,CHEMBL1208782,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(N(C)Cc2ccc(C(=O)O)cc2)c(C(F)(F)F)n1,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay relative to T0901317,CN(Cc1cccc(C(=O)O)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,CHEMBL1208782,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CN(Cc1cccc(C(=O)O)c1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,2010
Agonist activity at LXRalpha-LBD expressed in HEK293 cells assessed as Gal4-DBD interaction by cellular mammalian one hybrid assay relative to T0901317,CN(Cc1ccc(C(=O)O)cc1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,CHEMBL1208782,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CN(Cc1ccc(C(=O)O)cc1)c1ccc(OCc2c(-c3c(Cl)cccc3Cl)noc2C2CC2)nc1C(F)(F)F,2010
Agonist activity at LXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay,C=CCc1ccc(O)c(-c2ccc(O)c(CC=C)c2)c1,CHEMBL1212931,,,Activity,,,Activity,,,C=CCc1ccc(O)c(-c2ccc(O)c(CC=C)c2)c1,2010
Transactivation of LXRalpha,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(-c2nnn[nH]2)cn1,CHEMBL1221250,,,Activity,,,Activity,,,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(-c2nnn[nH]2)cn1,2010
Transactivation of LXRalpha,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)NO)cn1,CHEMBL1221250,,,Activity,,,Activity,,,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)NO)cn1,2010
Transactivation of LXRalpha,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,CHEMBL1221250,,,Activity,,,Activity,,,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,2010
Agonist activity at LXRalpha by TR-FRET assay,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F,CHEMBL1671812,>,>,EC50,nM,8300.0,EC50,uM,8.3,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F,2011
Agonist activity at LXRalpha by TR-FRET assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL1671812,=,=,EC50,nM,3.2,EC50,nM,3.2,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2011
Antagonist activity at LXRalpha by TR-FRET assay,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F,CHEMBL1671812,>,>,IC50,nM,8300.0,IC50,uM,8.3,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F,2011
Agonist activity at LXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL1687703,,,Activity,,,Activity,,,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2010
Agonist activity at LXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,CHEMBL1687703,,,Activity,,,Activity,,,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,2010
Agonist activity at LXRalpha transfected in human COS1 cells after 18 hrs by luciferase reporter gene transactivation assay,CCN(c1ccc(C(C)C)c(OCC(C)C)c1)c1ccc(C(=O)O)cn1,CHEMBL1687703,,,Activity,,,Activity,,,CCN(c1ccc(C(C)C)c(OCC(C)C)c1)c1ccc(C(=O)O)cn1,2010
Agonist activity at LXR,O=C(O)CCc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)CCc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Agonist activity at LXR,O=C(O)COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Agonist activity at LXR,O=C(O)CCCOc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)CCCOc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Antagonist activity at LXR,O=C(O)CCc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)CCc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Antagonist activity at LXR,O=C(O)COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)COc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Antagonist activity at LXR,O=C(O)CCCOc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,CHEMBL1811873,,,Activity,,,Activity,,,O=C(O)CCCOc1ccc(CCc2ccc(N3C(=O)c4ccccc4C3=O)cc2)cc1,2011
Effect on LXRA(NR1H3) dependent reporter activity in HEK293 cells at 20 uM,CCOC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,CHEMBL1961794,,,Inhibition,%,,Inhibition,,,CCOC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,2012
Effect on LXRA(NR1H3) dependent reporter activity in HEK293 cells at 20 uM,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,CHEMBL1961794,,,Inhibition,%,,Inhibition,,,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,=,=,IC50,nM,40.0,IC50,uM,0.04,CN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2010763,=,=,IC50,nM,100.0,IC50,uM,0.1,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(c2cccn2Cc2ccccc2)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,=,=,IC50,nM,800.0,IC50,uM,0.8,CN(c1ccc(C(O)(c2cccn2Cc2ccccc2)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(c1cccn1Cc1ccccc1)C(F)(F)F,CHEMBL2010763,>,>,IC50,nM,10000.0,IC50,uM,10.0,COC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)(c1cccn1Cc1ccccc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,=,=,IC50,nM,1500.0,IC50,uM,1.5,COCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(OC)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,=,=,IC50,nM,400.0,IC50,uM,0.4,COCCn1cccc1C(OC)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,=,=,IC50,nM,200.0,IC50,uM,0.2,COCCn1cccc1C(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCOCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,=,=,IC50,nM,500.0,IC50,uM,0.5,CCOCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCOCCn1cccc1C(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,=,=,IC50,nM,200.0,IC50,uM,0.2,CCOCCn1cccc1C(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(c2ccc[nH]2)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,,,Inhibition,%,,INH,,,CN(c1ccc(C(O)(c2ccc[nH]2)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(c2cccn2C)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,,,Inhibition,%,,INH,,,CN(c1ccc(C(O)(c2cccn2C)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,,,Inhibition,%,,INH,,,CCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,,,Inhibition,%,,INH,,,CCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(c2cccn2CCO)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,,,Inhibition,%,,INH,,,CN(c1ccc(C(O)(c2cccn2CCO)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCC(C)n1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,,,Inhibition,%,,INH,,,CCC(C)n1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,,,Inhibition,%,,INH,,,CCCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CN(c1ccc(C(O)(c2cccn2CCCO)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2010763,,,Inhibition,%,,INH,,,CN(c1ccc(C(O)(c2cccn2CCCO)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCCCCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,CHEMBL2010763,,,Inhibition,%,,INH,,,CCCCCCn1cccc1C(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)C(F)(F)F,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1Cc1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1Cc1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(=O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(=O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(OC)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(OC)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCOC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,CHEMBL2010763,,,Inhibition,%,,INH,,,CCOC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(C)(O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(C)(O)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(C)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(C)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCC(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,CHEMBL2010763,,,Inhibition,%,,INH,,,CCC(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,CHEMBL2010763,,,Inhibition,%,,INH,,,CCC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCCC(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,CHEMBL2010763,,,Inhibition,%,,INH,,,CCCC(O)(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",CCCC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,CHEMBL2010763,,,Inhibition,%,,INH,,,CCCC(c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1)c1cccn1CCOC,2012
"Displacement of [3H]N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzenesulfonamide from LXRalpa by scintillation proximity assay",COCCn1cccc1C(CO)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,CHEMBL2010763,,,Inhibition,%,,INH,,,COCCn1cccc1C(CO)c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1,2012
Induction of LXRalpha enhancer activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,CHEMBL2034959,,,Activity,,,Activity,,,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,2012
Induction of LXRalpha-mediated ABCA1 promoter activity in human THP1 cells after 24 hrs by luciferase reporter gene analysis,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,CHEMBL2034959,,,Activity,,,Activity,,,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,2012
Increase in LXRalpha-mediated ABCA1 mRNA expression in human THP1 cells at 5 to 15 uM after 24 hrs by RT-PCR analysis,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,CHEMBL2034959,,,Activity,,,Activity,,,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,2012
Increase in LXRalpha-mediated ABCA1 protein expression in human THP1 cells at 5 to 15 uM after 48 hrs by Western blotting analysis,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,CHEMBL2034959,,,Activity,,,Activity,,,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,2012
Agonist activity at LXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,CHEMBL2146420,,,Activity,,,Activity,,,CCN(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc(C(=O)O)cn1,2012
Agonist activity at LXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay,Cc1cc2c(cc1-n1c(C)nc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,CHEMBL2146420,,,Activity,,,Activity,,,Cc1cc2c(cc1-n1c(C)nc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,2012
Agonist activity at LXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay,Cc1cc2c(cc1-n1nnc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,CHEMBL2146420,,,Activity,,,Activity,,,Cc1cc2c(cc1-n1nnc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,2012
Antagonist activity at recombinant LXRalpha LBD expressed in HEK293T cells co-expressing GAL4 DBD assessed as inhibition of TO901317-induced transactivation at 20 uM by luciferase reporter gene assay,COc1cc(/C=C2\C(=O)N(c3cccc([N+](=O)[O-])c3)N=C2c2ccccc2)ccc1O,CHEMBL2169822,,,Inhibition,%,,INH,,,COc1cc(/C=C2\C(=O)N(c3cccc([N+](=O)[O-])c3)N=C2c2ccccc2)ccc1O,2012
Agonist activity at recombinant LXRalphaLBD expressed in HEK293T cells co-expressing GAL4 DBD at 20 uM by transactivation assay,COc1cc(/C=C2\C(=O)N(c3cccc([N+](=O)[O-])c3)N=C2c2ccccc2)ccc1O,CHEMBL2169822,,,Activity,,,Activity,,,COc1cc(/C=C2\C(=O)N(c3cccc([N+](=O)[O-])c3)N=C2c2ccccc2)ccc1O,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-DRIP205 assessed as DRIP205 recruitment at 0.03 to 10 uM after 16 hrs by mammalian two-hybrid assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SRC1 assessed as SRC1 recruitment at 0.03 to 10 uM after 16 hrs by mammalian two-hybrid assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)=O)cc21,CHEMBL2169742,=,=,IC50,nM,4900.0,IC50,uM,4.9,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)=O)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(=O)O)cc21,CHEMBL2169742,=,=,IC50,nM,14000.0,IC50,uM,14.0,C=C1c2ccccc2C(=O)N(C)c2ccc(C(=O)O)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CO)cc21,CHEMBL2169742,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=C1c2ccccc2C(=O)N(C)c2ccc(CO)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,CHEMBL2169742,=,=,IC50,nM,4100.0,IC50,uM,4.1,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(N)cc21,CHEMBL2169742,=,=,IC50,nM,19000.0,IC50,uM,19.0,C=C1c2ccccc2C(=O)N(C)c2ccc(N)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc([N+](=O)[O-])cc21,CHEMBL2169742,=,=,IC50,nM,6100.0,IC50,uM,6.1,C=C1c2ccccc2C(=O)N(C)c2ccc([N+](=O)[O-])cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)=O)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)=O)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(=O)O)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(=O)O)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CO)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CO)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(N)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(N)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc([N+](=O)[O-])cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc([N+](=O)[O-])cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccc(-c3ccc(CC(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,=,=,IC50,nM,2200.0,IC50,uM,2.2,C=C1c2ccc(-c3ccc(CC(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccc(-c3cccc(CC(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,=,=,IC50,nM,21000.0,IC50,uM,21.0,C=C1c2ccc(-c3cccc(CC(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,=,=,IC50,nM,1300.0,IC50,uM,1.3,C=C1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccc(-c3cccc(C(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,>,>,IC50,nM,30000.0,IC50,uM,30.0,C=C1c2ccc(-c3cccc(C(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccc(-c3ccc(CC(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccc(-c3ccc(CC(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccc(-c3cccc(CC(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccc(-c3cccc(CC(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccc(-c3ccc(C(=O)O)cc3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccc(-c3cccc(C(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccc(-c3cccc(C(=O)O)c3)cc2C(=O)N(C)c2ccc(CC)cc21,2012
Binding affinity to human GST-tagged LXRalpha expressed in Escherichia coli BL21(DE3) at 1 uM after 1 hr by fluorescence polarization assay,COc1ccc(CCc2ccc(N3C(=O)c4ccc(N(C)C)cc4C3=O)cc2)cc1,CHEMBL2169742,,,Activity,,,Activity,,,COc1ccc(CCc2ccc(N3C(=O)c4ccc(N(C)C)cc4C3=O)cc2)cc1,2012
"Binding affinity to human GST-tagged LXRalpha expressed in Escherichia coli BL21(DE3) assessed as inhibition of 2-(4-(4-methoxyphenethyl)phenyl)-5- (dimethylamino)isoindoline-1,3-dione binding after 1 hr by fluorescence polarization assay",C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
"Binding affinity to human GST-tagged LXRalpha expressed in Escherichia coli BL21(DE3) assessed as inhibition of 2-(4-(4-methoxyphenethyl)phenyl)-5- (dimethylamino)isoindoline-1,3-dione binding after 1 hr by fluorescence polarization assay",C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
"Binding affinity to human GST-tagged LXRalpha expressed in Escherichia coli BL21(DE3) assessed as inhibition of 2-(4-(4-methoxyphenethyl)phenyl)-5- (dimethylamino)isoindoline-1,3-dione binding after 1 hr by fluorescence polarization assay",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SMRT assessed as SMRT recruitment at 0.03 to 10 uM after 16 hrs by reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-NCoR assessed as NCoR recruitment at 0.03 to 10 uM after 16 hrs by reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SMRT assessed as SMRT recruitment after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-NCoR assessed as NCoR recruitment after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SMRT assessed as SMRT recruitment after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-NCoR assessed as NCoR recruitment after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-DRIP205 assessed as DRIP205 recruitment at 10 uM after 16 hrs by mammalian two-hybrid assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SRC1 assessed as SRC1 recruitment at 10 uM after 16 hrs by mammalian two-hybrid assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-DRIP205 assessed as DRIP205 recruitment at 10 uM after 16 hrs by mammalian two-hybrid assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells coexpressing CMX-Gal4N-SRC1 assessed as SRC1 recruitment at 10 uM after 16 hrs by mammalian two-hybrid assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,=,=,IC50,nM,5400.0,IC50,uM,5.4,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)C)cc21,CHEMBL2169742,=,=,IC50,nM,1700.0,IC50,uM,1.7,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)C)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCCCCCCCC)cc21,CHEMBL2169742,>,>,IC50,nM,30000.0,IC50,uM,30.0,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCCCCCCCC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCC)cc21,CHEMBL2169742,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,>,>,IC50,nM,30000.0,IC50,uM,30.0,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C)cc21,CHEMBL2169742,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=C1c2ccccc2C(=O)N(C)c2ccc(C)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccccc21,CHEMBL2169742,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=C1c2ccccc2C(=O)N(C)c2ccccc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)(C)C)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(C)C)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCCCCCCCC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCCCCCCCC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CCCCCC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(CC)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C)cc21,CHEMBL2169742,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity at 30 uM after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL2169742,,,Inhibition,%,,INH,,,C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity at 30 uM after 16 hrs by reporter gene assay,CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,,,Inhibition,%,,INH,,,CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity at 30 uM after 16 hrs by reporter gene assay,CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,,,Inhibition,%,,INH,,,CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity at 30 uM after 16 hrs by reporter gene assay,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,Inhibition,%,,INH,,,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,Cn1c(=O)c2ccccc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,=,=,IC50,nM,4100.0,IC50,uM,4.1,Cn1c(=O)c2ccccc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational antagonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as inhibition of T1317-induced luciferase activity after 16 hrs by reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,,,IC50,,,IC50,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
"Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay relative to N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzamide",C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL2169742,=,=,Efficacy,%,45.0,Efficacy,%,45.0,C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2012
"Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay relative to N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzamide",CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,=,=,Efficacy,%,117.0,Efficacy,%,117.0,CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
"Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay relative to N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzamide",CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,=,=,Efficacy,%,12.0,Efficacy,%,12.0,CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
"Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay relative to N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzamide",CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,=,=,Efficacy,%,100.0,Efficacy,%,100.0,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
"Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay relative to N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-methylbenzamide",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,=,=,Efficacy,%,124.0,Efficacy,%,124.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity at 30 uM after 16 hrs by reporter gene assay,Cn1c(=O)c2ccccc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,,,Activity,,,Activity,,,Cn1c(=O)c2ccccc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL2169742,=,=,EC50,nM,1700.0,EC50,uM,1.7,C=C1c2ccccc2C(=O)N(C)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay,CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,=,=,EC50,nM,910.0,EC50,uM,0.91,CN1C(=O)c2ccccc2CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay,CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL2169742,=,=,EC50,nM,4200.0,EC50,uM,4.2,CN1C(=O)c2ccccc2Oc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,=,=,EC50,nM,630.0,EC50,uM,0.63,CN(C(=O)c1ccccc1)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivational agonist activity at human LXRalpha transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2169742,=,=,EC50,nM,340.0,EC50,uM,0.34,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Agonist activity at human LXR-alpha assessed as increase in recruitment of Trap 220/Drip2 coactivator peptide by TR-FRET assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,=,=,EC50,nM,1500.0,EC50,uM,1.5,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at LXR-alpha in human THP1 cells assessed as reduced cellular cholesterol concentration at 1 uM,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2203118,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Agonist activity at LXR-alpha in human Caco2 cells assessed as reduction in cellular cholesterol level,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at LXR-alpha in human HepG2 cells assessed as reduction in cellular cholesterol level,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at LXR-alpha in human THP1 cells assessed as reduced cellular cholesterol concentration,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at LXR-alpha in human THP1 cells assessed as increase cholesterol efflux to HDL by FACs analysis,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Binding affinity to human LXR-alpha LBD by SPR-Biacore assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at human LXR-alpha assessed as increase in recruitment of Trap 220/Drip2 coactivator peptide by TR-FRET assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2203118,=,=,EC50,nM,1430.0,EC50,uM,1.43,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Agonist activity at LXR-alpha in human THP1 cells assessed as increase cholesterol efflux to HDL at 1 uM by FACs analysis,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2203118,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Agonist activity at human LXR-alpha assessed as increase in recruitment of Trap 220/Drip2 coactivator peptide by TR-FRET assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Transactivation of human LXR-alpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2203118,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2012
Transactivation of human LXR-alpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,,,Activity,,,Activity,,,CCOC(=O)c1c(O)cc(O)cc1O,2012
Transactivation of human LXR-alpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,=,=,EC50,nM,80760.0,EC50,uM,80.76,CCOC(=O)c1c(O)cc(O)cc1O,2012
Transactivation of human LXR-alpha transfected in HEK293 cells at 100 uM after 24 hrs by luciferase reporter gene assay,CCOC(=O)c1c(O)cc(O)cc1O,CHEMBL2203118,=,=,Activity,%,64.0,Activity,%,64.0,CCOC(=O)c1c(O)cc(O)cc1O,2012
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3046494,=,=,FC,,2.61,FC,,2.61,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,1.9,FC,,1.9,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,1.7,FC,,1.7,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of ABCA1 gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3046494,=,=,FC,,2.6,FC,,2.6,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 1 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,2.26,FC,,2.26,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,3.42,FC,,3.42,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 1 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,2.3,FC,,2.3,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,4.52,FC,,4.52,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of SREBP1c gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as PEPCK gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as PEPCK gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,0.94,FC,,0.94,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as PEPCK gene expression at 1 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,0.65,FC,,0.65,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as PEPCK gene expression at 1 uM after 48 hr by luciferase reporter gene assay relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3046494,=,=,FC,,0.66,FC,,0.66,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as PEPCK gene expression at 1 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,0.62,FC,,0.62,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as decrease in PEPCK gene transactivation at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,Activity,%,58.0,Activity,%,58.0,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as decrease in PEPCK gene transactivation at 10 uM after 48 hr by luciferase reporter gene assay relative to control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,Activity,%,46.0,Activity,%,46.0,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transrepression of PEPCK gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transrepression of PEPCK gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to vehicle-treated control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to vehicle-treated control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression at 100 nM after 48 hr by luciferase reporter gene assay relative to vehicle-treated control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3046494,=,=,FC,,2.2,FC,,2.2,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to vehicle-treated control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,2.0,FC,,2.0,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression at 10 uM after 48 hr by luciferase reporter gene assay relative to vehicle-treated control,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,=,=,FC,,2.0,FC,,2.0,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)C[C@H](O)[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression after 48 hr by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3046494,=,=,EC50,nM,190.0,EC50,nM,190.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at Homo sapiens (human) LXRalpha expressed in HepG2 cells assessed as transactivation of CYP7A1 gene expression after 48 hr by luciferase reporter gene assay,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,CHEMBL3046494,,,Activity,,,Activity,,,C=C1C(=O)O[C@@H]2C[C@H](C)[C@@]3(O)CC[C@@](C)(C[C@@H](OC(=O)C(C)C)[C@@H]12)O3,2013
Modulation of LXR-alpha (unknown origin),COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccc3c(c2)OCO3)c(OC)c1,CHEMBL2311492,,,Activity,,,Activity,,,COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccc3c(c2)OCO3)c(OC)c1,2013
Antagonist activity at LXRalpha (unknown origin) expressed in HEK293t cells,COc1cc(O)c(C(CC(=O)N2C[C@H](C)C[C@H](C)C2)c2ccc3c(c2)OCO3)c(OC)c1,CHEMBL2321802,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cc(O)c(C(CC(=O)N2C[C@H](C)C[C@H](C)C2)c2ccc3c(c2)OCO3)c(OC)c1,2013
Induction of recruitment of Trap220 peptide to LXRalpha (unknown origin) by TR-FRET LXR-alpha co-activator assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2321801,,,Activity,,,Activity,,,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2013
Induction of recruitment of Trap220 peptide to LXRalpha (unknown origin) by TR-FRET LXR-alpha co-activator assay,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,,,Activity,,,Activity,,,CC12CCC(CC1)C(C)(C)O2,2013
Binding affinity to LXRalpha (unknown origin),CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL2321801,=,=,EC50,nM,320.0,EC50,uM,0.32,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2013
Agonist activity at LXRalpha (unknown origin) transfected in human CHO-K1 cells assessed as induction of transactivation at 200 microM by luciferase reporter gene transactivation assay relative to control,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,=,=,FC,,2.3,FC,,2.3,CC12CCC(CC1)C(C)(C)O2,2013
Agonist activity at LXRalpha (unknown origin) transfected in human CHO-K1 cells assessed as induction of transactivation at 100 microM by luciferase reporter gene transactivation assay relative to control,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,=,=,FC,,2.0,FC,,2.0,CC12CCC(CC1)C(C)(C)O2,2013
Agonist activity at LXRalpha (unknown origin) transfected in human CHO-K1 cells assessed as induction of transactivation at 50 microM by luciferase reporter gene transactivation assay relative to control,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,=,=,FC,,1.4,FC,,1.4,CC12CCC(CC1)C(C)(C)O2,2013
Agonist activity at LXRalpha (unknown origin) transfected in human CHO-K1 cells assessed as induction of transactivation by luciferase reporter gene transactivation assay relative to control,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,,,Activity,,,Activity,,,CC12CCC(CC1)C(C)(C)O2,2013
Agonist activity at LXRalpha (unknown origin) transfected in human CHO-K1 cells assessed as induction of transactivation at 50 to 200 microM by luciferase reporter gene transactivation assay relative to control,CC12CCC(CC1)C(C)(C)O2,CHEMBL2321801,>,>,Activity,%,75.0,Activity,%,75.0,CC12CCC(CC1)C(C)(C)O2,2013
Transactivation of LXRalpha (unknown origin) by luciferase reporter gene assay relative to carba-T0901317,Cc1cc2c(cc1-n1c(C(F)(F)F)nc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,CHEMBL2331224,,,Activity,,,Activity,,,Cc1cc2c(cc1-n1c(C(F)(F)F)nc3cc(C(=O)O)ccc31)C(C)(C)CCC2(C)C,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,COc1ccc(CN(Cc2cccnc2)Cc2ccc(C#N)s2)cc1,CHEMBL2380244,>,>,IC50,nM,100000.0,IC50,uM,100.0,COc1ccc(CN(Cc2cccnc2)Cc2ccc(C#N)s2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Clc1ccc(CN(Cc2cccnc2)Cc2ncc[nH]2)cc1,CHEMBL2380244,>,>,IC50,nM,100000.0,IC50,uM,100.0,Clc1ccc(CN(Cc2cccnc2)Cc2ncc[nH]2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,O=[N+]([O-])c1ccc(CN(Cc2ccccc2)Cc2ccc(Cl)cc2)s1,CHEMBL2380244,>,>,IC50,nM,100000.0,IC50,uM,100.0,O=[N+]([O-])c1ccc(CN(Cc2ccccc2)Cc2ccc(Cl)cc2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Cc1cc(Cl)ccc1CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,=,=,IC50,nM,63000.0,IC50,uM,63.0,Cc1cc(Cl)ccc1CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Clc1ccc(CN(Cc2cccnc2)Cc2nccs2)cc1,CHEMBL2380244,=,=,IC50,nM,50000.0,IC50,uM,50.0,Clc1ccc(CN(Cc2cccnc2)Cc2nccs2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Clc1ccc(CN(Cc2cccnc2)Cc2sccc2-n2cccc2)cc1,CHEMBL2380244,=,=,IC50,nM,40000.0,IC50,uM,40.0,Clc1ccc(CN(Cc2cccnc2)Cc2sccc2-n2cccc2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Clc1ccc(CN(Cc2cccnc2)Cc2cc3ccccc3s2)cc1,CHEMBL2380244,=,=,IC50,nM,40000.0,IC50,uM,40.0,Clc1ccc(CN(Cc2cccnc2)Cc2cc3ccccc3s2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,O=[N+]([O-])c1ccc(CN(Cc2ccc(F)cc2)Cc2cccnc2)s1,CHEMBL2380244,=,=,IC50,nM,40000.0,IC50,uM,40.0,O=[N+]([O-])c1ccc(CN(Cc2ccc(F)cc2)Cc2cccnc2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Cc1ccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)cc1,CHEMBL2380244,=,=,IC50,nM,40000.0,IC50,uM,40.0,Cc1ccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccccc2F)s1,CHEMBL2380244,=,=,IC50,nM,32000.0,IC50,uM,32.0,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccccc2F)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Cc1sc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)cc1Br,CHEMBL2380244,=,=,IC50,nM,32000.0,IC50,uM,32.0,Cc1sc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)cc1Br,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,COc1ccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)cc1,CHEMBL2380244,=,=,IC50,nM,32000.0,IC50,uM,32.0,COc1ccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)cc1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Cc1ccccc1CN(Cc1cccnc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,=,=,IC50,nM,32000.0,IC50,uM,32.0,Cc1ccccc1CN(Cc1cccnc1)Cc1ccc([N+](=O)[O-])s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,Cc1cccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)c1,CHEMBL2380244,=,=,IC50,nM,25000.0,IC50,uM,25.0,Cc1cccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)c1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,N#Cc1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,CHEMBL2380244,=,=,IC50,nM,20000.0,IC50,uM,20.0,N#Cc1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,O=[N+]([O-])c1ccc(CN(Cc2ccc(Cl)cc2)Cc2ccccc2F)s1,CHEMBL2380244,=,=,IC50,nM,20000.0,IC50,uM,20.0,O=[N+]([O-])c1ccc(CN(Cc2ccc(Cl)cc2)Cc2ccccc2F)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccc(F)c(F)c2)s1,CHEMBL2380244,=,=,IC50,nM,16000.0,IC50,uM,16.0,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccc(F)c(F)c2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,O=[N+]([O-])c1ccc(CN(Cc2cccnc2)Cc2cccc(C(F)(F)F)c2)s1,CHEMBL2380244,=,=,IC50,nM,16000.0,IC50,uM,16.0,O=[N+]([O-])c1ccc(CN(Cc2cccnc2)Cc2cccc(C(F)(F)F)c2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,CC(C)CCN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,=,=,IC50,nM,16000.0,IC50,uM,16.0,CC(C)CCN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,O=[N+]([O-])c1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,CHEMBL2380244,=,=,IC50,nM,13000.0,IC50,uM,13.0,O=[N+]([O-])c1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,CHEMBL2380244,=,=,IC50,nM,13000.0,IC50,uM,13.0,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,COc1cccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)c1,CHEMBL2380244,=,=,IC50,nM,10000.0,IC50,uM,10.0,COc1cccc(CN(Cc2cccnc2)Cc2ccc([N+](=O)[O-])s2)c1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,N#Cc1ccc(CN(Cc2cccnc2)Cc2cc(F)ccc2F)s1,CHEMBL2380244,=,=,IC50,nM,6300.0,IC50,uM,6.3,N#Cc1ccc(CN(Cc2cccnc2)Cc2cc(F)ccc2F)s1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,CCOC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,CHEMBL2380244,=,=,IC50,nM,6300.0,IC50,uM,6.3,CCOC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,2013
Binding affinity to LXRalpha (unknown origin) by radioligand displacement assay,CC(C)(C)OC(=O)CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,=,=,IC50,nM,5000.0,IC50,uM,5.0,CC(C)(C)OC(=O)CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as effect on LPS-stimulated ABCA1 mRNA expression at 1 uM after 6 hrs by RT-qPCR analysis,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccc(F)c(F)c2)s1,CHEMBL2380244,,,Activity,,,Activity,,,N#Cc1ccc(CN(Cc2cccnc2)Cc2ccc(F)c(F)c2)s1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as effect on LPS-stimulated ABCA1 mRNA expression at 1 uM after 6 hrs by RT-qPCR analysis,N#Cc1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,CHEMBL2380244,,,Activity,,,Activity,,,N#Cc1ccc(CN(Cc2ccc(Cl)cc2)Cc2cccnc2)s1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as effect on LPS-stimulated ABCA1 mRNA expression at 1 uM after 6 hrs by RT-qPCR analysis,O=[N+]([O-])c1ccc(CN(Cc2ccc(F)cc2)Cc2cccnc2)s1,CHEMBL2380244,,,Activity,,,Activity,,,O=[N+]([O-])c1ccc(CN(Cc2ccc(F)cc2)Cc2cccnc2)s1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as effect on LPS-stimulated ABCA1 mRNA expression at 1 uM after 6 hrs by RT-qPCR analysis,Cc1cc(Cl)ccc1CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,,,Activity,,,Activity,,,Cc1cc(Cl)ccc1CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as upregulation of LPS-stimulated ABCA1 mRNA expression at 10 uM after 6 hrs by RT-qPCR analysis,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,CHEMBL2380244,,,Activity,,,Activity,,,CCCCCNC(=O)N1CCC(CN(Cc2ccc(Cl)cc2)Cc2ccc([N+](=O)[O-])s2)C1,2013
Agonist activity at LXRalpha in human THP1 cells assessed as upregulation of LPS-stimulated ABCA1 mRNA expression at 10 uM after 6 hrs by RT-qPCR analysis,CC(C)(C)OC(=O)CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,CHEMBL2380244,,,Activity,,,Activity,,,CC(C)(C)OC(=O)CN(Cc1ccc(Cl)cc1)Cc1ccc([N+](=O)[O-])s1,2013
Agonist activity at LXRalpha LBD (unknown origin) transfected in human HepG2 cells co-expressing GAL4-DBD at 10 uM after 18 hrs by luciferase reporter gene assay,CC1(C)CCC[C@]2(C)[C@H]3CC[C@@H](CCCO)[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12,CHEMBL2385005,,,Activity,,,Activity,,,CC1(C)CCC[C@]2(C)[C@H]3CC[C@@H](CCCO)[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12,2013
Agonist activity at LXRalpha LBD (unknown origin) transfected in human HepG2 cells co-expressing GAL4-DBD at 10 uM after 18 hrs by luciferase reporter gene assay,CC1(C)CCC[C@]2(C)[C@H]3CC[C@H](O)[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12,CHEMBL2385005,,,Activity,,,Activity,,,CC1(C)CCC[C@]2(C)[C@H]3CC[C@H](O)[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12,2013
Agonist activity at LXRalpha LBD (unknown origin) transfected in human HepG2 cells co-expressing GAL4-DBD at 10 uM after 18 hrs by luciferase reporter gene assay,CC1(C)CCC[C@]2(C)[C@H]3CC/C(=C\OS(=O)(=O)[O-])[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12.[Na+],CHEMBL2385005,,,Activity,,,Activity,,,CC1(C)CCC[C@]2(C)[C@H]3CC/C(=C\OS(=O)(=O)[O-])[C@H](CCc4ccoc4)[C@@]3(C)CC[C@@H]12.[Na+],2013
Induction of LXRalpha transcription in human HepG2 cells at 50 to 100 uM after 24 hrs by RT-qPCR analysis relative to control,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,CHEMBL2401661,=,=,FC,,1.5,FC,,1.5,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,2013
Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL2401661,=,=,EC50,nM,1000.0,EC50,uM,1.0,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2013
Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay,O=Cc1c(O)cc(O)cc1O,CHEMBL2401661,,,Activity,,,Activity,,,O=Cc1c(O)cc(O)cc1O,2013
Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay,O=C(O)c1ccc(O)c(O)c1,CHEMBL2401661,,,Activity,,,Activity,,,O=C(O)c1ccc(O)c(O)c1,2013
Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2401661,=,=,EC50,nM,91.1,EC50,nM,91.1,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,CHEMBL2401661,=,=,EC50,nM,3500.0,EC50,uM,3.5,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,2013
Binding affinity to human LXRalpha-LBD by surface plasmon resonance,O=Cc1c(O)cc(O)cc1O,CHEMBL2401661,,,Activity,,,Activity,,,O=Cc1c(O)cc(O)cc1O,2013
Binding affinity to human LXRalpha-LBD by surface plasmon resonance,O=C(O)c1ccc(O)c(O)c1,CHEMBL2401661,,,Activity,,,Activity,,,O=C(O)c1ccc(O)c(O)c1,2013
Binding affinity to human LXRalpha-LBD by surface plasmon resonance,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2401661,=,=,Kd,nM,92.4,Kd,nM,92.4,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Binding affinity to human LXRalpha-LBD by surface plasmon resonance,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,CHEMBL2401661,=,=,Kd,nM,2200.0,Kd,uM,2.2,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,2013
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells assessed as induction of transactivation activity at 2 uM after 24 hrs by luciferase reporter gene assay relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL2401661,=,=,Activity,%,96.0,Activity,%,96.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells assessed as induction of transactivation activity at 100 uM after 24 hrs by luciferase reporter gene assay relative to control,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,CHEMBL2401661,=,=,Activity,%,59.0,Activity,%,59.0,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,2013
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells assessed as induction of transactivation activity at 50 uM after 24 hrs by luciferase reporter gene assay relative to control,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,CHEMBL2401661,=,=,Activity,%,32.0,Activity,%,32.0,Oc1cc(O)c2cc(O)c(-c3ccc(O)c(O)c3)[o+]c2c1,2013
Agonist activity at LXRalpha (unknown origin) transfected in mouse SN4741 cells at 10 uM after 24 hrs by luciferase reporter gene assay,C/C(=C/CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)CO,CHEMBL2417471,,,Activity,,,Activity,,,C/C(=C/CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)CO,2013
Agonist activity at LXRalpha (unknown origin) transfected in mouse SN4741 cells at 10 uM after 24 hrs by luciferase reporter gene assay,C/C(=C\CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)CO,CHEMBL2417471,,,Activity,,,Activity,,,C/C(=C\CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)CO,2013
Agonist activity at LXRalpha (unknown origin) transfected in mouse SN4741 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL2417471,,,Activity,,,Activity,,,CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL2417463,=,=,FC,,2.38,FC,,2.38,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 0.1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL2417463,=,=,FC,,1.53,FC,,1.53,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 0.1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,Nc1ccc(C(=O)/C=C/c2ccc3ccccc3c2)c(O)c1,CHEMBL2417463,=,=,FC,,1.06,FC,,1.06,Nc1ccc(C(=O)/C=C/c2ccc3ccccc3c2)c(O)c1,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,Nc1ccc(C(=O)/C=C/c2ccc3ccccc3c2)c(O)c1,CHEMBL2417463,=,=,FC,,1.11,FC,,1.11,Nc1ccc(C(=O)/C=C/c2ccc3ccccc3c2)c(O)c1,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,Cc1ccc(/C=C/C(=O)c2ccc(N)cc2O)o1,CHEMBL2417463,=,=,FC,,1.19,FC,,1.19,Cc1ccc(/C=C/C(=O)c2ccc(N)cc2O)o1,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=c1cc(-c2c[nH]c3ccccc23)oc2cc(O)ccc12,CHEMBL2417463,=,=,FC,,1.02,FC,,1.02,O=c1cc(-c2c[nH]c3ccccc23)oc2cc(O)ccc12,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 0.1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=c1cc(-c2c[nH]c3ccccc23)oc2cc(O)ccc12,CHEMBL2417463,=,=,FC,,1.32,FC,,1.32,O=c1cc(-c2c[nH]c3ccccc23)oc2cc(O)ccc12,2013
Agonist activity at human LXRalpha transfected in HEK293 cells at 0.1 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,Cc1ccc(/C=C/C(=O)c2ccc(N)cc2O)o1,CHEMBL2417463,=,=,FC,,0.99,FC,,0.99,Cc1ccc(/C=C/C(=O)c2ccc(N)cc2O)o1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay relative to apo-receptor,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL3091433,=,=,FC,,349.0,FC,,349.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay relative to apo-receptor,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3091433,=,=,FC,,303.0,FC,,303.0,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay relative to apo-receptor,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3091433,=,=,FC,,643.0,FC,,643.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,CHEMBL3091433,=,=,EC50,nM,3000.0,EC50,uM,3.0,CCN(c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)S(=O)(=O)c1ccccc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3091433,=,=,EC50,nM,719.0,EC50,uM,0.719,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,N#Cc1ccc(S(=O)(=O)N(CC(F)(F)F)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,CHEMBL3091433,>,>,EC50,nM,10000.0,EC50,uM,10.0,N#Cc1ccc(S(=O)(=O)N(CC(F)(F)F)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,2013
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3091433,=,=,EC50,nM,373.0,EC50,uM,0.373,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Activation of LXRalpha in human HepG2 cells at 25 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL3120163,=,=,FC,,4.67,FC,,4.67,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,COC(=O)[C@]12C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,CHEMBL3120163,=,=,FC,,1.11,FC,,1.11,COC(=O)[C@]12C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,COC(=O)[C@]12C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O)[C@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,CHEMBL3120163,=,=,FC,,1.06,FC,,1.06,COC(=O)[C@]12C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O)[C@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,COC(=O)[C@]12C[C@@H](O)[C@@H](O)[C@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,CHEMBL3120163,=,=,FC,,1.22,FC,,1.22,COC(=O)[C@]12C[C@@H](O)[C@@H](O)[C@H](O1)[C@@H](COC(=O)/C=C/c1ccc(O)c(O)c1)O2,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@H]1O2,CHEMBL3120163,=,=,FC,,1.14,FC,,1.14,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@H]1O2,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O)[C@@H]1O2,CHEMBL3120163,=,=,FC,,1.59,FC,,1.59,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](OC(=O)/C=C/c3ccc(O)c(O)c3)[C@@H](O)[C@@H]1O2,2014
Activation of LXRalpha in human HepG2 cells at 30 uM after 24 hrs by luciferase reporter gene assay relative to vehicle-treated control,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](O)[C@@H](O)[C@@H]1O2,CHEMBL3120163,=,=,FC,,1.12,FC,,1.12,O=C(/C=C/c1ccc(O)c(O)c1)OC[C@H]1O[C@@]2(C(=O)O)C[C@@H](O)[C@@H](O)[C@@H]1O2,2014
Agonist activity at GAL4-fused LXR alpha (unknown origin) expressed in HEK293T cells after 20 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3217638,=,=,EC50,nM,250.0,EC50,uM,0.25,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2013
Activation of GAL4-fused LXR alpha (unknown origin) expressed in HEK293T cells after 20 hrs relative to T0901317,OC(c1ccc(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)c(F)c1)(C(F)(F)F)C(F)(F)F,CHEMBL3217638,<,<,Activity,%,5.0,Activity,%,5.0,OC(c1ccc(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)c(F)c1)(C(F)(F)F)C(F)(F)F,2013
Activation of GAL4-fused LXR alpha (unknown origin) expressed in HEK293T cells after 20 hrs relative to T0901317,CC(=O)N1CCN(Cc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)cc2)CC1,CHEMBL3217638,<,<,Activity,%,5.0,Activity,%,5.0,CC(=O)N1CCN(Cc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)cc2)CC1,2013
Displacement of [3H]T0901317 from LXRalpha (unknown origin),CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,=,=,IC50,nM,29000.0,IC50,uM,29.0,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,=,=,EC50,nM,2700.0,EC50,uM,2.7,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,=,=,EC50,nM,3700.0,EC50,uM,3.7,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,=,=,EC50,nM,2300.0,EC50,uM,2.3,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,=,=,EC50,nM,3600.0,EC50,uM,3.6,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-induced transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,,,Activity,,,Activity,,,CC(C)CN(Cc1ccc(-c2cccc(S(C)(=O)=O)c2)s1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,,,Activity,,,Activity,,,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)s1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,,,Activity,,,Activity,,,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,,,Activity,,,Activity,,,CC(C)CN(Cc1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human GAL4-fused LXRalpha expressed in HEK293 cells assessed as transcriptional activity after 5 hrs by luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3259641,,,Activity,,,Activity,,,CC(C)CN(Cc1ccc(-c2ccc(C(N)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at human LXR-alpha expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3259582,=,=,EC50,nM,290.0,EC50,uM,0.29,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2014
Antagonist activity at human LXR-alpha expressed in HEK293 cells assessed as inhibition of T0901317-induced effect after 16 hrs by luciferase reporter gene assay,CCCCn1c(=O)c2ccc(Cl)cc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL3259582,>,>,IC50,nM,3000.0,IC50,uM,3.0,CCCCn1c(=O)c2ccc(Cl)cc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2014
Antagonist activity at human LXR-alpha expressed in HEK293 cells assessed as inhibition of T0901317-induced effect after 16 hrs by luciferase reporter gene assay,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,CHEMBL3259582,,,IC50,,,IC50,,,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,2014
Antagonist activity at human LXR-alpha expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3259582,,,IC50,,,IC50,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2014
Agonist activity at human LXR-alpha expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay,CCCCn1c(=O)c2ccc(Cl)cc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL3259582,,,EC50,,,EC50,,,CCCCn1c(=O)c2ccc(Cl)cc2c2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2014
Agonist activity at human LXR-alpha expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,CHEMBL3259582,,,EC50,,,EC50,,,CC(=O)Nc1nc(C)c(S(=O)(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)s1,2014
Agonist activity at LXR-alpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay,C=C[C@]1(C)C=C2CC[C@H]3[C@@](C)(CCC[C@@]3(C)C(=O)O)[C@@H]2CC1,CHEMBL3286315,,,Activity,,,Activity,,,C=C[C@]1(C)C=C2CC[C@H]3[C@@](C)(CCC[C@@]3(C)C(=O)O)[C@@H]2CC1,2014
Agonist activity at LXR-alpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay,CC(C)C1=CC2=CC[C@@H]3[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1,CHEMBL3286315,,,Activity,,,Activity,,,CC(C)C1=CC2=CC[C@@H]3[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1,2014
Agonist activity at LXR-alpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activation at 1 to 25 uM after 40 hrs by luciferase reporter gene assay,C=C[C@@]1(C)C=C2CC[C@@H]3[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1,CHEMBL3286315,,,Activity,,,Activity,,,C=C[C@@]1(C)C=C2CC[C@@H]3[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(Cc1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(NC2CCN(S(C)(=O)=O)CC2)cc1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(Cc1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(NC2CCN(S(C)(=O)=O)CC2)cc1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(c1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(NC2CCN(S(C)(=O)=O)CC2)cc1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(c1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(NC2CCN(S(C)(=O)=O)CC2)cc1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(c1ccc(F)cc1)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cc1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(c1ccc(F)cc1)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cc1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(c1ccc(C#N)cc1)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cc1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(c1ccc(C#N)cc1)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cc1,2014
Inverse agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(Cc1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cn1,CHEMBL3352095,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(C)CN(Cc1ccccc1C(F)(F)F)S(=O)(=O)c1ccc(OC2CCN(S(C)(=O)=O)CC2)cn1,2014
Activation of human LXR-alpha expressed in HEK293 cells coexpressing with pGL4.1-DR4-Luc after 24 hrs by luciferase reporter gene assay,CC(C)=CCc1cc([C@@H]2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)cc2c1OC(C)(C)C(O)C2,CHEMBL3351942,,,Activity,,,Activity,,,CC(C)=CCc1cc([C@@H]2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)cc2c1OC(C)(C)C(O)C2,2014
Activation of human LXR-alpha expressed in HEK293 cells coexpressing with pGL4.1-DR4-Luc after 24 hrs by luciferase reporter gene assay,CC(C)=CCc1cc([C@@H]2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)cc2c1OC(C(C)(C)O)C2,CHEMBL3351942,,,Activity,,,Activity,,,CC(C)=CCc1cc([C@@H]2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)cc2c1OC(C(C)(C)O)C2,2014
Agonist activity at LXRalpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activity by GAL4 NR reporter cell-based assay,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3351629,=,=,EC50,nM,720.0,EC50,uM,0.72,O=S(=O)(c1ccc(F)cc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2014
Agonist activity at LXRalpha (unknown origin) expressed in HEK293 cells assessed as transcriptional activity by GAL4 NR reporter cell-based assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3351629,=,=,EC50,nM,370.0,EC50,uM,0.37,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2014
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,CHEMBL3352759,=,=,EC50,nM,2300.0,EC50,uM,2.3,CC(C)CN(Cc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)S(=O)(=O)Cc1ccccc1,2014
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(CN(CC(C)C)S(=O)(=O)Cc3ccccc3)cc2)CC1,CHEMBL3352759,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(=O)N1CCN(c2ccc(CN(CC(C)C)S(=O)(=O)Cc3ccccc3)cc2)CC1,2014
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3)cc2)CC1,CHEMBL3352759,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3)cc2)CC1,2014
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(CN(C(C)C)S(=O)(=O)Cc3ccccc3)cc2)CC1,CHEMBL3352759,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(=O)N1CCN(c2ccc(CN(C(C)C)S(=O)(=O)Cc3ccccc3)cc2)CC1,2014
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(CN(CC(F)(F)F)S(=O)(=O)Cc3ccccc3)cc2)CC1,CHEMBL3352759,>,>,EC50,nM,10000.0,EC50,uM,10.0,CC(=O)N1CCN(c2ccc(CN(CC(F)(F)F)S(=O)(=O)Cc3ccccc3)cc2)CC1,2014
Antagonist activity against LXRalpha ligand binding domain (unknown origin) expressed in human MCF7 cells assessed as inhibition of T09-induced receptor transactivation at 10 uM after 18 hrs by luciferase reporter gene based mammalian one-hybrid assay,Cc1cc(=O)oc2c(/C=N/NC(=O)CSc3nc4ccccc4s3)c(O)ccc12,CHEMBL3352174,,,Inhibition,%,,INH,,,Cc1cc(=O)oc2c(/C=N/NC(=O)CSc3nc4ccccc4s3)c(O)ccc12,2014
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3351420,=,=,EC50,nM,230.0,EC50,nM,230.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,CHEMBL3351420,=,=,EC50,nM,85.0,EC50,nM,85.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2C(F)(F)F)n1,CHEMBL3351420,=,=,EC50,nM,200.0,EC50,nM,200.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2C(F)(F)F)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2c(Cl)cccc2Cl)n1,CHEMBL3351420,>,>,EC50,nM,10000.0,EC50,nM,10000.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2c(Cl)cccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2ccccc2Cl)n1,CHEMBL3351420,>,>,EC50,nM,10000.0,EC50,nM,10000.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(-c2ccccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-n3cc(C(F)(F)F)nc3-c3ccccc3Cl)cc2)c1,CHEMBL3351420,=,=,EC50,nM,52.0,EC50,nM,52.0,CS(=O)(=O)c1cccc(-c2ccc(-n3cc(C(F)(F)F)nc3-c3ccccc3Cl)cc2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CC(C)(O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,CHEMBL3351420,=,=,EC50,nM,540.0,EC50,nM,540.0,CC(C)(O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,COC(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,CHEMBL3351420,=,=,EC50,nM,65.0,EC50,nM,65.0,COC(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,CHEMBL3351420,=,=,EC50,nM,320.0,EC50,nM,320.0,CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,CHEMBL3351420,=,=,EC50,nM,220.0,EC50,nM,220.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,CHEMBL3351420,=,=,EC50,nM,120.0,EC50,nM,120.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,CHEMBL3351420,=,=,EC50,nM,140.0,EC50,nM,140.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,CHEMBL3351420,=,=,EC50,nM,18.0,EC50,nM,18.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,CHEMBL3351420,=,=,EC50,nM,570.0,EC50,nM,570.0,Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,CHEMBL3351420,=,=,EC50,nM,20.0,EC50,nM,20.0,N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,CHEMBL3351420,=,=,EC50,nM,4.0,EC50,nM,4.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,2015
Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3351420,=,=,EC50,nM,28.0,EC50,nM,28.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3351420,=,=,Efficacy,%,100.0,Efficacy,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,CHEMBL3351420,=,=,Efficacy,%,100.0,Efficacy,%,100.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)c(C#N)c(=O)n3Cc3ccc(F)cc3F)s2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,CHEMBL3351420,=,=,Efficacy,%,100.0,Efficacy,%,100.0,N#Cc1c(C(F)(F)F)cc(-c2ccc(Oc3ccccc3)cc2)n(Cc2ccc(F)cc2F)c1=O,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,CHEMBL3351420,=,=,Efficacy,%,96.0,Efficacy,%,96.0,Cc1cc(CC(=O)O)ccc1-c1ccc(-c2cc(C(F)(F)F)c(C#N)c(=O)n2Cc2ccc(F)cc2F)s1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,CHEMBL3351420,=,=,Efficacy,%,98.0,Efficacy,%,98.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3Cc3ccc(F)cc3F)s2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,CHEMBL3351420,=,=,Efficacy,%,65.0,Efficacy,%,65.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)s2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,CHEMBL3351420,=,=,Efficacy,%,39.0,Efficacy,%,39.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3C(F)(F)F)s2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,CHEMBL3351420,=,=,Efficacy,%,30.0,Efficacy,%,30.0,CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,CHEMBL3351420,=,=,Efficacy,%,66.0,Efficacy,%,66.0,CS(=O)(=O)c1cccc(-c2cccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)c2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",COC(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,CHEMBL3351420,=,=,Efficacy,%,20.0,Efficacy,%,20.0,COC(=O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,CHEMBL3351420,=,=,Efficacy,%,13.0,Efficacy,%,13.0,CC(C)(O)c1cc(-c2ccc(-c3cccc(S(C)(=O)=O)c3)s2)n(-c2ccccc2Cl)n1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CS(=O)(=O)c1cccc(-c2ccc(-n3cc(C(F)(F)F)nc3-c3ccccc3Cl)cc2)c1,CHEMBL3351420,=,=,Efficacy,%,19.0,Efficacy,%,19.0,CS(=O)(=O)c1cccc(-c2ccc(-n3cc(C(F)(F)F)nc3-c3ccccc3Cl)cc2)c1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2C(F)(F)F)n1,CHEMBL3351420,=,=,Efficacy,%,15.0,Efficacy,%,15.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2C(F)(F)F)n1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,CHEMBL3351420,=,=,Efficacy,%,28.0,Efficacy,%,28.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,2015
"Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay relative to 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3351420,=,=,Efficacy,%,38.0,Efficacy,%,38.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3399967,=,=,Emax,%,60.0,Emax,%,60.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(C(=O)O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(C(=O)O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc4c(c3)OCO4)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc4c(c3)OCO4)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)c(OC)c3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)c(OC)c3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccccc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccccc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,EC50,nM,2400.0,EC50,uM,2.4,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)CN(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)CN(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(O)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(O)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(=O)O)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(=O)O)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(c2ccccc2)C1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(c2ccccc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)C1=O,CHEMBL3399967,=,=,EC50,nM,1500.0,EC50,uM,1.5,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3399967,=,=,EC50,nM,11000.0,EC50,uM,11.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)C(C)N(C)C1=O,CHEMBL3399967,=,=,EC50,nM,1700.0,EC50,uM,1.7,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)C(C)N(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCCC1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCCC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCOC1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCOC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CCC1=O,CHEMBL3399967,,,EC50,,,EC50,,,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CCC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CN(C)C1=O,CHEMBL3399967,=,=,EC50,nM,2600.0,EC50,uM,2.6,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CN(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CSC1=O,CHEMBL3399967,=,=,EC50,nM,2600.0,EC50,uM,2.6,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CSC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3399967,=,=,EC50,nM,1300.0,EC50,uM,1.3,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CSC1=O,CHEMBL3399967,=,=,Efficacy,%,6.0,Efficacy,%,6.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CSC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CN(C)C1=O,CHEMBL3399967,=,=,Efficacy,%,10.0,Efficacy,%,10.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CN(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CCC1=O,CHEMBL3399967,=,=,Efficacy,%,2.0,Efficacy,%,2.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)CCC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCOC1=O,CHEMBL3399967,=,=,Efficacy,%,1.0,Efficacy,%,1.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCOC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCCC1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1CCCC1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)C(C)N(C)C1=O,CHEMBL3399967,=,=,Efficacy,%,16.0,Efficacy,%,16.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)C(C)N(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3399967,=,=,Efficacy,%,21.0,Efficacy,%,21.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)C1=O,CHEMBL3399967,=,=,Efficacy,%,5.0,Efficacy,%,5.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(c2ccccc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)N(C)C(C)(c2ccccc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3399967,=,=,Efficacy,%,2.0,Efficacy,%,2.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(=O)O)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(=O)O)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(O)cc2)C1=O,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1cc2c(C(F)(F)F)cc(=O)oc2c(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(O)cc2)C1=O,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)CN(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,4.0,Efficacy,%,4.0,CCCc1c(OCCCCN2C(=O)CN(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,7.0,Efficacy,%,7.0,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccccc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccccc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,2.0,Efficacy,%,2.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)c(OC)c3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)c(OC)c3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc4c(c3)OCO4)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,4.0,Efficacy,%,4.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc4c(c3)OCO4)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(C(=O)O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(C(=O)O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3399967,=,=,Efficacy,%,0.0,Efficacy,%,0.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(O)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3399967,=,=,EC50,nM,490.0,EC50,uM,0.49,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3399967,=,=,Emax,%,100.0,Emax,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1c(OCCCN2C(=O)CSC2=O)ccc2c(C(F)(F)F)noc12,CHEMBL3399967,=,=,EC50,nM,1300.0,EC50,uM,1.3,CCCc1c(OCCCN2C(=O)CSC2=O)ccc2c(C(F)(F)F)noc12,2015
Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells assessed as maximal efficacy at 10 uM after 24 hrs by luciferase reporter gene assay relative to T0901317 luminescence intensity,CCCc1c(OCCCN2C(=O)CSC2=O)ccc2c(C(F)(F)F)noc12,CHEMBL3399967,=,=,Emax,%,105.0,Emax,%,105.0,CCCc1c(OCCCN2C(=O)CSC2=O)ccc2c(C(F)(F)F)noc12,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3F)c(F)c2)CC1,CHEMBL3580623,=,=,EC50,nM,9200.0,EC50,uM,9.2,CC(=O)N1CCN(c2ccc(CN(C3CCC3)S(=O)(=O)Cc3ccccc3F)c(F)c2)CC1,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,51.0,Emax,%,51.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3588803,=,=,Emax,%,107.0,Emax,%,107.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,12.0,Emax,%,12.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3588803,=,=,Emax,%,97.0,Emax,%,97.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,CHEMBL3588803,=,=,Emax,%,81.0,Emax,%,81.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,CHEMBL3588803,=,=,Emax,%,82.0,Emax,%,82.0,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1OCCC2C(F)(F)F,CHEMBL3588803,=,=,Emax,%,3.0,Emax,%,3.0,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1OCCC2C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3588803,=,=,Emax,%,2.0,Emax,%,2.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3588803,=,=,Emax,%,7.0,Emax,%,7.0,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,Emax,%,118.0,Emax,%,118.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,85.0,Emax,%,85.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,31.0,Emax,%,31.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,21.0,Emax,%,21.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,Emax,%,94.0,Emax,%,94.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,Emax,%,89.0,Emax,%,89.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,62.0,Emax,%,62.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,26.0,Emax,%,26.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,43.0,Emax,%,43.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,Emax,%,88.0,Emax,%,88.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CCC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,Emax,%,42.0,Emax,%,42.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CCC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,Emax,%,72.0,Emax,%,72.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,48.0,Emax,%,48.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,CHEMBL3588803,=,=,Emax,%,51.0,Emax,%,51.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,10.0,Emax,%,10.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,108.0,Emax,%,108.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)c(Cl)c2)C1=O,CHEMBL3588803,=,=,Emax,%,4.0,Emax,%,4.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)c(Cl)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,23.0,Emax,%,23.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,8.0,Emax,%,8.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,Emax,%,71.0,Emax,%,71.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,Emax,%,54.0,Emax,%,54.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,33.0,Emax,%,33.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,67.0,Emax,%,67.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,89.0,Emax,%,89.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,CHEMBL3588803,=,=,Emax,%,13.0,Emax,%,13.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,CHEMBL3588803,=,=,Emax,%,15.0,Emax,%,15.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,CHEMBL3588803,=,=,Emax,%,7.0,Emax,%,7.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,8.0,Emax,%,8.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,CHEMBL3588803,=,=,Emax,%,37.0,Emax,%,37.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay relative to 10 uM T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,CHEMBL3588803,=,=,Emax,%,42.0,Emax,%,42.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1600.0,EC50,uM,1.6,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3588803,=,=,EC50,nM,710.0,EC50,uM,0.71,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2800.0,EC50,uM,2.8,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)N(C)C(C)(C)C1=O,CHEMBL3588803,=,=,EC50,nM,3200.0,EC50,uM,3.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)N(C)C(C)(C)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,CHEMBL3588803,=,=,EC50,nM,1700.0,EC50,uM,1.7,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,CHEMBL3588803,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1COC2(C(F)(F)F)C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1OCCC2C(F)(F)F,CHEMBL3588803,,,EC50,,,EC50,,,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c1OCCC2C(F)(F)F,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3588803,=,=,EC50,nM,2400.0,EC50,uM,2.4,CCCc1c(OCCCCN2C(=O)N(C)C(C)(C)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,600.0,EC50,uM,0.6,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1200.0,EC50,uM,1.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1200.0,EC50,uM,1.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1800.0,EC50,uM,1.8,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,500.0,EC50,uM,0.5,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,400.0,EC50,uM,0.4,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1800.0,EC50,uM,1.8,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1100.0,EC50,uM,1.1,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,900.0,EC50,uM,0.9,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,1500.0,EC50,uM,1.5,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CCC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,2300.0,EC50,uM,2.3,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CCC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,1500.0,EC50,uM,1.5,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2300.0,EC50,uM,2.3,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(CC)(c2ccc(OC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc([N+](=O)[O-])cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2500.0,EC50,uM,2.5,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1400.0,EC50,uM,1.4,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(-c3ccccc3)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)c(Cl)c2)C1=O,CHEMBL3588803,=,=,EC50,nM,1700.0,EC50,uM,1.7,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)c(Cl)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(Cl)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(N(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,1200.0,EC50,uM,1.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,CHEMBL3588803,=,=,EC50,nM,1700.0,EC50,uM,1.7,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc3c(c2)OCO3)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2800.0,EC50,uM,2.8,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(F)(F)F)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1800.0,EC50,uM,1.8,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1300.0,EC50,uM,1.3,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OCC)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,CHEMBL3588803,=,=,EC50,nM,2400.0,EC50,uM,2.4,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(OC)c(OC)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,CHEMBL3588803,=,=,EC50,nM,2400.0,EC50,uM,2.4,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2cccc(OC)c2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,CHEMBL3588803,=,=,EC50,nM,2700.0,EC50,uM,2.7,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2OC)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,1900.0,EC50,uM,1.9,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C(C)C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2200.0,EC50,uM,2.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccc(C)cc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,CHEMBL3588803,=,=,EC50,nM,2000.0,EC50,uM,2.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1OCCCCN1C(=O)NC(C)(c2ccccc2)C1=O,2015
Agonist activity at LXRalpha (unknown origin) relative to control,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3588803,=,=,Emax,%,60.0,Emax,%,60.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at LXRalpha (unknown origin) relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3588803,=,=,Emax,%,100.0,Emax,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Agonist activity at LXRalpha (unknown origin),O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3588803,=,=,EC50,nM,1300.0,EC50,uM,1.3,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at LXRalpha (unknown origin),O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3588803,=,=,EC50,nM,500.0,EC50,uM,0.5,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Agonist activity at LXRalpha (unknown origin) expressed in CHOK1 cells at 10 uM incubated for 24 hrs by GAL4-responsive luciferase reporter gene assay,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3588803,,,Activity,,,Activity,,,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1O,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1O,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)c(F)c1,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)c(F)c1,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)c(F)c1,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)c(F)c1,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3c2CCCC3)c(F)c1,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3c2CCCC3)c(F)c1,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as activation of basal transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3cccnc23)cc1O,CHEMBL3596163,>,>,EC50,nM,10000.0,EC50,uM,10.0,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3cccnc23)cc1O,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1O,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)cc1O,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)c(F)c1,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3ccccc23)c(F)c1,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)c(F)c1,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C(F)(F)F)n3c2CCCC3)c(F)c1,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3c2CCCC3)c(F)c1,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3c2CCCC3)c(F)c1,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317-induced basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3cccnc23)cc1O,CHEMBL3596163,,,Inhibition,%,,INH,,,O=C(O)c1ccc(-c2nc(C(=O)c3c(Cl)cccc3C3CC3)n3cccnc23)cc1O,2015
Antagonist activity at Gal4 DNA binding domain-tagged human LXRalpha ligand binding domain expressed in HEK293 cells assessed as inhibition of receptor-mediated transcriptional activity by luciferase reporter gene assay,[2H]C([2H])([2H])N(C(=O)c1c(F)cccc1Cl)c1ccc(-c2cc(C(N)=O)ccc2Cl)cc1OCC(F)(F)F,CHEMBL3596154,=,=,Inhibition,%,53.0,INH,%,53.0,[2H]C([2H])([2H])N(C(=O)c1c(F)cccc1Cl)c1ccc(-c2cc(C(N)=O)ccc2Cl)cc1OCC(F)(F)F,2015
Agonist activity at Gal4 DNA binding domain-tagged human LXRalpha ligand binding domain expressed in HEK293 cells assessed as activation of receptor-mediated transcriptional activity by luciferase reporter gene assay,[2H]C([2H])([2H])N(C(=O)c1c(F)cccc1Cl)c1ccc(-c2cc(C(N)=O)ccc2Cl)cc1OCC(F)(F)F,CHEMBL3596154,<,<,Activity,%,50.0,Activity,%,50.0,[2H]C([2H])([2H])N(C(=O)c1c(F)cccc1Cl)c1ccc(-c2cc(C(N)=O)ccc2Cl)cc1OCC(F)(F)F,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay relative to T0901317,CC(C)(C)OC(=O)c1c(COc2ccc(-c3ccc(CC(=O)O)cc3)cc2)ccc(C(F)(F)F)c1O,CHEMBL3608222,=,=,Efficacy,%,79.0,Efficacy,%,79.0,CC(C)(C)OC(=O)c1c(COc2ccc(-c3ccc(CC(=O)O)cc3)cc2)ccc(C(F)(F)F)c1O,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay relative to T0901317,CC(C)(C)OC(=O)c1c(COc2ccc(-c3cccc(CC(=O)O)c3)cc2)ccc(C(F)(F)F)c1O,CHEMBL3608222,=,=,Efficacy,%,39.0,Efficacy,%,39.0,CC(C)(C)OC(=O)c1c(COc2ccc(-c3cccc(CC(=O)O)c3)cc2)ccc(C(F)(F)F)c1O,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay relative to T0901317,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,CHEMBL3608222,=,=,Efficacy,%,89.0,Efficacy,%,89.0,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay relative to T0901317,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,CHEMBL3608222,=,=,Efficacy,%,27.0,Efficacy,%,27.0,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay relative to T0901317,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3608222,=,=,Efficacy,%,40.0,Efficacy,%,40.0,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,CC(C)(C)OC(=O)c1c(COc2ccc(-c3ccc(CC(=O)O)cc3)cc2)ccc(C(F)(F)F)c1O,CHEMBL3608222,=,=,EC50,nM,510.0,EC50,uM,0.51,CC(C)(C)OC(=O)c1c(COc2ccc(-c3ccc(CC(=O)O)cc3)cc2)ccc(C(F)(F)F)c1O,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,CC(C)(C)OC(=O)c1c(COc2ccc(-c3cccc(CC(=O)O)c3)cc2)ccc(C(F)(F)F)c1O,CHEMBL3608222,=,=,EC50,nM,1300.0,EC50,uM,1.3,CC(C)(C)OC(=O)c1c(COc2ccc(-c3cccc(CC(=O)O)c3)cc2)ccc(C(F)(F)F)c1O,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,CHEMBL3608222,=,=,EC50,nM,280.0,EC50,uM,0.28,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)c(O)c2C(=O)OC(C)(C)C)cc1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,CHEMBL3608222,=,=,EC50,nM,310.0,EC50,uM,0.31,CC(=O)N(C)c1ccc(OCc2ccc(C(F)(F)F)cc2C(=O)OC(C)(C)C)cc1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3608222,=,=,EC50,nM,540.0,EC50,uM,0.54,O=C(O)c1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2015
Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3608222,=,=,EC50,nM,30.0,EC50,uM,0.03,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-stimulated transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1F,CHEMBL3616373,=,=,EC50,nM,4100.0,EC50,uM,4.1,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1F,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as activation of basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1F,CHEMBL3616373,,,Activity,,,Activity,,,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1F,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-stimulated transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CC2)c1c(F)cccc1F,CHEMBL3616373,=,=,EC50,nM,4200.0,EC50,uM,4.2,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CC2)c1c(F)cccc1F,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as activation of basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CC2)c1c(F)cccc1F,CHEMBL3616373,,,Activity,,,Activity,,,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CC2)c1c(F)cccc1F,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-stimulated transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1ccccc1Cl,CHEMBL3616373,=,=,EC50,nM,2600.0,EC50,uM,2.6,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1ccccc1Cl,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as activation of basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1ccccc1Cl,CHEMBL3616373,,,Activity,,,Activity,,,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1ccccc1Cl,2015
Antagonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as inhibition of T0901317-stimulated transcriptional activity after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1Cl,CHEMBL3616373,=,=,EC50,nM,3900.0,EC50,uM,3.9,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1Cl,2015
Agonist activity at GAL4-fused human LXRalpha expressed in HEK293 cells assessed as activation of basal transcriptional activity up to 10 uM after 20 hrs by dual-glo luciferase reporter gene assay,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1Cl,CHEMBL3616373,,,Activity,,,Activity,,,O=C(Nc1ccc2c(c1)N(S(=O)(=O)c1ccc(F)cc1)CCC2)c1c(F)cccc1Cl,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1,CHEMBL3621179,,,Activity,,,Activity,,,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,,,Activity,,,Activity,,,COc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,CC(C)(C)c1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,CC(C)(C)c1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(C(F)(F)F)cc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(C(F)(F)F)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,N#Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,N#Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL3621179,,,Activity,,,Activity,,,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,,,Activity,,,Activity,,,Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,CHEMBL3621179,,,Activity,,,Activity,,,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,Cc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,,,Activity,,,Activity,,,Cc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,Cc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL3621179,,,Activity,,,Activity,,,Cc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1ccc(/C=C\c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,,,Activity,,,Activity,,,COc1ccc(/C=C\c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,CHEMBL3621179,,,Activity,,,Activity,,,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL3621179,=,=,IC50,nM,13000.0,IC50,uM,13.0,O=C1c2ccccc2C(=O)N1c1ccccc1CCc1ccccc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,CHEMBL3621179,=,=,IC50,nM,11000.0,IC50,uM,11.0,O=C1c2ccccc2C(=O)N1c1cccc(CCc2ccccc2)c1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",N#Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,IC50,nM,27000.0,IC50,uM,27.0,N#Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(C(F)(F)F)cc1,CHEMBL3621179,=,=,IC50,nM,23000.0,IC50,uM,23.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(C(F)(F)F)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",CC(C)(C)c1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,IC50,nM,6800.0,IC50,uM,6.8,CC(C)(C)c1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL3621179,=,=,IC50,nM,30000.0,IC50,uM,30.0,COc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,=,=,IC50,nM,30000.0,IC50,uM,30.0,COc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,=,=,IC50,nM,3300.0,IC50,uM,3.3,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1,CHEMBL3621179,=,=,IC50,nM,13000.0,IC50,uM,13.0,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(/C=C\c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,=,=,IC50,nM,17000.0,IC50,uM,17.0,COc1ccc(/C=C\c2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,CHEMBL3621179,=,=,IC50,nM,23000.0,IC50,uM,23.0,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,CHEMBL3621179,=,=,IC50,nM,22000.0,IC50,uM,22.0,Cc1ccccc1/C=C/c1ccccc1N1C(=O)c2ccccc2C1=O,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,=,=,IC50,nM,25000.0,IC50,uM,25.0,Cc1cccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,>,>,IC50,nM,30000.0,IC50,uM,30.0,Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3621179,,,IC50,,,IC50,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,CHEMBL3621179,=,=,IC50,nM,4100.0,IC50,uM,4.1,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,CHEMBL3621179,=,=,Inhibition,%,20.0,INH,%,20.0,O=C1c2ccccc2C(=O)N1c1ccc(CCc2ccccc2)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,Inhibition,%,30.0,INH,%,30.0,COc1ccc(CCc2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,CHEMBL3621179,=,=,Inhibition,%,40.0,INH,%,40.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccccc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,Inhibition,%,30.0,INH,%,30.0,COc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,CHEMBL3621179,=,=,Inhibition,%,48.0,INH,%,48.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(F)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,CHEMBL3621179,=,=,Inhibition,%,21.0,INH,%,21.0,O=C1c2ccccc2C(=O)N1c1ccccc1/C=C/c1ccc(Br)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,Inhibition,%,49.0,INH,%,49.0,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,CHEMBL3621179,=,=,Inhibition,%,38.0,INH,%,38.0,CCCCc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,CHEMBL3621179,=,=,Inhibition,%,44.0,INH,%,44.0,COc1cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc(OC)c1OC,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,CHEMBL3621179,=,=,Inhibition,%,41.0,INH,%,41.0,Cc1ccc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)cc1C,2015
"Antagonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay in presence of 0.3 uM N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide",Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,CHEMBL3621179,=,=,Inhibition,%,43.0,INH,%,43.0,Cc1cc(C)cc(/C=C/c2ccccc2N2C(=O)c3ccccc3C2=O)c1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3621179,=,=,EC50,nM,210.0,EC50,uM,0.21,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2015
Agonist activity at human LXR-alpha transfected in HEK293 cells at 30 uM after 16 hrs by luciferase reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,CHEMBL3621179,,,Activity,,,Activity,,,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,987.0,Ki,nM,987.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)N(C)C)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,2130.0,Ki,nM,2130.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)N(C)C)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,74.0,Ki,nM,74.0,CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,=,=,Ki,nM,1770.0,Ki,nM,1770.0,CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,160.0,Ki,nM,160.0,CCCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,56.0,Ki,nM,56.0,CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@H]1c2cc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2cc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,237.0,Ki,nM,237.0,CC(C)[C@@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,198.0,Ki,nM,198.0,CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,=,=,Ki,nM,318.0,Ki,nM,318.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,106.0,Ki,nM,106.0,CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,236.0,Ki,nM,236.0,CCCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CNC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CNC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",COC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,129.0,Ki,nM,129.0,COC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",Cc1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,83.0,Ki,nM,83.0,Cc1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,3240.0,Ki,nM,3240.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,277.0,Ki,nM,277.0,CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@H]1c2cc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2cc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@@H]1c2cc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,=,=,Ki,nM,43.0,Ki,nM,43.0,CC(C)[C@@H]1c2cc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,1400.0,Ki,nM,1400.0,CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCOC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CCOC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CCC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CNC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CNC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,149.0,Ki,nM,149.0,CC(=O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C2CC2)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C2CC2)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,1600.0,Ki,nM,1600.0,CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,83.0,Ki,nM,83.0,CC(C)[C@@H]1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(C(N)=O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCOC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,26.0,Ki,nM,26.0,CCOC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,23.0,Ki,nM,23.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C2CC2)n1,CHEMBL3638683,=,=,Ki,nM,1764.0,Ki,nM,1764.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C2CC2)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]TO901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at rt.",CC(C)[C@@H]1c2cc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,CHEMBL3638786,=,=,Ki,nM,398.0,Ki,nM,398.0,CC(C)[C@@H]1c2cc3ccc(S(C)(=O)=O)cc3n2CCN1c1nccc(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,136.0,Ki,nM,136.0,CCC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,65.0,Ki,nM,65.0,CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,253.0,Ki,nM,253.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,409.0,Ki,nM,409.0,CC(C)[C@@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",COc1nc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)ncc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,70.0,Ki,nM,70.0,COc1nc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)ncc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3638683,=,=,Ki,nM,1540.0,Ki,nM,1540.0,CC(C)C1c2nc3ccc(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,46.0,Ki,nM,46.0,CC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)C2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(CO)c(C(F)(F)F)n1,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",Cc1nc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)ncc1CO,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,Cc1nc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)ncc1CO,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(O)c1cnc(N2CCn3c(nc4ccc(S(C)(=O)=O)cc43)[C@@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,72.0,Ki,nM,72.0,CCC(O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CCOC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,CHEMBL3638683,=,=,Ki,nM,49.0,Ki,nM,49.0,CCOC(=O)c1cnc(N2CCn3c(nc4cc(CO)c(S(C)(=O)=O)cc43)[C@H]2C(C)C)nc1C(F)(F)F,2015
"Radioligand Binding Assay: Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligand binding domain (LBD) in the presence of radiolabeled LXR ligand [3H]TO901317. The amount of the LXR-LBD that complexed with [3H]T0901317 was measured by scintillation proximity assay (SPA) employing non-specific binding of LXR-LBD to poly-lysine coated Yttrium silicate beads. Partially purified LXR alpha or beta LBD protein (15-45 nM) was incubated at rt for 30 min with 15 nM [3H]T0901317 (25-40 Ci/mmol) and different concentrations of test compounds in 80 uL of phosphate buffered saline (PBS) buffer containing 2.5% DMSO, 1% glycerol, 2 mM EDTA, 2 mM CHAPS and 5 mM DTT in 96-well plates. Poly-lysine SPA beads (50 ug) were added to each well and the total volume was adjusted to 120 uL. The plates were shaken on an orbital shaker for 20 min and then allowed to settle for 10 more minutes at room temperature.",CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)N(C)C)c(C(F)(F)F)n1,CHEMBL3638683,>,>,Ki,nM,3330.0,Ki,nM,3330.0,CC(C)[C@H]1c2nc3cc(CO)c(S(C)(=O)=O)cc3n2CCN1c1ncc(C(=O)N(C)C)c(C(F)(F)F)n1,2015
Agonist activity at human LXRalpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3779847,=,=,EC50,nM,400.0,EC50,uM,0.4,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Agonist activity at human LXRalpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,C[Si](C)(O)c1ccc(N(CC(F)(F)F)S(=O)(=O)c2ccccc2)cc1,CHEMBL3779847,,,EC50,,,EC50,,,C[Si](C)(O)c1ccc(N(CC(F)(F)F)S(=O)(=O)c2ccccc2)cc1,2016
Agonist activity at human LXRalpha transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)(O)c1ccc(N(CC(F)(F)F)S(=O)(=O)c2ccccc2)cc1,CHEMBL3779847,,,EC50,,,EC50,,,CC(C)(O)c1ccc(N(CC(F)(F)F)S(=O)(=O)c2ccccc2)cc1,2016
Partial agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,Emax,%,104.0,Emax,%,104.0,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,EC50,nM,1480.0,EC50,uM,1.48,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,EC50,nM,280.0,EC50,uM,0.28,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,Emax,%,40.0,Emax,%,40.0,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay T1317,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,Emax,%,50.0,Emax,%,50.0,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)OC(C)(C)C)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,EC50,nM,41.0,EC50,uM,0.041,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,Emax,%,66.0,Emax,%,66.0,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay T1317,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,Emax,%,62.0,Emax,%,62.0,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(N2CCC(C3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)CC2)cc1Cl,CHEMBL3808288,=,=,EC50,nM,500.0,EC50,uM,0.5,CN(C)C(=O)c1ccc(N2CCC(C3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)CC2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(N2CCC(C3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)CC2)cc1Cl,CHEMBL3808288,=,=,Emax,%,24.0,Emax,%,24.0,CN(C)C(=O)c1ccc(N2CCC(C3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)CC2)cc1Cl,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3808288,=,=,EC50,nM,20.0,EC50,uM,0.02,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3808288,=,=,Emax,%,100.0,Emax,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Partial agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,EC50,nM,420.0,EC50,uM,0.42,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Partial agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,EC50,nM,830.0,EC50,uM,0.83,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Partial agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,Emax,%,31.0,Emax,%,31.0,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Agonist activity at GST-tagged LXRalpha-LBD (unknown origin) by LanthaScreen TR-FRET liver X receptor coactivator assay T1317,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,Emax,%,49.0,Emax,%,49.0,CC(C)[C@@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CC(C)[C@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,EC50,nM,2000.0,EC50,uM,2.0,CC(C)[C@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CC(C)[C@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,CHEMBL3808288,=,=,Emax,%,31.0,Emax,%,31.0,CC(C)[C@](O)(C(=O)N1CCC(C2CCN(c3ccc(C(=O)N(C)C)c(Cl)c3)CC2)CC1)C(F)(F)F,2016
Agonist activity at LXRalpha (unknown origin) expressed in human HepG2 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,CHEMBL3808288,=,=,EC50,nM,45.0,EC50,uM,0.045,CN(C)C(=O)c1ccc(-c2cnc(N3CCN(C(=O)[C@](O)(c4ccccc4)C(F)(F)F)CC3)c(C#N)c2)cc1Cl,2016
Agonist activity at human LXRalpha by Gal4 assay,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3813625,=,=,EC50,nM,1128.0,EC50,nM,1128.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2016
Binding affinity to human LXRalpha,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL3813625,>,>,EC50,nM,20000.0,EC50,uM,20.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2016
Binding affinity to human LXRalpha,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3813625,=,=,EC50,nM,22.0,EC50,nM,22.0,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2016
Binding affinity to human LXRalpha,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,EC50,nM,19.0,EC50,nM,19.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Agonist activity at human LXRalpha coexpressed in African green monkey CV1 cells by Gal4 responsive reporter gene assay,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL3813625,=,=,EC50,nM,117.0,EC50,nM,117.0,C[C@H](CC[C@@H]1OC1(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2016
Agonist activity at human LXRalpha coexpressed in African green monkey CV1 cells by Gal4 responsive reporter gene assay,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,EC50,nM,205.0,EC50,nM,205.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,>,>,Ki,nM,3300.0,Ki,nM,3300.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Ki,nM,2200.0,Ki,nM,2200.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,>,>,Ki,nM,3300.0,Ki,nM,3300.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,FC(F)(F)c1ccc(CN2CCN(c3ccccc3)CC2c2ccccc2)cn1,CHEMBL3813625,,,Ki,,,Ki,,,FC(F)(F)c1ccc(CN2CCN(c3ccccc3)CC2c2ccccc2)cn1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Ki,nM,1100.0,Ki,nM,1100.0,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Ki,nM,1552.0,Ki,nM,1552.0,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,EC50,nM,1120.0,EC50,uM,1.12,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C/CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,EC50,nM,1230.0,EC50,uM,1.23,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C/CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCC#CCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,EC50,nM,860.0,EC50,uM,0.86,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCC#CCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,CHEMBL3813680,=,=,EC50,nM,1960.0,EC50,uM,1.96,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,CHEMBL3813680,=,=,EC50,nM,2890.0,EC50,uM,2.89,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,CHEMBL3813680,=,=,EC50,nM,3140.0,EC50,uM,3.14,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,=,=,EC50,nM,360.0,EC50,uM,0.36,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,CHEMBL3813680,=,=,EC50,nM,400.0,EC50,uM,0.4,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,CHEMBL3813680,=,=,EC50,nM,3740.0,EC50,uM,3.74,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,CHEMBL3813680,=,=,EC50,nM,340.0,EC50,uM,0.34,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,=,=,EC50,nM,330.0,EC50,uM,0.33,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,=,=,EC50,nM,200.0,EC50,uM,0.2,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3813680,=,=,EC50,nM,490.0,EC50,uM,0.49,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,CHEMBL3813680,=,=,Emax,%,2.0,Emax,%,2.0,CCCc1c(OCCCCN2C(=O)NC(C)(c3ccc(OC)cc3)C2=O)ccc2c(C(F)(F)F)cc(=O)oc12,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,Emax,%,26.0,Emax,%,26.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCCCCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C\CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,Emax,%,0.0,Emax,%,0.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C\CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C/CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,Emax,%,40.0,Emax,%,40.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C/CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCC#CCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,=,=,Emax,%,27.0,Emax,%,27.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OCC#CCN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,CHEMBL3813680,=,=,Emax,%,53.0,Emax,%,53.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,=,=,Emax,%,0.0,Emax,%,0.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,CHEMBL3813680,=,=,Emax,%,23.0,Emax,%,23.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1cccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,=,=,Emax,%,1.0,Emax,%,1.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,CHEMBL3813680,=,=,Emax,%,53.0,Emax,%,53.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,CHEMBL3813680,=,=,Emax,%,0.0,Emax,%,0.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,CHEMBL3813680,=,=,Emax,%,1.0,Emax,%,1.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,=,=,Emax,%,5.0,Emax,%,5.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,=,=,Emax,%,46.0,Emax,%,46.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,CHEMBL3813680,=,=,Emax,%,71.0,Emax,%,71.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(C)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,CHEMBL3813680,=,=,Emax,%,38.0,Emax,%,38.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,CHEMBL3813680,=,=,Emax,%,55.0,Emax,%,55.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,=,=,Emax,%,68.0,Emax,%,68.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,=,=,Emax,%,164.0,Emax,%,164.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,=,=,Emax,%,25.0,Emax,%,25.0,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay in presence of T0901317,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3813680,=,=,Emax,%,100.0,Emax,%,100.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C\CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(CCC)c1OC/C=C\CN1C(=O)NC(C)(c2ccc(OC(C)C)cc2)C1=O,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(OC)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(CCN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)c(O)c1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cc3)C2=O)cc1,2016
Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells at 10 uM after 24 hrs by luciferase reporter gene assay,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,CHEMBL3813680,,,Activity,,,Activity,,,CCCc1cc(C(O)(C(F)(F)F)C(F)(F)F)ccc1Oc1ccc(C(=O)CN2C(=O)NC(C)(c3ccc(OC(C)C)cn3)C2=O)c(O)c1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,43.0,Ki,nM,43.0,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,25.0,Ki,nM,25.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,3.0,Ki,nM,3.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,146.0,Ki,nM,146.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,157.0,Ki,nM,157.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,81.0,Ki,nM,81.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Ki,nM,1072.0,Ki,nM,1072.0,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of [3H]TO901317 from LXRalpha ligand binding domain (unknown origin) after 30 mins by liquid scintillation counting,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,Ki,nM,20.0,Ki,nM,20.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,EC50,nM,5375.0,EC50,nM,5375.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,EC50,nM,2500.0,EC50,nM,2500.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,>,>,EC50,nM,20000.0,EC50,nM,20000.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,FC(F)(F)c1ccc(CN2CCN(c3ccccc3)CC2c2ccccc2)cn1,CHEMBL3813625,>,>,EC50,nM,20000.0,EC50,nM,20000.0,FC(F)(F)c1ccc(CN2CCN(c3ccccc3)CC2c2ccccc2)cn1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,EC50,nM,3825.0,EC50,nM,3825.0,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,CHEMBL3813625,>,>,EC50,nM,10000.0,EC50,nM,10000.0,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,257.0,EC50,nM,257.0,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,254.0,EC50,nM,254.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,92.0,EC50,nM,92.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,590.0,EC50,nM,590.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,763.0,EC50,nM,763.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,244.0,EC50,nM,244.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,EC50,nM,1734.0,EC50,nM,1734.0,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,EC50,nM,205.0,EC50,nM,205.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Efficacy,%,17.0,Efficacy,%,17.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Efficacy,%,19.0,Efficacy,%,19.0,CS(=O)(=O)c1cccc(N2CCN(Cc3ccc(C(F)(F)F)nc3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,CHEMBL3813625,=,=,Efficacy,%,35.0,Efficacy,%,35.0,CS(=O)(=O)c1cccc(N2CCN(c3nccc(C(F)(F)F)n3)C(c3ccccc3)C2)c1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,85.0,Efficacy,%,85.0,CC(C)[C@@H]1CN(c2cccc(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,92.0,Efficacy,%,92.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,113.0,Efficacy,%,113.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(Cl)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,57.0,Efficacy,%,57.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,37.0,Efficacy,%,37.0,CC(C)[C@@H]1CN(c2ccc(F)c(S(C)(=O)=O)c2)CCN1c1ncc(C(C)(C)O)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,60.0,Efficacy,%,60.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3813625,=,=,Efficacy,%,95.0,Efficacy,%,95.0,CC(C)[C@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at human LXRalpha ligand binding domain(167 to 447 residues) transfected in HEK293 cells after 16 hrs by Gal4-luciferase reporter gene assay relative to TO901317,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,Efficacy,%,51.0,Efficacy,%,51.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Binding affinity to human LXRalpha by radioligand displacement assay,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,CHEMBL3813625,=,=,IC50,nM,34.0,IC50,nM,34.0,CS(=O)(=O)c1cc(-c2ccc(CN(Cc3ccccc3)S(=O)(=O)c3ccccc3C(F)(F)F)s2)ccc1CO,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL3853334,=,=,Ki,nM,24.0,Ki,nM,24.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,81.0,Ki,nM,81.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,71.0,Ki,nM,71.0,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,383.0,Ki,nM,383.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,1365.0,Ki,nM,1365.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,63.0,Ki,nM,63.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,20.0,Ki,nM,20.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,204.0,Ki,nM,204.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,CHEMBL3853334,=,=,Ki,nM,186.0,Ki,nM,186.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,CHEMBL3853334,=,=,Ki,nM,32.0,Ki,nM,32.0,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,Ki,nM,218.0,Ki,nM,218.0,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,CHEMBL3853334,=,=,Ki,nM,22.0,Ki,nM,22.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,Ki,nM,136.0,Ki,nM,136.0,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,CHEMBL3853334,=,=,Ki,nM,7.0,Ki,nM,7.0,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,CHEMBL3853334,=,=,Ki,nM,51.0,Ki,nM,51.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,CHEMBL3853334,=,=,Ki,nM,86.0,Ki,nM,86.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,2016
Displacement of radiolabeled T0901317 from LXRalpha LBD (unknown origin),COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,CHEMBL3853334,=,=,Ki,nM,48.0,Ki,nM,48.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,244.0,EC50,nM,244.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,214.0,EC50,nM,214.0,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,1376.0,EC50,nM,1376.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,2241.0,EC50,nM,2241.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,249.0,EC50,nM,249.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,111.0,EC50,nM,111.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,567.0,EC50,nM,567.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,CHEMBL3853334,=,=,EC50,nM,199.0,EC50,nM,199.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,CHEMBL3853334,=,=,EC50,nM,72.0,EC50,nM,72.0,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,EC50,nM,271.0,EC50,nM,271.0,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,CHEMBL3853334,=,=,EC50,nM,57.0,EC50,nM,57.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,EC50,nM,491.0,EC50,nM,491.0,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,CHEMBL3853334,=,=,EC50,nM,37.0,EC50,nM,37.0,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,CHEMBL3853334,=,=,EC50,nM,94.0,EC50,nM,94.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,CHEMBL3853334,=,=,EC50,nM,189.0,EC50,nM,189.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,CHEMBL3853334,=,=,EC50,nM,166.0,EC50,nM,166.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,60.0,Efficacy,%,60.0,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,79.0,Efficacy,%,79.0,CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,74.0,Efficacy,%,74.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,74.0,Efficacy,%,74.0,CC(C)C1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,67.0,Efficacy,%,67.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,104.0,Efficacy,%,104.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,57.0,Efficacy,%,57.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,CHEMBL3853334,=,=,Efficacy,%,88.0,Efficacy,%,88.0,CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,CHEMBL3853334,=,=,Efficacy,%,95.0,Efficacy,%,95.0,Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,Efficacy,%,5.0,Efficacy,%,5.0,COc1nc(C)cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,CHEMBL3853334,=,=,Efficacy,%,91.0,Efficacy,%,91.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,CHEMBL3853334,=,=,Efficacy,%,45.0,Efficacy,%,45.0,COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,CHEMBL3853334,=,=,Efficacy,%,96.0,Efficacy,%,96.0,COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,CHEMBL3853334,=,=,Efficacy,%,88.0,Efficacy,%,88.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,CHEMBL3853334,=,=,Efficacy,%,72.0,Efficacy,%,72.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1,2016
Agonist activity at LXRalpha LBD (unknown origin) fused with Gal4-DNA binding domain expressed in HEK293 cells assessed as modulation of receptor transcription activity by luciferase reporter gene assay relative to T0901317,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,CHEMBL3853334,=,=,Efficacy,%,83.0,Efficacy,%,83.0,COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,99.0,EC50,nM,99.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,100.0,EC50,nM,100.0,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,110.0,EC50,nM,110.0,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(O)c1ccc(-c2ccc(-n3cc(C(C)(C)O)nc3C(C)(C)c3ccccc3Cl)cc2)cc1S(C)(=O)=O,CHEMBL3867488,=,=,EC50,nM,120.0,EC50,nM,120.0,CC(O)c1ccc(-c2ccc(-n3cc(C(C)(C)O)nc3C(C)(C)c3ccccc3Cl)cc2)cc1S(C)(=O)=O,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,76.0,EC50,nM,76.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,38.0,Efficacy,%,38.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,20.0,Efficacy,%,20.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,39.0,Efficacy,%,39.0,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2ccccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,46.0,Efficacy,%,46.0,CC(C)(O)c1cn(-c2ccc(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(O)c1ccc(-c2ccc(-n3cc(C(C)(C)O)nc3C(C)(C)c3ccccc3Cl)cc2)cc1S(C)(=O)=O,CHEMBL3867488,=,=,Efficacy,%,47.0,Efficacy,%,47.0,CC(O)c1ccc(-c2ccc(-n3cc(C(C)(C)O)nc3C(C)(C)c3ccccc3Cl)cc2)cc1S(C)(=O)=O,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,29.0,Efficacy,%,29.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,220.0,EC50,nM,220.0,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2F)n1,CHEMBL3867488,=,=,EC50,nM,130.0,EC50,nM,130.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2F)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2F)n1,CHEMBL3867488,=,=,Efficacy,%,13.0,Efficacy,%,13.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2F)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,30.0,EC50,nM,30.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,25.0,Efficacy,%,25.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2cccc(F)c2Cl)n1,CHEMBL3867488,=,=,EC50,nM,72.0,EC50,nM,72.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2cccc(F)c2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2cccc(F)c2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,12.0,Efficacy,%,12.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2cccc(F)c2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,57.0,EC50,nM,57.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2ccccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2ccccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,25.0,Efficacy,%,25.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2ccccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,8.0,EC50,nM,8.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,20.0,Efficacy,%,20.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Antagonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs in presence of LXR pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile by luciferase reporter gene assay",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,IC50,nM,69.0,IC50,nM,69.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Antagonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs in presence of LXR pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile by luciferase reporter gene assay relative to control",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Inhibition,%,83.0,INH,%,83.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(F)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,11.0,EC50,nM,11.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(F)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(F)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,15.0,Efficacy,%,15.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(F)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2Cl)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,8.0,EC50,nM,8.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2Cl)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2Cl)c(C(C)(C)c2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,6.0,Efficacy,%,6.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2Cl)c(C(C)(C)c2c(Cl)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,EC50,nM,69.0,EC50,nM,69.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2c(Cl)cccc2Cl)n1,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2c(Cl)cccc2Cl)n1,CHEMBL3867488,=,=,Efficacy,%,17.0,Efficacy,%,17.0,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2)c(Cc2c(Cl)cccc2Cl)n1,2016
Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay,CC(c1c(Cl)cccc1Cl)c1nc(C(C)(C)O)cn1-c1ccc(-c2cc(F)c(CO)c(S(C)(=O)=O)c2)cc1F,CHEMBL3867488,=,=,EC50,nM,12.0,EC50,nM,12.0,CC(c1c(Cl)cccc1Cl)c1nc(C(C)(C)O)cn1-c1ccc(-c2cc(F)c(CO)c(S(C)(=O)=O)c2)cc1F,2016
"Agonist activity at human LXR-alpha expressed in African green monkey CV1 cells measured after 18 to 20 hrs by luciferase reporter gene assay relative to pan agonist 1-(2,4-difluorobenzyl)-2-oxo-6-(4-phenoxyphenyl)-4-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile",CC(c1c(Cl)cccc1Cl)c1nc(C(C)(C)O)cn1-c1ccc(-c2cc(F)c(CO)c(S(C)(=O)=O)c2)cc1F,CHEMBL3867488,=,=,Efficacy,%,18.0,Efficacy,%,18.0,CC(c1c(Cl)cccc1Cl)c1nc(C(C)(C)O)cn1-c1ccc(-c2cc(F)c(CO)c(S(C)(=O)=O)c2)cc1F,2016
Activation of human LXRalpha expressed in HEK293 cells co-expressing human RXRalpha at 10 uM after 20 hrs by luciferase reporter gene assay,Cc1c(CCO)c(CO)cc2c1C(=O)[C@H](C)[C@@H]2O,CHEMBL3997777,,,Activity,,,Activity,,,Cc1c(CCO)c(CO)cc2c1C(=O)[C@H](C)[C@@H]2O,2016
Activation of human LXRalpha expressed in HEK293 cells co-expressing human RXRalpha at 10 uM after 20 hrs by luciferase reporter gene assay,Cl.O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL3997777,,,Activity,,,Activity,,,Cl.O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2016
Binding affinity to human LXRalpha at 4 uM by TR-FRET assay,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O,CHEMBL4017496,,,Activity,,,Activity,,,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to human LXRalpha at 4 uM by TR-FRET assay,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O,CHEMBL4017496,,,Activity,,,Activity,,,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O,2017
Transactivation of human GAL4-fused LXRalpha ligand binding domain expressed in HEL293T cells at 10 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC(C)(C)c1ccc(C(=O)NCc2ccc(NS(C)(=O)=O)cc2Cl)cc1,CHEMBL4017509,,,Activity,,,Activity,,,CC(C)(C)c1ccc(C(=O)NCc2ccc(NS(C)(=O)=O)cc2Cl)cc1,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@@H](C(C)C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,,,EC50,,,EC50,,,CC[C@@H](C(C)C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,1500.0,EC50,uM,1.5,CC(C)[C@@H](C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,4110.0,EC50,uM,4.11,CC(C)[C@@H](C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@@H](C(C)C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,16430.0,EC50,uM,16.43,CC[C@@H](C(C)C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@@H](C(C)C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,2090.0,EC50,uM,2.09,CC[C@@H](C(C)C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,6710.0,EC50,uM,6.71,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)C(=O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,5580.0,EC50,uM,5.58,CC(C)[C@@H](C)C(=O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@H](CC(=O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,,,EC50,,,EC50,,,CC[C@H](CC(=O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@H](C(=O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,=,=,EC50,nM,14510.0,EC50,uM,14.51,CC[C@H](C(=O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,,,EC50,,,EC50,,,CC(C)[C@@H](C)C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,15750.0,EC50,uM,15.75,CC(C)[C@@H](C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,6610.0,EC50,uM,6.61,CC(C)[C@@H](C)C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,8070.0,EC50,uM,8.07,CC(C)[C@@H](C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@H](C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,=,=,EC50,nM,6930.0,EC50,uM,6.93,CC[C@H](C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@@H](C(C)C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,3200.0,EC50,uM,3.2,CC[C@@H](C(C)C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC[C@H](C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,,,EC50,,,EC50,,,CC[C@H](C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay,CC(C)[C@@H](C)CC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,EC50,nM,8510.0,EC50,uM,8.51,CC(C)[C@@H](C)CC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC[C@@H](C(C)C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,488.8,Efficacy,%,488.8,CC[C@@H](C(C)C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC[C@@H](C(C)C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,56.8,Efficacy,%,56.8,CC[C@@H](C(C)C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,93.2,Efficacy,%,93.2,CC(C)[C@@H](C)[C@H]1O[C@@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,51.7,Efficacy,%,51.7,CC(C)[C@@H](C)[C@@H]1O[C@H]1[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC[C@@H](C(C)C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,489.3,Efficacy,%,489.3,CC[C@@H](C(C)C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC[C@H](C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,=,=,Efficacy,%,208.3,Efficacy,%,208.3,CC[C@H](C[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,159.3,Efficacy,%,159.3,CC(C)[C@@H](C)[C@@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,74.7,Efficacy,%,74.7,CC(C)[C@@H](C)C[C@H](O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,63.9,Efficacy,%,63.9,CC(C)[C@@H](C)[C@H](O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC[C@H](C(=O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,CHEMBL4038329,=,=,Efficacy,%,12.4,Efficacy,%,12.4,CC[C@H](C(=O)C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)C(=O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,150.6,Efficacy,%,150.6,CC(C)[C@@H](C)C(=O)C[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Activation of GAL4 fused human LXR alpha expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay relative to 22R-HC,CC(C)[C@@H](C)CC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4038329,=,=,Efficacy,%,70.2,Efficacy,%,70.2,CC(C)[C@@H](C)CC(=O)[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Antagonist activity at GAL4-tagged human LXRalpha ligand binding domain expressed in HEK293T cells at 1 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay,COc1ccc(CNc2c(-c3cc(Cl)ccn3)nc3ccc(Cl)cn23)cc1,CHEMBL4038333,,,Inhibition,%,,INH,,,COc1ccc(CNc2c(-c3cc(Cl)ccn3)nc3ccc(Cl)cn23)cc1,2017
Transactivation of GAL4-tagged human LXRalpha ligand binding domain expressed in HEK293T cells at 1 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay,COc1ccc(CNc2c(-c3cc(Cl)ccn3)nc3ccc(Cl)cn23)cc1,CHEMBL4038333,,,Activity,,,Activity,,,COc1ccc(CNc2c(-c3cc(Cl)ccn3)nc3ccc(Cl)cn23)cc1,2017
Agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 to 20 uM in presence of RXR-antagonist HX531 measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4049385,,,Activity,,,Activity,,,CC(C)CC[C@@H](O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2017
Agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 uM in presence of RXR-antagonist HX531 measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,,,Activity,,,Activity,,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of WAY252623-induced receptor activation at 1 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL4049385,,,Inhibition,%,,INH,,,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2017
Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of GW3965-induced receptor activation at 1 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL4049385,,,Inhibition,%,,INH,,,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2017
Agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 1 uM in presence of LXR-agonist 22(R)-hydroxycholesterol measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL4049385,,,Activity,,,Activity,,,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2017
Agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 uM in presence of LXR-agonist 22(R)-hydroxycholesterol measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,,,Activity,,,Activity,,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of WAY252623-induced receptor activation at 10 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,,,Inhibition,%,,INH,,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Partial antagonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells assessed as inhibition of GW3965-induced receptor activation at 10 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,,,Inhibition,%,,INH,,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4049385,=,=,EC50,nM,940.0,EC50,uM,0.94,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,CHEMBL4049385,=,=,EC50,nM,1440.0,EC50,uM,1.44,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL4049385,=,=,EC50,nM,196.0,EC50,uM,0.196,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,=,=,EC50,nM,1090.0,EC50,uM,1.09,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay relative to T0901317,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,CHEMBL4049385,=,=,FC,,1.82,FC,,1.82,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,2017
Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells at 10 uM measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay relative to T0901317,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,CHEMBL4049385,=,=,FC,,1.39,FC,,1.39,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,2017
Agonist activity at recombinant GST-tagged human LXRalpha LBD assessed as fluorescein-labeled coactivator peptide recruitment preincubated with enzyme followed by coactivator addition by LanthaScreen TR-FRET assay,CN1CC[C@@H](N2C(=O)S/C(=C\c3ccc4c(cnn4Cc4ccc(Cl)cc4C(F)(F)F)c3)C2=O)[C@H](F)C1,CHEMBL4130359,>,>,EC50,nM,10000.0,EC50,uM,10.0,CN1CC[C@@H](N2C(=O)S/C(=C\c3ccc4c(cnn4Cc4ccc(Cl)cc4C(F)(F)F)c3)C2=O)[C@H](F)C1,2017
Antagonist activity at recombinant GST-tagged human LXRalpha LBD assessed as inhibition of TO901317-induced fluorescein-labeled coactivator peptide recruitment preincubated with enzyme followed by coactivator addition by LanthaScreen TR-FRET assay,CN1CC[C@@H](N2C(=O)S/C(=C\c3ccc4c(cnn4Cc4ccc(Cl)cc4C(F)(F)F)c3)C2=O)[C@H](F)C1,CHEMBL4130359,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1CC[C@@H](N2C(=O)S/C(=C\c3ccc4c(cnn4Cc4ccc(Cl)cc4C(F)(F)F)c3)C2=O)[C@H](F)C1,2017
Antagonist activity at LXRalpha (unknown origin) by cell based GAL4 reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,CHEMBL4130640,,,Inhibition,%,,INH,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,2018
Agonist activity at LXRalpha (unknown origin) by TR-FRET assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,CHEMBL4130640,,,Activity,,,Activity,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,2018
Antagonist activity at LXRalpha (unknown origin) by TR-FRET assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,CHEMBL4130640,,,Inhibition,%,,INH,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,2018
Agonist activity at LXRalpha (unknown origin) by cell based GAL4 reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,CHEMBL4130640,,,Activity,,,Activity,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cnc(O[C@@H](C)c3ccccc3)c(Cl)c2)cc1,2018
Antagonist activity at LXRalpha (unknown origin) assessed as inhibition of TO901317-induced response at 1 uM by luciferase reporter gene assay,Cc1ccc2nc([C@H](CC3CCN(C(=O)C(C)C)CC3)N3C(=O)CN(c4ccc(Oc5ccccc5)cc4)C3=O)n(C)c2c1,CHEMBL4138296,,,Inhibition,%,,INH,,,Cc1ccc2nc([C@H](CC3CCN(C(=O)C(C)C)CC3)N3C(=O)CN(c4ccc(Oc5ccccc5)cc4)C3=O)n(C)c2c1,2018
Agonist activity at LXRalpha (unknown origin) at 1 uM by luciferase reporter gene assay,Cc1ccc2nc([C@H](CC3CCN(C(=O)C(C)C)CC3)N3C(=O)CN(c4ccc(Oc5ccccc5)cc4)C3=O)n(C)c2c1,CHEMBL4138296,,,Activity,,,Activity,,,Cc1ccc2nc([C@H](CC3CCN(C(=O)C(C)C)CC3)N3C(=O)CN(c4ccc(Oc5ccccc5)cc4)C3=O)n(C)c2c1,2018
Agonist activity at LXRalpha (unknown origin) assessed as co-activator recruitment after 30 mins by Alpha Screen assay,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4145453,,,Activity,,,Activity,,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Agonist activity at LXRalpha (unknown origin) assessed as co-activator recruitment after 30 mins by Alpha Screen assay,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4145453,,,Activity,,,Activity,,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Antagonist activity at LXRalpha (unknown origin) assessed as reduction in co-activator recruitment after 30 mins by Alpha Screen assay,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4145453,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Antagonist activity at LXRalpha (unknown origin) assessed as reduction in co-activator recruitment after 30 mins by Alpha Screen assay,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4145453,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Transactivation of human Gal4-fused LXRalpha LBD expressed in HEK293T cells at 30 uM after 12 to 14 hrs by dual-glo luciferase assay,CC1=C2[C@H](/C=C(\C)C(=O)O)CC[C@@H](C)[C@H]2CC1,CHEMBL4145619,,,Activity,,,Activity,,,CC1=C2[C@H](/C=C(\C)C(=O)O)CC[C@@H](C)[C@H]2CC1,2018
Antagonist activity at human GAL4N-fused LXRalpha LBD expressed in HEK293 cells assessed as reduction in T0901317-induced transactivation activity after 24 hrs by luciferase reporter gene assay,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1ccccc12,CHEMBL4145662,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1ccccc12,2018
Antagonist activity at human GAL4N-fused LXRalpha LBD expressed in HEK293 cells assessed as reduction in T0901317-induced transactivation activity after 24 hrs by luciferase reporter gene assay,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1cc(F)ccc12,CHEMBL4145662,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1cc(F)ccc12,2018
Antagonist activity at human GAL4N-fused LXRalpha LBD expressed in HEK293 cells assessed as reduction in T0901317-induced transactivation activity after 24 hrs by luciferase reporter gene assay,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c3ccc(F)cc3c(=O)n(C)c12,CHEMBL4145662,>,>,IC50,nM,20000.0,IC50,uM,20.0,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c3ccc(F)cc3c(=O)n(C)c12,2018
Agonist activity at human LXRalpha expressed in Escherichia coli assessed as induction of calcium flux at 10 uM by fluorimetry,Cc1noc(C)c1-c1ccc(C(=O)N2[C@@H](c3ccccc3Cl)SC[C@H]2C(=O)O)cc1,CHEMBL4152367,,,Activity,,,Activity,,,Cc1noc(C)c1-c1ccc(C(=O)N2[C@@H](c3ccccc3Cl)SC[C@H]2C(=O)O)cc1,2018
Antagonist activity at human LXRalpha expressed in Escherichia coli assessed as inhibition of T0901317-induced calcium flux at 10 uM by fluorimetry,Cc1noc(C)c1-c1ccc(C(=O)N2[C@@H](c3ccccc3Cl)SC[C@H]2C(=O)O)cc1,CHEMBL4152367,,,Inhibition,%,,INH,,,Cc1noc(C)c1-c1ccc(C(=O)N2[C@@H](c3ccccc3Cl)SC[C@H]2C(=O)O)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4177737,=,=,EC50,nM,359.0,EC50,nM,359.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccc(F)cc1)N1CCSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,EC50,nM,190.0,EC50,nM,190.0,O=S(=O)(c1ccc(F)cc1)N1CCSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccc(F)cc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,EC50,nM,265.0,EC50,nM,265.0,O=S(=O)(c1ccc(F)cc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccc(F)cc1)N1CCNc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,EC50,nM,310.0,EC50,nM,310.0,O=S(=O)(c1ccc(F)cc1)N1CCNc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CN1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,EC50,nM,385.0,EC50,nM,385.0,CN1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=S(=O)(c1ccc(F)cc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,EC50,nM,163.0,EC50,nM,163.0,O=S(=O)(c1ccc(F)cc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,EC50,nM,70.0,EC50,nM,70.0,CC1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC1(C)CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,EC50,nM,290.0,EC50,nM,290.0,CC1(C)CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,COC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,250.0,EC50,nM,250.0,COC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=C(O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,NC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,970.0,EC50,nM,970.0,NC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,2403.0,EC50,nM,2403.0,CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1nncs1,CHEMBL4177737,=,=,EC50,nM,342.0,EC50,nM,342.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1nncs1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CCOCC1,CHEMBL4177737,=,=,EC50,nM,980.0,EC50,nM,980.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CCOCC1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1ccncc1,CHEMBL4177737,=,=,EC50,nM,2070.0,EC50,nM,2070.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1ccncc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CC(O)C1,CHEMBL4177737,=,=,EC50,nM,1300.0,EC50,nM,1300.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CC(O)C1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,2770.0,EC50,nM,2770.0,CC(C)(O)CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)C[C@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,2820.0,EC50,nM,2820.0,CC(C)(O)CNC(=O)C[C@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)C[C@@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,3280.0,EC50,nM,3280.0,CC(C)(O)CNC(=O)C[C@@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CC(=O)NCC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,EC50,nM,374.0,EC50,nM,374.0,CC(C)(O)CC(=O)NCC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,EC50,nM,792.0,EC50,nM,792.0,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,EC50,nM,315.0,EC50,nM,315.0,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)CC1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,EC50,nM,1030.0,EC50,nM,1030.0,CC(C)(O)CNC(=O)CC1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)C[C@@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(C)(O)CNC(=O)C[C@@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)CNC(=O)C[C@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,EC50,nM,320.0,EC50,nM,320.0,CC(C)(O)CNC(=O)C[C@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay,CC(C)(O)[C@H](F)CNC(=O)C[C@@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(C)(O)[C@H](F)CNC(=O)C[C@@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4177737,=,=,%max,%,90.0,%max,%,90.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=S(=O)(c1ccc(F)cc1)N1CCSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,%max,%,80.0,%max,%,80.0,O=S(=O)(c1ccc(F)cc1)N1CCSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=S(=O)(c1ccc(F)cc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,%max,%,78.0,%max,%,78.0,O=S(=O)(c1ccc(F)cc1)N1CCOc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=S(=O)(c1ccc(F)cc1)N1CCNc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,%max,%,64.0,%max,%,64.0,O=S(=O)(c1ccc(F)cc1)N1CCNc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CN1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,%max,%,47.0,%max,%,47.0,CN1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=S(=O)(c1ccc(F)cc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,CHEMBL4177737,=,=,%max,%,70.0,%max,%,70.0,O=S(=O)(c1ccc(F)cc1)N1CCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,%max,%,60.0,%max,%,60.0,CC1CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC1(C)CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4177737,=,=,%max,%,39.0,%max,%,39.0,CC1(C)CCN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc21,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,COC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,75.0,%max,%,75.0,COC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,NC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,50.0,%max,%,50.0,NC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,48.0,%max,%,48.0,CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1nncs1,CHEMBL4177737,=,=,%max,%,23.0,%max,%,23.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1nncs1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CCOCC1,CHEMBL4177737,=,=,%max,%,40.0,%max,%,40.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CCOCC1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1ccncc1,CHEMBL4177737,=,=,%max,%,27.0,%max,%,27.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)Nc1ccncc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CC(O)C1,CHEMBL4177737,=,=,%max,%,30.0,%max,%,30.0,O=C(CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1)N1CC(O)C1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,39.0,%max,%,39.0,CC(C)(O)CNC(=O)CC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)C[C@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,40.0,%max,%,40.0,CC(C)(O)CNC(=O)C[C@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)C[C@@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,34.0,%max,%,34.0,CC(C)(O)CNC(=O)C[C@@H]1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CC(=O)NCC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,CHEMBL4177737,=,=,%max,%,74.0,%max,%,74.0,CC(C)(O)CC(=O)NCC1CN(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2S1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,%max,%,100.0,%max,%,100.0,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,%max,%,93.0,%max,%,93.0,CC(C)(O)CNC(=O)CC1CSc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)CC1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,%max,%,83.0,%max,%,83.0,CC(C)(O)CNC(=O)CC1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Agonist activity at GAL4-tagged human LXRalpha assessed as receptor activation expressed in African green monkey CV1 cells by luciferase reporter gene assay relative to untreated control,CC(C)(O)CNC(=O)C[C@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,CHEMBL4177737,=,=,%max,%,78.0,%max,%,78.0,CC(C)(O)CNC(=O)C[C@H]1CCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc2N1S(=O)(=O)c1ccc(F)cc1,2018
Transactivation of recombinant human GST-tagged LXRalpha-LBD at 10 uM by TR-FRET assay,O=CN1CCc2c([nH]c3ccccc23)C1c1cccc2cccnc12,CHEMBL4184241,,,Activity,,,Activity,,,O=CN1CCc2c([nH]c3ccccc23)C1c1cccc2cccnc12,2018
Transactivation of recombinant human GST-tagged LXRalpha-LBD at 30 uM by TR-FRET assay,c1cnc2c(C3NCCc4c3[nH]c3ccccc43)cccc2c1,CHEMBL4184241,,,Activity,,,Activity,,,c1cnc2c(C3NCCc4c3[nH]c3ccccc43)cccc2c1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase incubated for 16 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4184249,=,=,EC50,nM,6.0,EC50,uM,0.006,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1CCc1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc2ccccc12,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1cccc2ccccc12,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C\c1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C\c1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1-c1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1-c1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1Cc1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1Cc1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1Oc1ccccc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1Oc1ccccc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccccn1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccccn1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccnc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccnc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccncc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccncc1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccco1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccco1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1nccs1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1nccs1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells co-expressing CMX-beta-galactosidase at 30 uM incubated for 16 hrs by luciferase reporter gene assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccsc1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1ccsc1,2018
Agonist activity at LXRbeta ligand-binding domain (unknown origin) incubated for 1.5 hrs using fluorescein-labeled coactivator peptide by TR-FRET competitive binding assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,CHEMBL4184249,=,=,EC50,nM,40.4,EC50,nM,40.4,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,2018
Agonist activity at LXRbeta ligand-binding domain (unknown origin) at 3 uM incubated for 1.5 hrs using fluorescein-labeled coactivator peptide by TR-FRET competitive binding assay relative to T0901317,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,CHEMBL4184249,=,=,Efficacy,%,14.0,Efficacy,%,14.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,2018
Agonist activity at LXRalpha ligand-binding domain (unknown origin) at 0.3 uM incubated for 1.5 hrs using fluorescein-labeled coactivator peptide by TR-FRET competitive binding assay relative to T0901317,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,CHEMBL4184249,=,=,Efficacy,%,6.0,Efficacy,%,6.0,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,2018
Agonist activity at LXRalpha ligand-binding domain (unknown origin) at 3 uM incubated for 1.5 hrs using fluorescein-labeled coactivator peptide by TR-FRET competitive binding assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4184249,,,Activity,,,Activity,,,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2018
Agonist activity at LXRbeta ligand-binding domain (unknown origin) incubated for 1.5 hrs using fluorescein-labeled coactivator peptide by TR-FRET competitive binding assay,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,CHEMBL4184249,,,Activity,,,Activity,,,O=C1c2c(Cl)c(Cl)c(Cl)c(Cl)c2C(=O)N1c1ccccc1/C=C/c1cccs1,2018
Agonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha at 10 uM after 18 hrs by luciferase reporter gene assay relative to GW3965,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4219067,,,Activity,,,Activity,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Agonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha at 10 uM after 18 hrs by luciferase reporter gene assay relative to GW3965,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@@H]4OC[C@@]5(CC[C@@H](O)C=C45)[C@H]3CC[C@]12C,CHEMBL4219067,,,Activity,,,Activity,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@@H]4OC[C@@]5(CC[C@@H](O)C=C45)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@@H]4OC[C@@]5(CC[C@@H](O)C=C45)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3C[C@@H]4OC[C@@]5(CC[C@@H](O)C=C45)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Agonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha at 10 uM after 18 hrs by luciferase reporter gene assay relative to GW3965,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4219067,,,Activity,,,Activity,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,2018
Agonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha at 10 uM after 18 hrs by luciferase reporter gene assay relative to GW3965,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,CHEMBL4219067,,,Activity,,,Activity,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,2018
Agonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha at 10 uM after 18 hrs by luciferase reporter gene assay relative to GW3965,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,CHEMBL4219067,,,Activity,,,Activity,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,2018
Antagonist activity at human full length LXRalpha expressed in human BHK21 cells co-expressing human pSG5/RXRalpha assessed as inhibition of GW3965-induced receptor activation at 10 uM after 18 hrs by luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,CHEMBL4219067,,,Inhibition,%,,INH,,,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H]5C[C@]4(CO5)[C@H]3CC[C@]12C,2018
Agonist activity at GAL4-fused human LXRalpha LBD expressed in HEK293T cells at 1 uM after 12 to 14 hrs by luciferase reporter gene assay,COc1cc(C(C)(C)C)ccc1C(=O)Nc1ccc(CC(=O)O)cc1,CHEMBL4229454,,,Activity,,,Activity,,,COc1cc(C(C)(C)C)ccc1C(=O)Nc1ccc(CC(=O)O)cc1,2018
Antagonist activity at GAL4-fused human LXRalpha LBD expressed in HEK293T cells at 1 uM after 12 to 14 hrs by luciferase reporter gene assay,COc1cc(C(C)(C)C)ccc1C(=O)Nc1ccc(CC(=O)O)cc1,CHEMBL4229454,,,Inhibition,%,,INH,,,COc1cc(C(C)(C)C)ccc1C(=O)Nc1ccc(CC(=O)O)cc1,2018
Agonist activity at human GAL-tagged LXRbeta-LBD R305G mutant transfected in HEK293T cells assessed as co-activator recruitment using TRAP220 as co-activator by TR-FRET assay relative to TO901317,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,CHEMBL4257563,=,=,Activity,%,18.0,Activity,%,18.0,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,2018
Agonist activity at human GAL-tagged LXRbeta-LBD R305G mutant transfected in HEK293T cells assessed as co-activator recruitment using NCoR as co-repressor by TR-FRET assay relative to TO901317,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,CHEMBL4257563,=,=,Activity,%,31.0,Activity,%,31.0,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,2018
Agonist activity at human LXRalpha-LBD (182 to 447 amino acids) expressed in HEK293T cells by luciferase reporter gene assay,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,CHEMBL4257563,=,=,EC50,nM,150.0,EC50,uM,0.15,CN(CC(=O)Nc1ccc(F)c(F)c1F)C(=O)c1ccc2c(c1)OCCO2,2018
Agonist activity at human LXRalpha expressed in HEK293 cells after 24 hrs by One-Glo luciferase reporter gene assay,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4257563,=,=,EC50,nM,422.0,EC50,nM,422.0,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Agonist activity at human LXRalpha expressed in HEK293 cells after 24 hrs by One-Glo luciferase reporter gene assay relative to TO901317,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4257563,=,=,Emax,%,45.0,Emax,%,45.0,C[C@H](CCC(=O)N(C)C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2018
Agonist activity at human LXRalpha expressed in HEK293 cells after 24 hrs by One-Glo luciferase reporter gene assay,COC1CCN(C(=O)CC[C@@H](C)[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)CC1,CHEMBL4257563,=,=,EC50,nM,230.0,EC50,nM,230.0,COC1CCN(C(=O)CC[C@@H](C)[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)CC1,2018
Agonist activity at human LXRalpha expressed in HEK293 cells after 24 hrs by One-Glo luciferase reporter gene assay relative to TO901317,COC1CCN(C(=O)CC[C@@H](C)[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)CC1,CHEMBL4257563,=,=,Emax,%,58.0,Emax,%,58.0,COC1CCN(C(=O)CC[C@@H](C)[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)CC1,2018
Antagonist activity at human LXRalpha expressed in HEK293T cells by luciferase reporter gene assay,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,CHEMBL4257563,=,=,IC50,nM,3500.0,IC50,uM,3.5,C=C1c2ccccc2C(=O)N(C)c2ccc(O)cc21,2018
Inverse agonist activity at LXRalpha (unknown origin) expressed in HEK293 cells 24 hrs by Dual-Glo luciferase assay,CCOC(=O)c1ccc(CN(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)S(=O)(=O)c2c(C)cc(C)cc2C)o1,CHEMBL4257563,=,=,IC50,nM,214.0,IC50,nM,214.0,CCOC(=O)c1ccc(CN(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)S(=O)(=O)c2c(C)cc(C)cc2C)o1,2018
Transrepression of recombinant human GAL4-DBD fused LXRalpha LBD expressed in HEK293 cells after 20 hrs by luciferase reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3)cc2)cc1,CHEMBL4261613,>,>,EC50,nM,30000.0,EC50,uM,30.0,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3)cc2)cc1,2018
Transrepression of recombinant human GAL4-DBD fused LXRalpha LBD expressed in HEK293 cells after 20 hrs by luciferase reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3)c(F)c2)cc1,CHEMBL4261613,>,>,EC50,nM,30000.0,EC50,uM,30.0,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3)c(F)c2)cc1,2018
Transrepression of recombinant human GAL4-DBD fused LXRalpha LBD expressed in HEK293 cells after 20 hrs by luciferase reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3F)c(F)c2)cc1,CHEMBL4261613,>,>,EC50,nM,30000.0,EC50,uM,30.0,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3ccc(F)cc3F)c(F)c2)cc1,2018
Transrepression of recombinant human GAL4-DBD fused LXRalpha LBD expressed in HEK293 cells after 20 hrs by luciferase reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3cc(C#N)ccn3)c(F)c2)cc1,CHEMBL4261613,>,>,EC50,nM,30000.0,EC50,uM,30.0,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)(C)C(=O)Nc3cc(C#N)ccn3)c(F)c2)cc1,2018
Agonist activity at Gal4 DNA binding domain-fused LXRalpha LBD transfected in human HepG2 cells at 1 uM after 24 hrs relative to control,CC(C)C(=O)N1CCC(c2cn(C)c3ncc(NC(=O)c4cccc(C#N)c4)c(C(F)(F)F)c23)CC1,CHEMBL4265880,>,>,Activity,%,20.0,Activity,%,20.0,CC(C)C(=O)N1CCC(c2cn(C)c3ncc(NC(=O)c4cccc(C#N)c4)c(C(F)(F)F)c23)CC1,2018
Agonist activity at LXR alpha (unknown origin) up to 10 uM by reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,CHEMBL4304769,,,Activity,,,Activity,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1,2019
Binding affinity to LXRalpha (unknown origin) at 30 uM by TR-FRET assay,O=c1cc(CCc2ccccc2)oc2ccccc12,CHEMBL4330147,,,Activity,,,Activity,,,O=c1cc(CCc2ccccc2)oc2ccccc12,2019
Binding affinity to LXRalpha (unknown origin) at 30 uM by TR-FRET assay,COc1ccc2oc(CCc3ccccc3)cc(=O)c2c1,CHEMBL4330147,,,Activity,,,Activity,,,COc1ccc2oc(CCc3ccccc3)cc(=O)c2c1,2019
Binding affinity to LXRalpha (unknown origin) at 30 uM by TR-FRET assay,COc1ccc2c(=O)cc(CCc3ccccc3)oc2c1,CHEMBL4330147,,,Activity,,,Activity,,,COc1ccc2c(=O)cc(CCc3ccccc3)oc2c1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),Cc1ccc(S(=O)(=O)[C@@]23CCN(C(=O)[C@H]4CC[C@H](C(=O)O)CC4)[C@@H]2CCc2cc(C(F)(C(F)(F)F)C(F)(F)F)ccc23)cc1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1ccc(S(=O)(=O)[C@@]23CCN(C(=O)[C@H]4CC[C@H](C(=O)O)CC4)[C@@H]2CCc2cc(C(F)(C(F)(F)F)C(F)(F)F)ccc23)cc1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4cccc(F)c4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4cccc(F)c4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4cccc(Cl)c4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4cccc(Cl)c4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),Cc1cccc(S(=O)(=O)[C@@]23CCN(C(=O)[C@H]4CC[C@H](C(=O)O)CC4)[C@@H]2CCc2cc(C(F)(C(F)(F)F)C(F)(F)F)ccc23)c1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,Cc1cccc(S(=O)(=O)[C@@]23CCN(C(=O)[C@H]4CC[C@H](C(=O)O)CC4)[C@@H]2CCc2cc(C(F)(C(F)(F)F)C(F)(F)F)ccc23)c1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccccc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccccc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)Cc4ccccc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)Cc4ccccc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)C12CCC(C(=O)N3CC[C@@]4(S(=O)(=O)c5ccc(F)cc5)c5ccc(C(F)(C(F)(F)F)C(F)(F)F)cc5CC[C@@H]34)(CC1)CC2,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)C12CCC(C(=O)N3CC[C@@]4(S(=O)(=O)c5ccc(F)cc5)c5ccc(C(F)(C(F)(F)F)C(F)(F)F)cc5CC[C@@H]34)(CC1)CC2,2019
Activity at LXRalpha (unknown origin),O=C(O)C12CC(C(=O)N3CC[C@@]4(S(=O)(=O)c5ccc(F)cc5)c5ccc(C(F)(C(F)(F)F)C(F)(F)F)cc5CC[C@@H]34)(C1)C2,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)C12CC(C(=O)N3CC[C@@]4(S(=O)(=O)c5ccc(F)cc5)c5ccc(C(F)(C(F)(F)F)C(F)(F)F)cc5CC[C@@H]34)(C1)C2,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@](O)(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@](O)(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@](F)(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@](F)(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),C[C@]1(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC[C@H](C(=O)O)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@]1(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC[C@H](C(=O)O)CC1,2019
Activity at LXRalpha (unknown origin),C[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,C[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),CC(=O)N1CCC(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,CC(=O)N1CCC(C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4CC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,2019
Activity at LXRalpha (unknown origin),O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4NC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4NC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),CN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,2019
Activity at LXRalpha (unknown origin),CCN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,2019
Activity at LXRalpha (unknown origin),CCCN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCCN1C[C@H]2N(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,2019
Activity at LXRalpha (unknown origin),O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4OC[C@@H]23)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccc(F)cc4)c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4OC[C@@H]23)CC1,2019
Activity at LXRalpha (unknown origin),O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3OC[C@@H]12)C1(O)CCS(=O)(=O)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3OC[C@@H]12)C1(O)CCS(=O)(=O)CC1,2019
Activity at LXRalpha (unknown origin),O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3NC[C@@H]12)C1(O)CCS(=O)(=O)CC1,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3NC[C@@H]12)C1(O)CCS(=O)(=O)CC1,2019
Activity at LXRalpha (unknown origin),CN1C[C@H]2N(C(=O)C3(O)CCS(=O)(=O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,CHEMBL4334512,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN1C[C@H]2N(C(=O)C3(O)CCS(=O)(=O)CC3)CC[C@@]2(S(=O)(=O)c2ccc(F)cc2)c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc21,2019
Agonist activity at LXRalpha (unknown origin) by Gal4-Luc reporter gene assay,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1,CHEMBL4334512,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=S(=O)(c1ccc(F)cc1)[C@@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,CHEMBL4339200,=,=,EC50,nM,2920.0,EC50,nM,2920.0,O=S(=O)(c1ccc(F)cc1)[C@@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,COC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4339200,=,=,EC50,nM,408.0,EC50,nM,408.0,COC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CCNC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CCNC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(C1CCCC1)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(C1CCCC1)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CS(=O)(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CS(=O)(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCN(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCN(C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,3750.0,EC50,nM,3750.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=S(=O)(c1ccc(F)cc1)[C@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=S(=O)(c1ccc(F)cc1)[C@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCN(C(=O)N2CC[C@@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCN(C(=O)N2CC[C@@](c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CS(=O)(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CS(=O)(=O)N1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CC(=O)N1CCN(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CC(=O)N1CCN(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)[C@H]1CC[C@@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)C1CCN(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)C1CCN(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccccc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccccc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,Cc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,Cc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CCc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CCc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(Cl)cc3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(Cl)cc3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,COc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,COc1ccc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)cc1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,Cc1cc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)ccc1F,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,Cc1cc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)ccc1F,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,CCc1cc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)ccc1F,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,CCc1cc(S(=O)(=O)[C@@]2(c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)C2)ccc1F,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)c(C4CC4)c3)C2)CC1,CHEMBL4339200,>,>,EC50,nM,7500.0,EC50,nM,7500.0,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)c(C4CC4)c3)C2)CC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells relative to T0901317,O=S(=O)(c1ccc(F)cc1)[C@@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,CHEMBL4339200,=,=,%max,%,58.0,%max,%,58.0,O=S(=O)(c1ccc(F)cc1)[C@@]1(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)CCNC1,2019
Agonist activity at LXRalpha (unknown origin) expressed in African green monkey CV1 cells relative to T0901317,COC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4339200,=,=,%max,%,62.0,%max,%,62.0,COC(=O)N1CCC(c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Antagonist activity at human LXRalpha expressed in HuH7 cells assessed as inhibition of TO901317-induced response at 1 uM incubated for 24 hrs LXRalpha response element driven luciferase reporter gene assay,COc1ccc(Oc2ccc(N3CC(=O)N([C@@H](CC4CCN(C(=O)C(C)C)CC4)c4nc5ccc(C)cc5n4C)C3=O)cc2)cc1,CHEMBL4340545,,,Inhibition,%,,INH,,,COc1ccc(Oc2ccc(N3CC(=O)N([C@@H](CC4CCN(C(=O)C(C)C)CC4)c4nc5ccc(C)cc5n4C)C3=O)cc2)cc1,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs by luciferase reporter gene assay relative to control,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,CHEMBL4359918,=,=,FC,,2.19,FC,,2.19,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs by luciferase reporter gene assay relative to control,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4359918,=,=,FC,,4.27,FC,,4.27,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs by luciferase reporter gene assay relative to control,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4359918,=,=,FC,,2.36,FC,,2.36,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs by luciferase reporter gene assay relative to control,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(=O)C(C)C)[C@@]4(C)CC[C@@H]32)C1,CHEMBL4359918,=,=,FC,,2.63,FC,,2.63,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(=O)C(C)C)[C@@]4(C)CC[C@@H]32)C1,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs in presence of LXR antagonist SR9243 by luciferase reporter gene assay relative to control,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4359918,,,Activity,,,Activity,,,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Agonist activity at human LXRalpha transfected in HEK293T cells at 10 uM incubated for 20 hrs in presence of LXR antagonist SR9243 by luciferase reporter gene assay relative to control,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4359918,,,Activity,,,Activity,,,CC(C)C(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(-c2nc(-c3ccccc3)n(C3CC3)n2)cc1,CHEMBL4371087,,,Emax,,,Emax,,,c1ccc(-c2nc(-c3ccccc3)n(C3CC3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CCCCn1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,65.0,Emax,%,65.0,CCCCn1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CCn1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,,,Emax,,,Emax,,,CCn1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Cn1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,64.0,Emax,%,64.0,Cn1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Clc1ccc(-c2n[nH]c(Cc3ccccc3)n2)cc1,CHEMBL4371087,,,Emax,,,Emax,,,Clc1ccc(-c2n[nH]c(Cc3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Clc1ccccc1-c1n[nH]c(Cc2ccccc2)n1,CHEMBL4371087,=,=,Emax,%,46.0,Emax,%,46.0,Clc1ccccc1-c1n[nH]c(Cc2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,CHEMBL4371087,,,Emax,,,Emax,,,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,CHEMBL4371087,=,=,Emax,%,45.0,Emax,%,45.0,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(-c2n[nH]c(-c3cccnc3)n2)cc1,CHEMBL4371087,,,Emax,,,Emax,,,c1ccc(-c2n[nH]c(-c3cccnc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,COc1cccc(-c2n[nH]c(-c3ccccc3)n2)c1,CHEMBL4371087,=,=,Emax,%,60.0,Emax,%,60.0,COc1cccc(-c2n[nH]c(-c3ccccc3)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Cc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,62.0,Emax,%,62.0,Cc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Brc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,55.0,Emax,%,55.0,Brc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Clc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,51.0,Emax,%,51.0,Clc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Brc1ccccc1-c1n[nH]c(-c2ccccc2)n1,CHEMBL4371087,=,=,Emax,%,52.0,Emax,%,52.0,Brc1ccccc1-c1n[nH]c(-c2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Clc1ccccc1-c1n[nH]c(-c2ccccc2)n1,CHEMBL4371087,=,=,Emax,%,60.0,Emax,%,60.0,Clc1ccccc1-c1n[nH]c(-c2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,56.0,Emax,%,56.0,c1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Cc1ccc(S(=O)(=O)n2nc(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL4371087,=,=,EC50,nM,1705.0,EC50,nM,1705.0,Cc1ccc(S(=O)(=O)n2nc(-c3ccccc3)nc2-c2ccccc2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CC(=O)n1nc(Cc2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,701.0,EC50,nM,701.0,CC(=O)n1nc(Cc2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,COc1cccc(-c2nc(-c3ccccc3)n(C(C)=O)n2)c1,CHEMBL4371087,=,=,EC50,nM,115.0,EC50,nM,115.0,COc1cccc(-c2nc(-c3ccccc3)n(C(C)=O)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CC(=O)n1nc(-c2ccc(C)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,228.0,EC50,nM,228.0,CC(=O)n1nc(-c2ccc(C)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CC(=O)n1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,113.0,EC50,nM,113.0,CC(=O)n1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CC(=O)n1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,396.0,EC50,nM,396.0,CC(=O)n1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Brc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,5025.0,EC50,nM,5025.0,Brc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CCn1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,2237.0,EC50,nM,2237.0,CCn1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Clc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,2130.0,EC50,nM,2130.0,Clc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,2285.0,EC50,nM,2285.0,CCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Cn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,1189.0,EC50,nM,1189.0,Cn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,COc1cccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)c1,CHEMBL4371087,=,=,EC50,nM,903.0,EC50,nM,903.0,COc1cccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,c1ccc(Cn2nc(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL4371087,=,=,EC50,nM,2178.0,EC50,nM,2178.0,c1ccc(Cn2nc(-c3ccccc3)nc2-c2ccccc2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,CCCCn1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,2470.0,EC50,nM,2470.0,CCCCn1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Cn1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,EC50,nM,2468.0,EC50,nM,2468.0,Cn1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Clc1ccccc1-c1n[nH]c(Cc2ccccc2)n1,CHEMBL4371087,=,=,EC50,nM,570.0,EC50,nM,570.0,Clc1ccccc1-c1n[nH]c(Cc2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,CHEMBL4371087,=,=,EC50,nM,2202.0,EC50,nM,2202.0,c1ccc(Cc2nc(-c3ccccc3)n[nH]2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,COc1cccc(-c2n[nH]c(-c3ccccc3)n2)c1,CHEMBL4371087,=,=,EC50,nM,108.0,EC50,nM,108.0,COc1cccc(-c2n[nH]c(-c3ccccc3)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Cc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,77.0,EC50,nM,77.0,Cc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Brc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,164.0,EC50,nM,164.0,Brc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Clc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,309.0,EC50,nM,309.0,Clc1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Brc1ccccc1-c1n[nH]c(-c2ccccc2)n1,CHEMBL4371087,=,=,EC50,nM,390.0,EC50,nM,390.0,Brc1ccccc1-c1n[nH]c(-c2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,Clc1ccccc1-c1n[nH]c(-c2ccccc2)n1,CHEMBL4371087,=,=,EC50,nM,526.0,EC50,nM,526.0,Clc1ccccc1-c1n[nH]c(-c2ccccc2)n1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter by luciferase reporter gene assay,c1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,CHEMBL4371087,=,=,EC50,nM,142.0,EC50,nM,142.0,c1ccc(-c2n[nH]c(-c3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,c1ccc(Cn2nc(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL4371087,=,=,Emax,%,58.0,Emax,%,58.0,c1ccc(Cn2nc(-c3ccccc3)nc2-c2ccccc2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,COc1cccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)c1,CHEMBL4371087,=,=,Emax,%,62.0,Emax,%,62.0,COc1cccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Cn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,77.0,Emax,%,77.0,Cn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,60.0,Emax,%,60.0,CCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CCCCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,CHEMBL4371087,,,Emax,,,Emax,,,CCCCn1nc(-c2ccc(Cl)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Clc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,53.0,Emax,%,53.0,Clc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CCn1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,45.0,Emax,%,45.0,CCn1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Brc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,CHEMBL4371087,=,=,Emax,%,78.0,Emax,%,78.0,Brc1ccc(-c2nc(-c3ccccc3)n(Cc3ccccc3)n2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CC(=O)n1nc(-c2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,56.0,Emax,%,56.0,CC(=O)n1nc(-c2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CC(=O)n1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,58.0,Emax,%,58.0,CC(=O)n1nc(-c2ccc(Br)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CC(=O)n1nc(-c2ccc(C)cc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,53.0,Emax,%,53.0,CC(=O)n1nc(-c2ccc(C)cc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,COc1cccc(-c2nc(-c3ccccc3)n(C(C)=O)n2)c1,CHEMBL4371087,=,=,Emax,%,62.0,Emax,%,62.0,COc1cccc(-c2nc(-c3ccccc3)n(C(C)=O)n2)c1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,CC(=O)n1nc(Cc2ccccc2)nc1-c1ccccc1,CHEMBL4371087,=,=,Emax,%,50.0,Emax,%,50.0,CC(=O)n1nc(Cc2ccccc2)nc1-c1ccccc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,Cc1ccc(S(=O)(=O)n2nc(-c3ccccc3)nc2-c2ccccc2)cc1,CHEMBL4371087,=,=,Emax,%,75.0,Emax,%,75.0,Cc1ccc(S(=O)(=O)n2nc(-c3ccccc3)nc2-c2ccccc2)cc1,2019
Agonist activity at full length human LXRalpha expressed in HEK293 cells harboring LXRE-Luc promoter at 10 uM by luciferase reporter gene assay relative to T0901317,COc1cccc(-c2nc(-c3ccccc3)n(S(=O)(=O)c3ccc(C)cc3)n2)c1,CHEMBL4371087,,,Emax,,,Emax,,,COc1cccc(-c2nc(-c3ccccc3)n(S(=O)(=O)c3ccc(C)cc3)n2)c1,2019
Agonist activity at LXR alpha (unknown origin) by Alpha Screen assay,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4373669,>,>,EC50,nM,100000.0,EC50,uM,100.0,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Antagonist activity at LXR alpha (unknown origin) by Alpha Screen assay,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,CHEMBL4373669,>,>,IC50,nM,100000.0,IC50,uM,100.0,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,2019
Agonist activity at LXR alpha (unknown origin) by Alpha Screen assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4373669,=,=,EC50,nM,120.0,EC50,uM,0.12,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,C[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,C[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CC[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CC[C@]1(C(=O)O)CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C([C@H]1CC[C@](F)(C(=O)O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C([C@H]1CC[C@](F)(C(=O)O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,C[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,C[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CCC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CCC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CO[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CO[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,COC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,COC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)[C@H]1CC[C@](F)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)[C@H]1CC[C@](F)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)C1CCC(O)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)C1CCC(O)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)C1CCC(O)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)C1CCC(O)(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C([C@H]1CC[C@@](F)(C(=O)O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C([C@H]1CC[C@@](F)(C(=O)O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,C[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@@H](C(=O)O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,C[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@@H](C(=O)O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)[C@@H]1[C@@H]2C[C@@H](C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)C[C@@H]21,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)[C@@H]1[C@@H]2C[C@@H](C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)C[C@@H]21,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)[C@H]1[C@@H]2C[C@@H](C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)C[C@@H]21,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)[C@H]1[C@@H]2C[C@@H](C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)C[C@@H]21,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)[C@@H]1C[C@@H]2[C@H](C1)[C@H]2C(=O)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)[C@@H]1C[C@@H]2[C@H](C1)[C@H]2C(=O)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)C2,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)C2,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)CC2,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)CC2,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)OC2,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)OC2,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C12CCC(C(=O)O)(CC1)OC2,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C12CCC(C(=O)O)(CC1)OC2,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C([C@H]1CC[C@H](c2nnn[nH]2)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C([C@H]1CC[C@H](c2nnn[nH]2)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C1NC(=O)C2(CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)CC2)N1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C1NC(=O)C2(CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)CC2)N1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C1NC(=O)C2(CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)CC2)N1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C1NC(=O)C2(CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)CC2)N1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,NC(=O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,NC(=O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,COC(=O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,COC(=O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CS(=O)(=O)C1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CS(=O)(=O)C1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CS(=O)(=O)C1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CS(=O)(=O)C1CCC(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C([C@H]1CC[C@H](CO)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C([C@H]1CC[C@H](CO)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C([C@H]1CC[C@H](O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C([C@H]1CC[C@H](O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(C1CCS(=O)(=O)C1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(C1CCS(=O)(=O)C1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(C1CCS(=O)(=O)C1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(C1CCS(=O)(=O)C1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(C1CCS(=O)(=O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(C1CCS(=O)(=O)CC1)N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,CCC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,CCC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(F)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(F)CCS(=O)(=O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(O)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(O)CCS(=O)(=O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(CO)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,O=C(N1CC[C@](c2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)(S(=O)(=O)c2ccc(F)cc2)C1)C1(CO)CCS(=O)(=O)CC1,2019
Transactivation of human GAL4-fused LXRalpha expressed in African green monkey CV1 cells,COC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,CHEMBL4387773,>,>,EC50,nM,7500.0,EC50,uM,7.5,COC1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CCS(=O)(=O)CC1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4392864,=,=,FC,,19.3,FC,,19.3,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,FC,,3.5,FC,,3.5,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,CC[C@@H](C)C1=C2N=C3OC=CC=C[C@]3(OC)C(=O)N2[C@@H](Cc2ccccc2)C(=O)N1,CHEMBL4392864,=,=,FC,,2.7,FC,,2.7,CC[C@@H](C)C1=C2N=C3OC=CC=C[C@]3(OC)C(=O)N2[C@@H](Cc2ccccc2)C(=O)N1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,FC,,3.6,FC,,3.6,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,FC,,3.9,FC,,3.9,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,FC,,4.0,FC,,4.0,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(O)cccc1c2=O,CHEMBL4392864,=,=,FC,,4.2,FC,,4.2,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(O)cccc1c2=O,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,FC,,3.0,FC,,3.0,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,FC,,3.4,FC,,3.4,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,CO[C@@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,CHEMBL4392864,=,=,FC,,3.7,FC,,3.7,CO[C@@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay relative to control,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,CHEMBL4392864,=,=,FC,,3.2,FC,,3.2,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4392864,=,=,EC50,nM,530.0,EC50,uM,0.53,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,EC50,nM,47000.0,EC50,uM,47.0,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,CC[C@@H](C)C1=C2N=C3OC=CC=C[C@]3(OC)C(=O)N2[C@@H](Cc2ccccc2)C(=O)N1,CHEMBL4392864,=,=,EC50,nM,41000.0,EC50,uM,41.0,CC[C@@H](C)C1=C2N=C3OC=CC=C[C@]3(OC)C(=O)N2[C@@H](Cc2ccccc2)C(=O)N1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,EC50,nM,1700.0,EC50,uM,1.7,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,EC50,nM,1700.0,EC50,uM,1.7,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,CHEMBL4392864,=,=,EC50,nM,5300.0,EC50,uM,5.3,C[C@@H]1C(=O)N[C@](O)(Cc2ccccc2)c2nc3c(O)cccc3c(=O)n21,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(O)cccc1c2=O,CHEMBL4392864,=,=,EC50,nM,5100.0,EC50,uM,5.1,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(O)cccc1c2=O,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,EC50,nM,50000.0,EC50,uM,50.0,C[C@@H]1C(=O)N/C(=C\c2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,CHEMBL4392864,=,=,EC50,nM,16000.0,EC50,uM,16.0,C[C@@H]1C(=O)N[C@@](O)(Cc2ccccc2)c2nc3c(c(=O)n21)C=CC=CO3,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,CO[C@@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,CHEMBL4392864,=,=,EC50,nM,15000.0,EC50,uM,15.0,CO[C@@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,2019
Transactivation of recombinant GAL4-fused human LXRalpha LBD (163 to 447 residues) expressed in human L02 cells measured after 24 hrs by luciferase reporter gene assay,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,CHEMBL4392864,=,=,EC50,nM,15000.0,EC50,uM,15.0,CO[C@]1(Cc2ccccc2)NC(=O)[C@@H](C)n2c1nc1c(c2=O)C=CC=CO1,2019
Inverse agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,COC(=O)c1ccc(CS(=O)(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,CHEMBL4393668,,,IC50,,,IC50,,,COC(=O)c1ccc(CS(=O)(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,2019
Inverse agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,O=C(Cc1ccccc1[N+](=O)[O-])Nc1ccc(-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2F)cc1,CHEMBL4393668,,,IC50,,,IC50,,,O=C(Cc1ccccc1[N+](=O)[O-])Nc1ccc(-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2F)cc1,2019
Inverse agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,CS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,CHEMBL4393668,,,IC50,,,IC50,,,CS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,2019
Inverse agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,CHEMBL4393668,,,IC50,,,IC50,,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(C(O)(C(F)(F)F)C(F)(F)F)cc3F)cc2)cc1,2019
Inverse agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,CCCCCCC(=O)Nc1ccc(-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2F)cc1,CHEMBL4393668,,,IC50,,,IC50,,,CCCCCCC(=O)Nc1ccc(-c2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2F)cc1,2019
Agonist activity at Gal4-fused LXRalpha LBD (unknown origin) expressed in 293T cells measured after 24 hrs by dual-luciferase reporter gene assay,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4393668,=,=,IC50,nM,50.0,IC50,uM,0.05,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2019
Agonist activity at full length human GAL4-DBD fused LXRalpha LBD (164 to 447 residues) expressed in COS1 cells at 25 to 50 uM measured after 18 hrs by dual luciferase reporter gene assay,CCCCCCCc1cc(CCCCCC(=O)O)no1,CHEMBL4393735,,,Activity,,,Activity,,,CCCCCCCc1cc(CCCCCC(=O)O)no1,2019
Antagonist activity at human Gal4-fused LXRalpha expressed in HEK293T cells assessed as inhibition of T0901317 induced response at 1 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay,CN(c1cc(C(F)(F)F)nc(OCCC(=O)O)n1)c1cccc2c1CCC2,CHEMBL4411340,,,Activity,,,Activity,,,CN(c1cc(C(F)(F)F)nc(OCCC(=O)O)n1)c1cccc2c1CCC2,2019
Agonist activity LXRalpha (unknown origin),O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,CHEMBL4411340,=,=,EC50,nM,50.0,EC50,nM,50.0,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,2019
Activation of Gal4-fused human LXRalpha LBD transfected in HEK293T cells at 10 uM after 12 to 14 hrs by luciferase reporter gene assay,O=C(O)CCCc1nc(-c2ccc(Cl)c(Cl)c2)c(-c2ccccc2)o1,CHEMBL4414562,,,Activity,,,Activity,,,O=C(O)CCCc1nc(-c2ccc(Cl)c(Cl)c2)c(-c2ccccc2)o1,2019
Activation of Gal4-fused human LXRalpha LBD transfected in HEK293T cells at 10 uM after 12 to 14 hrs by luciferase reporter gene assay,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,CHEMBL4414562,,,Activity,,,Activity,,,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,2019
Inhibition of human LXRalpha transfected in human HEK293 cells co-expressing CMV-beta galactosidase assessed as inhibition on T0901317 response at 50 uM after 48 hrs by luciferase reporter gene assay,C=C(CO)[C@H]1CC=C2CC[C@@H](O)[C@H](C)[C@@]2(C)C1,CHEMBL4414674,,,Inhibition,%,,INH,,,C=C(CO)[C@H]1CC=C2CC[C@@H](O)[C@H](C)[C@@]2(C)C1,2019
Inhibition of human LXRalpha transfected in human HEK293 cells co-expressing CMV-beta galactosidase assessed as inhibition on T0901317 response at 50 uM after 48 hrs by luciferase reporter gene assay,C=C(CO)c1ccc([C@@H](C)C[C@@H](O)CO)c(C)c1,CHEMBL4414674,,,Inhibition,%,,INH,,,C=C(CO)c1ccc([C@@H](C)C[C@@H](O)CO)c(C)c1,2019
Inhibition of T0901317-induced human LXR-alpha transcriptional activity after 22 hrs by cell based luciferase reporter gene assay,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL4428033,,,Inhibition,%,,INH,,,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2016
Inhibition of T0901317-induced human LXR-alpha transcriptional activity at 10 uM after 22 hrs by cell based luciferase reporter gene assay,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL4428033,,,Inhibition,%,,INH,,,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2016
Transactivation of human LXR-alpha at 10 to 50 uM after 22 hrs by cell based luciferase reporter gene assay,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHEMBL4428033,,,Activity,,,Activity,,,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,2016
Agonist activity at LXRalpha (unknown origin) at < 20 uM,CC(=O)NC(C)c1nc(-c2ccc(Oc3ccc(OCc4ccccc4)cc3)cc2)no1,CHEMBL4428109,,,Activity,,,Activity,,,CC(=O)NC(C)c1nc(-c2ccc(Oc3ccc(OCc4ccccc4)cc3)cc2)no1,2016
Agonist activity at LXRalpha (unknown origin) at < 20 uM,CC(=O)NC(C)c1nc(-c2ccc(Oc3ccc(O)cc3)cc2)no1,CHEMBL4428109,,,Activity,,,Activity,,,CC(=O)NC(C)c1nc(-c2ccc(Oc3ccc(O)cc3)cc2)no1,2016
Transactivation of Gal4-fused LXRalpha LBD (unknown origin) expressed in HepG2 cells at 10 uM after 18 hrs by dual-glo luciferase assay,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(COc2ccc(C(=O)O)cc2)cc1,CHEMBL4433207,,,Activity,,,Activity,,,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(COc2ccc(C(=O)O)cc2)cc1,2019
Transactivation of Gal4-fused LXRalpha LBD (unknown origin) expressed in HepG2 cells at 10 uM after 18 hrs by dual-glo luciferase assay,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(COc2cccc(C(=O)O)c2)cc1,CHEMBL4433207,,,Activity,,,Activity,,,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(COc2cccc(C(=O)O)c2)cc1,2019
Agonist activity at human LXRalpha transfected in HepG2 at 10 uM by luciferase reporter assay,c1ccc2cc(-c3noc([C@@H]4CCCCN4)n3)ccc2c1,CHEMBL4433214,,,Activity,,,Activity,,,c1ccc2cc(-c3noc([C@@H]4CCCCN4)n3)ccc2c1,2019
Agonist activity at human LXRalpha transfected in HepG2 at 10 uM by luciferase reporter assay,c1ccc2cc(-c3noc(C4CCNCC4)n3)ccc2c1,CHEMBL4433214,,,Activity,,,Activity,,,c1ccc2cc(-c3noc(C4CCNCC4)n3)ccc2c1,2019
Antagonist activity at human LXRalpha transfected in HepG2 at 5 uM in presence of LXRalpha agonist GW3965 by luciferase reporter assay,c1ccc2cc(-c3noc(C4CCNCC4)n3)ccc2c1,CHEMBL4433214,,,Activity,,,Activity,,,c1ccc2cc(-c3noc(C4CCNCC4)n3)ccc2c1,2019
Antagonist activity at human LXRalpha transfected in HepG2 at 5 uM in presence of LXRalpha agonist GW3965 by luciferase reporter assay,c1ccc2cc(-c3noc([C@@H]4CCCCN4)n3)ccc2c1,CHEMBL4433214,,,Activity,,,Activity,,,c1ccc2cc(-c3noc([C@@H]4CCCCN4)n3)ccc2c1,2019
Transactivation of LXRalpha (unknown origin) by TR-FRET assay,C=CC(c1ccccc1)c1c(O)cc(O)c2c(=O)cc(-c3ccccc3)oc12,CHEMBL4665657,,,Activity,,,Activity,,,C=CC(c1ccccc1)c1c(O)cc(O)c2c(=O)cc(-c3ccccc3)oc12,2019
Binding affinity to human LXRalpha at 30 uM by competitive ligand binding based TR-FRET assay,COc1ccc(OC)c(/C=C/C(=O)OCc2cc(=O)c(O)co2)c1,CHEMBL4673218,,,Activity,,,Activity,,,COc1ccc(OC)c(/C=C/C(=O)OCc2cc(=O)c(O)co2)c1,2018
Agonist activity at recombinant human LXRalpha LBD (164 to 447 residues) expressed in African green monkey COS-1 cells at 25 to 50 uM incubated for 18 hrs by luciferase reporter gene assay,CCCCC/C=C/C(=O)CCCCCCCC(=O)O,CHEMBL4715825,,,Activity,,,Activity,,,CCCCC/C=C/C(=O)CCCCCCCC(=O)O,2018
Agonist activity at recombinant human LXRalpha LBD (164 to 447 residues) expressed in African green monkey COS-1 cells at 25 to 50 uM incubated for 18 hrs by luciferase reporter gene assay,CCCCCCCC(=O)/C=C/CCCCCC(=O)O,CHEMBL4715825,,,Activity,,,Activity,,,CCCCCCCC(=O)/C=C/CCCCCC(=O)O,2018
